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Idiosyncratic drug-induced liver injuries (DILI) are rare adverse events that inflict 
susceptible patients exposed to certain normally-mild drugs. A major obstacle in 
understanding idiosyncratic DILI etiology includes the lack of ideal animal models for its 
reproduction in the laboratory. Recently, ROS has been implicated in idiosyncratic DILI 
and the heterozygous superoxide dismutase 2 or Sod2+/- mouse (HET) is an ideal mutant 
model for studying DILI arising from diminished mitochondrial antioxidant defence. 
Using highly purified mitochondrial proteins from the HET liver, we performed 
comparative proteomics. The up-regulation of antioxidants such GPX1, GSTK1 and 
MGST1 suggested the increased effort to restore redox equilibrium. Our proteomic 
analysis indicated that HET mice exhibit a mild mitochondrial oxidative stress which is 
partly compensated by the antioxidant defense system linked to the tricarboxylic acid 
(TCA) cycle, urea cycle, β-oxidation, and oxidative phosphorylation (OXPHOS). This 
discreet and phenotypically silent mitochondrial proteome alteration represents a “1st hit” 
which is compatible with studying pathological DILI conditions (“2nd hit”).  
 
Applying integrative proteomics on the HET hepatic mitochondria treated with 
troglitazone, a withdrawn drug due to unacceptable hepatic liability, we generated a 
comprehensive view of proteomic changes that correlated well with toxicological and 
histological endpoints. 2D-DIGE and iTRAQ™ coupled to MALDI-TOF/TOF MS/MS 
analysis revealed a two-stage mitochondrial response upon short-term and long-term 
troglitazone administration, similar to the delayed hepatotoxicity observed in humans. 
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The small number of proteins common to both time-points (3 out of 70 proteins) reflected 
distinct changes that occurred at the molecular level. Early changes involved the 
induction of a mitochondrial stress response such as seen by increased levels of heat 
shock protein family members (mortalin, HSP7C), Lon protease, and catalase. In 
contrast, after 4 weeks, a number of critical proteins including ATP synthase β-subunit, 
aconitase-2 (ACO2), and mitochondrial dicarboxylate carrier (DIC) exhibited decreased 
abundance. In addition, mitochondrial protein carbonyls and nitrotyrosine adducts were 
significantly increased, suggesting uncompensated oxidative damage. Even in the 
presence of increased SOD2 levels, the threshold for toxicity has been reached and liver 
injury ensued. Building on clinical and biological evidence of mitochondrial ROS 
perturbation on troglitazone DILI, we observed that impairment of mitochondrial 
glutathione transport may play a role in precipitating the toxic effects of troglitazone 
under compromised mitochondrial ROS defence. This further confirms the contribution 
of glutathione and inheritable mitochondrial dysfunction in idiosyncratic DILI 
susceptibility. ACO2 was decreased at both time points, making this protein a potential 
sensitive and early biomarker for mitochondrial oxidative stress. ACO2 was decreased at 
both time points, making this protein a potential sensitive and early biomarker for 
mitochondrial oxidant stress. This integrative approach could signify a new paradigm in 
advancing and predicting mechanistic toxicity of idiosyncratic DILI.  
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1.1. Idiosyncratic drug-induced liver injury 
 
Drug-induced liver injury (DILI) is a major cause for the withdrawal of drugs 
from the market, regulatory actions and restriction of prescribing indications (US Food 
and Drug Administration. Draft guidance for industry. Drug-Induced Liver Injury: 
Premarketing Clinical Evaluation http://www.fda.gov/cder/guidance/7507dft.htm; 
accessed 13 March 2009). Figure 1 shows that from 1976 to 2005, hepatotoxicity formed 
the single most common toxicity as to why drugs were removed from the market. As 
such, there has been immense attention to address the challenges of detecting drugs early 
that can potentially cause DILI and mitigate their adverse consequential effects.  
 
Idiosyncratic DILI, by definition, is difficult to understand. It is unpredictable, 
rare occurring at the frequency of about 1:104 or more, delayed onset, dose-independent 
and may have an immune component (although the last two points are arguable). It is 
highly likely that genetic risk factors are also involved.  The term “idiosyncratic reaction” 
can be defined as “toxic responses determined by individual susceptibility to (host) 
factors that increase the penetrance and expressivity of the intrinsic toxicity of a drug or a 
drug metabolite” (Boelsterli, 2003b). This would imply that these factors encompass the 
penetrance (the proportion of individuals affected) and the expressivity (consistency or 
severity of the DILI phenotype) of such a drug. A distinct feature of idiosyncratic DILI is 
that these drugs do not cause liver injury in the vast majority of patients. It only manifests 
the injuries in a very small fraction of patients featuring susceptibility factors coupled 
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with by drug exposure over time. It is likely that a combination of susceptibility factors 
within an individual, rather than a single factor, that will trigger idiosyncratic DILI 
(Ulrich, 2007). Clinically, idiosyncratic DILI can be manifested by parenchymal necrosis, 
hepatocellular or cholestatic injury in the absence of necrosis, or a combination of both 
(Kaplowitz, 2005). In certain cases, delayed hypersensitivity or inflammatory responses 
may accompany the insult and drug rechallenge. Several clinical signatures can be 
recognized from serum chemistries – (i) marked increases in serum aminotransferases 
and bilirubin, and mild increases in alkaline phosphatases which resembles hepatitis, (ii) 
prominent elevations in alkaline phosphatase levels, more than serum aminotransferases 
which resembles cholestasis or (iii) a mix of hepatocellular and cholestatic features 
(Navarro & Senior, 2006). Typically, increases in serum alanine aminotransferase (ALT) 
levels and overt liver injury set in after a variable latency period (weeks to months and 
even after more than 1 year of treatment). Once started, the progression of the liver 
disease can often precipitate abruptly. When symptoms are present, drug-induced 
hepatotoxicity can be diagnosed and drug treatment halted. In most instances, the patient 
situation would improve. However liver injury can worsen in some cases even with 
progressive falls in ALT levels, the latter usually taken as a sign of liver recovery  
(Navarro & Senior, 2006). On rare occasions, the hepatic injury can result in acute liver 
failure and death. The reasons for these typical hallmarks of idiosyncratic DILI have 








Figure 1. Drug toxicities leading to market withdrawals in the period 1976 to 2005.  
Hepatotoxicity or DILI (21%) formed the majority cause for drug withdrawals. 
Cardiotoxicity refers to heart-related toxicities other than torsades de pointes. Torsades is 
a life-threatening arrhythmia and may present as sudden cardiac death in patients with 
structurally normal hearts. Rhabdomyolysis is the breakdown of muscle fibres resulting 
in the release of muscle fibre contents (myoglobin) into the bloodstream. ‘Other’ refers to 
haemolytic anaemia (1), skin disease (1), immune toxicity (2), gastrointestinal toxicity 
(1), respiratory toxicity (1), fatal (1), neurotoxicity (1), blood-related toxicity (1) and 
birth defects (1). Percentage of total and number of cases shown in brackets. Figure taken 




1.1.1. Susceptibility factors and mechanisms of idiosyncratic DILI 
 
Many attempts have been made to describe the mechanisms or hypotheses that 
underlie idiosyncratic DILI. The occasional susceptibility of patients to adverse effects of 
otherwise mild drugs means there is no intuitive consensus as to how idiosyncrasy 
occurs. 
 
Drug-allergic reactions have been suspected to play a role in various idiosyncratic 
drug-induced hepatotoxicities (Uetrecht, 2007). Fever, rash, eosinophilia, auto-antibodies 
accompanying hepatotoxicity and the rapid recurrence of liver injury upon drug re-
challenge (Gunawan & Kaplowitz, 2004) are features supporting the hypothesis of 
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immune-mediated idiosyncratic DILI. However, not all idiosyncratic DILI-causing drugs 
have an allergic-mediated component (Kaplowitz, 2005). The frequent encounter of drugs 
that elicit hypersensitivity and non-allergic reactions prompted Kaplowitz to classify 
idiosyncratic reactions into allergic and non-allergic drug-induced reactions (Kaplowitz, 
2005). Yet it is difficult to exclude allergic reactions based solely on the presentation of 
clinical evidence noted above. Furthermore, the development of hapten, a reactive drug 
metabolite that covalently binds to proteins, elicits an immune response one to five weeks 
after drug exposure. In contrast, the clinical latency of idiosyncratic DILI usually occurs 
several months to more than a year after the first drug exposure. In this regard, 
Zimmerman classified this as metabolic idiosyncrasy (Zimmerman, 1976), although no 
metabolic pathway or mechanism has yet been associated with the cause for idiosyncratic 
DILI. Another hypothesis that has been put forward is the inflammagen hypothesis 
(Uetrecht, 2008). This is based on a combination of drugs in doses normally tolerated and 
inflammagens such as liposaacharide (LPS) that lead to acute hepatic injury in mice. In 
contrast to an acute inflammatory phase, the onset of idiosyncratic drug reactions is 
characteristically delayed and chronic. LPS itself is a confounding factor, thus making it 
difficult to differentiate if the hepatic injuries were potentiated or caused by LPS, or the 
drug was amplifying the liver toxic effects of LPS. Therefore it can be argued that 
immune-mediated toxic response and inflammagens cannot satisfactorily explain the 
uniqueness and pathogenesis of idiosyncratic DILI. 
 
 Genetic risk factors may increase the toxic potency of drugs by shifting the dose-
response curve (effectively LC50) to the left. However, presently, clinical evidence 
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supporting the presence of polymorphisms in causing idiosyncratic DILI has been 
sporadic. Therefore, current hypotheses do not adequately describe possible mechanisms 
that predispose susceptible patients to the adverse effects of drug and new paradigms are 
urgently needed to explain the unpredictable nature of idiosyncratic DILI. 
 
1.2. Troglitazone as a model drug for the study of idiosyncratic DILI 
 
Troglitazone (Rezulin™, Pfzier; Figure 2), a first-generation thiazolidinedione 
drug used in the treatment of type-2 diabetes mellitus was withdrawn from the market 
due to an unacceptable risk of idiosyncratic hepatotoxicity (Graham et al., 2002). In early 
drug safety assessments, even in long-term studies, troglitazone did not cause 
hepatotoxicity in normal healthy rodents and monkeys, (Matsunuma et al., 1993, 
Mayfield et al., 1993, Rothwell et al., 1997). Moreover, while subsequent post-market 
withdrawal experiments showed that troglitazone caused mitochondrial injury in vitro at 
high concentrations, troglitazone was allowed to progress to the clinical testing phase 
stage.  
 
A hallmark of troglitazone-induced hepatic injury is the seemingly random and 
delayed onset of liver injury, which could abruptly progress to life-threatening and 
irreversible liver failure ranging from one month to more than a year’s interval (Graham, 
et al., 2002, Iwase et al., 1999).  This idiosyncratic hepatotoxicity of troglitazone was not 
repeated in 13 double-blind clinical trial studies with the other thiazolidinedione 
members of safer profiles, namely rosglitazone and pioglitazone. In this clinical trial 
study, 1.91% of 2510 patients (versus 0.6% in the placebo group), 0.26% of 1526 
 6 
patients, and 0.17% of 3503 patients who received troglitazone, pioglitazone, and 
rosiglitazone respectively had three times the upper limit of normal (ULN) of ALT 
(Lebovitz et al., 2002). ALT is released from dead or injured hepatocytes and is generally 
used as indicators to measure liver health1
                                                 
1 Healthy ALT range is placed at around 5 IU/L to 50 IU/L but this range changes slightly with the 
ethnicity of the population and gender with males slightly higher. IU, international units 
. However, it must be stated that ALT above 
three times ULN alone does not always predict severe liver toxicity and therefore may 
require use of additional clinical parameters (Kaplowitz, 2005). Out of these patients, two 
individuals were hospitalised with drug-induced hepatitis while another two individuals 
had jaundice although no cases of acute liver failure was reported (Graham et al., 2001, 
Watkins & Whitcomb, 1998). Despite the mild elevations in ALT, such irregularity was 
not necessarily indicative of subsequent cases of equal or worse severity and hence 
troglitazone was brought into the market in 1997.  Soon thereafter, several cases of acute 
liver failure associated with troglitazone prescription was reported and by 2000, 
troglitazone was removed from the market culminating in 94 reported cases of 
troglitazone-associated liver failure (U.S. Department of Health and Human Services, 
March 21, 2000 ). Ever since, numerous attempts to study the underlying mechanisms 
troglitazone-induced liver toxicity have been made, but the in vitro results and ensuing 
hypotheses provided little mechanistic relevance to address clinical troglitazone-induced 
DILI (Chojkier, 2005, Smith, 2003). Studying the mechanisms behind the idiosyncratic 
toxicity of troglitazone not only explain why only a subset of patients develop liver 
injury, but also bring us closer to explain how a spectrum of drugs can induce 
idiosyncratic DILI. With better understanding of the idiosyncractic DILI mechanisms, 
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potential idiosyncratic liabilities of drugs in preclinical development can be identified 
early. 
 
Being lipophilic, troglitazone readily enters the cell and nucleus and bind to 
PPARγ with Kd2
 
 around 40 nM (Lehmann et al., 1995). When liganded, this causes a 
conformational change of PPARγ and its heterodimer partner, retinoid X receptor (RXR) 
and binds to specific PPAR-response element (PPRE) in or near the transcriptional start 
site of target genes (Germain et al., 2002, Kliewer et al., 1992). The conformational 
change of PPAR also causes the recruitment of co-activator and co-repressor proteins that 
influences the set of transcribed genes (Heinaniemi & Carlberg, 2008). PPRE consists of 
two hexameric half-sites of the consensus motif AGGTCA in a direct repeat interspaced 
by a nucleotide. PPARγ binds to the first PPRE site while RXR binds the second, 
resulting in the initiation of DNA transcription and expression of PPARγ-responsive 
genes (Chandra et al., 2008). However, the PPRE sequences are not PPAR isoform-
specific (Lemay & Hwang, 2006).  In a similar fashion, troglitazone binds to and activate 
PPARγ to elicit its therapeutic effects in tissues. It is therefore interesting to understand 
how a normally-mild and beneficial drug used for ameliorating diabetic symptoms can 







                                                 














Figure 3. Crystal structure of PPARγ and RXR 
Crystal structure at 3.1 to 3.2Å resolution of PPARγ (red) and RXRα (blue) binding to 
PPRE to initiate DNA transcription. The optimal PPRE consensus motif AGGTCA-A-
AGGTCAG.The spacer nucleotide which also forms the minor groove of PPRE 
consensus sequence interacts with the DNA-binding domains of PPARγ and RXRα and 
shields the highly polar side chains of the interacting residues (Asn 160 from PPARγ, and 
Arg 209 and Gln 206 of RXRα) from an aqueous environment. Figure taken from Nature 





1.2.1. Mitochondrial dysfunction and threshold effect as a possible mechanism 
for idiosyncratic DILI  
 
There is growing evidence showing the linkage of mutations in mitochondrial 
proteins to reactive oxygen species / reactive nitrogen species (ROS /RNS) in the 
pathogenesis of both rare and common human diseases (Droge, 2002). Mitochondrial 
diseases due to mutations in nDNA and mtDNA encoding for mitochondrial proteins are 
complex, and are confounded by a heterogeneous mix of clinical symptoms and 
inheritance patterns (Wallace, 1999). Elevated levels in free radicals under non-regulated 
conditions have been implicated with pathophysiological conditions that include 
neurodegenerative diseases, aging, ischemia / reperfusion cycles, cancer and 
mitochondrial diseases arising from mtDNA mutations and drug-induced toxicities 
(Wallace, 1999).  
 
mtDNA has high mutation rates, presumably due to their proximity to sites of 
mitochondrial ROS production and the lack of protective histones (Ott et al., 2007). As 
some mtDNA gets mutated, each cell could possess a mix of mtDNA variants, some 
mutant and some WT, a condition known as heteroplasmy. During cell division of 
heteroplasmic cells, cytokinesis will lead to the distribution of mutant mtDNA to other 
daughter cells, and as a consequence may lead to an expansion of homoplasmic cells of 
mutant mtDNA. Likewise, mtDNAs copy numbers can increase within cells during 
clonally expansion, fission and fusion of mitochondria. A mutant mtDNA variant could 
be tolerated at low copies, but once a dominance of detrimental mtDNA has been 
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reached, the mitochondrial dysfunction set in and clinical symptoms become apparent. 
This is known as the threshold effect (DiMauro & Schon, 2003). 
 
Defects in any of the many mitochondrial functions can in principle manifest as 
diseases. However, due to the mode of genetic inheritance, it is likely that there are many 
clinically silent mitochondrial abnormalities that would only be unmasked after exposure 
to hazardous chemicals and toxic substances. Moreover, mitochondrial diseases are not as 
rare as commonly thought – the prevalence of pathologies associated with ETC 
dysfunction was estimated at 10 to 15 per 100, 000 persons (Chinnery & Turnbull, 2001). 
A epidemiological study of mtDNA disease in Finland (3243A>G mutation3
 
) which has 
an estimated prevalence of 16.3 per 100, 000 persons, found that 14% of patients had 
hypertrophic cardiomyopathy, 13% of patients with ophthalmoplegia, 7.4% of maternally 
inherited deafness, and 6.9% of those with occipital stroke (Majamaa et al., 1998). This 
highlighted the wide-ranging implications of mitochondrial diseases in many organs. 
Many lines of evidence have also implicated inherited mitochondrial defects (mtDNA 
and nDNA encoded) in the etiology of type 2 diabetes (Guo et al., 2005, Petersen et al., 
2004), neurodegenerative diseases (Lin & Beal, 2006), cardiac disorders (Corral-
Debrinski et al., 1992b, Murray et al., 2007) and obesity and alcohol-induced liver 
diseases (Mantena et al., 2008).  
Inherited mitochondrial mutations are known to affect tissues with high energy 
requirements, and mitochondrial disorders in the liver are uncommon (Schon, 2000). 
However, this can dramatically change under chemical insults. The selective hepatic 
                                                 
3 The most frequent mtDNA mutation found in humans is the A to G transition at nucleotide 3243 
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targeting of liver by drugs and xenobiotics appear to be the consequence of two dominant 
features of the liver, vascular and metabolic. About 75% of hepatic blood comes directly 
from the gastrointestinal tract and spleen via the portal vein, bringing blood with 
concentrated amounts drugs and xenobiotics absorbed by the gut directly to the liver. 
Drug-metabolizing enzymes detoxify many xenobiotics but bioactivate the toxicity of 
others to reactive intermediates. This leads to the hypothesis that underlying silent 
mitochondrial abnormalities could sensitise the liver to such normally mild drugs, and 
overwhelm any inherent biological defence, eventually triggering overt liver injury. The 
notion of abnormal mitochondria playing the role of a susceptibility factor in DILI is 
relatively new, and recent evidence implicates the role of mitochondrial ROS in drug-
induced toxicity in various organs (Pessayre et al., 1999, Wallace, 2008, Wallace & 
Starkov, 2000). Experimentally, it has been shown that many of the drugs implicated in 
idiosyncratic DILI impair mitochondrial function or induce mitochondrial 
permeabilization (Table 1). In humans, a recent review of clinical evidence suggests the 
contribution of mitochondrial dysfunction in the development of idiosyncratic DILI 
(Table 2), providing a plausible link between the two (Boelsterli & Lim, 2007). 
 
Although most pieces of clinical evidence are sporadic and indirect, they fuel the 
working hypothesis that heteroplasmic mitochondria undergo gradual damage until the 
critical threshold is crossed. For example, the late onset and abrupt progression of 
idiosyncratic DILI can be explained by an accumulation of a drug effect rather than an 
accumulation of the drug itself. If a drug causes cumulative injury to mitochondria, these 
changes may not become detectable until the threshold effect comes into play (i.e., a 
large number of mitochondria have been severely damaged and many hepatocytes being 
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compromised that is sufficient to trigger detectable hepatic injury). Because many 
mitochondria are lethally damaged, the injury may sometimes progress even after 
discontinuation of the drug (Boelsterli, 2003b).  
 
By far, as for many drugs, age is the major risk factors in idiosyncratic DILI 
(Navarro & Senior, 2006). It is well established that mtDNA accumulates mutations with 
aging, especially large-scale deletions and point mutations (Corral-Debrinski et al., 
1992a). The accumulation of these deletions and point mutations with aging results in the 
decline in ETC activity and ATP production. In addition to being primary targets of 
elevated ROS themselves, net production of ROS is another important mechanism by 
which mitochondria are thought to contribute to aging. Thus, it is conceivable that aging 
mitochondria become sensitized and susceptible to ROS-damaging effects, and the effect 
is even more pronounced if it stems from superimposed drug stress.  
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Table 1. Selected drugs causing idiosyncratic DILI experimentally incriminated 
with mitochondrial dysfunction 
  
Drug Therapeutic class Reference 
 
Amiodarone Anti-arhythmic Fromenty et al. (1990); Berson et al. (1998); Spaniol et 
al. (2001); Kaufmann et al. (2005) 
Dantrolene  Antiepileptic Darios et al. (2003); Munns et al. (2005) 
Diclofenac  NSAIDa Petrescu and Tarba (1997); Bort et al. (1998); 
Masubuchi et al. (1998); Masubuchi et al. (1999); 
Masubuchi et al. (2000); Masubuchi et al. (2003); 
Gomez-Lechon et al. (2003a); Gomez-Lechon et al. 
(2003b); Lim et al. (2006) 
Fialuridine  Anti-viral (Hepatitis B) McKenzie et al. (1995); Horn et al. (1997); Lewis et al. 
(1997) 
Flutamide Anti-cancer (Prostate) Coe et al. (2007) 
Isoniazid  Antibiotics Schwab and Tuschl (2003); Chowdhury et al. (2006) 
Lamivudine  Anti-viral (HIV) Note et al. (2003); Desai et al. (2008) 
Leflunomide  DMARDb Spodnik et al. (2002) 
Mefenamic acid  NSAID McDougall et al. (1983); Masubuchi et al. (2000) 
Nimesulide  NSAID Mingatto et al. (2000); Caparroz-Assef et al. (2001); 
Mingatto et al. (2002); Tay et al. (2005); Ong et al. 
(2006); Lim et al. 2008 
Perhexiline  Anti-aginal Deschamps et al. (1994); Berson et al. (1998) 
Simvastatin  Statinc Velho et al. (2006) 
Sulindac  NSAID Leite et al. (2006) 
Stavudine  NSAID Gaou et al. (2001); Gerschenson et al. (2001); Pace et 
al. (2003); Velsor et al. (2004) 
Tolcapone  Parkinson’s Haasio et al. (2002a,b,c) 
Troglitazone  
 
Diabetes Bedoucha et al. (2001); Haskins et al. (2001); 
Tirmenstein et al. (2002); Narayanan et al. (2003); 
Shishido et al. (2003); Bova et al. (2005); Masubuchi 
et al. (2006); Ong et al. (2007) 
Trovafloxacin  Antibiotics Liguori et al. (2005) 
Valproic acid  Antiepileptic Bjorge and Baillie (1991); Keller et al. (1992); 
Ponchaut et al. (1992); Tang et al. (1995); Trost and 
Lemasters (1996); Sobaniec-Lotowska (1997); Tong et 
al. (2005) 
Mitochondrial dysfunction is defined as having experimental in vitro or in vivo evidence of 
one or a combination of the following traits: depolarization of the inner transmembrane 
potential due to either uncoupling or inhibiting ETC complexes, induction of the mPT, 
cytochrome c release, inhibition of β-oxidation, ATP depletion by reasons not specified. a, 
non-steroidal anti-inflammatory drugs by inhibiting both cyclooxygenase-1and 2; b, disease-
modifying antirheumatic drug, and in leflunomide, inhibits dihydroorotate dehydrogenase, a 
mitochondrial enzyme involved in de novo pyrimidine synthesis; c, Statins control 
cardiovascular complications by lowering cholesterol through inhibiting HMG-CoA reductase, 




Table 2. Summary of clinical evidence linking DILI with mitochondrial 
dysfunction 
 
Clinical evidence  
 
• Ultrastructural alterations in hepatocellular mitochondria (megamitochondria, 
swollen mitochondria, changes in cristae structure) 
• Delayed time to onset of overt DILI after drug administration (weeks to 
months), compatible with the threshold effect (accumulating but clinically 
silent mitochondrial injury) 
• Abrupt progression of DILI, in line with crossing a threshold at the point-of-no-return 
• Continued course of disease, in some severe cases despite discontinuation of drug 
administration, consistent with the concept of accumulation of an irreversible effect 
(e.g., mtDNA damage), rather than of the drug 
• Lactic acidosis (in severe cases, e.g. NRTI), as a result of liver mitochondria's failure 
to oxidize substrate 
• Symptoms accompanied by diarrhoea or rhabdomyolysis (rare), compatible with 
intestinal or striated muscle mitochondrial injury 
• Similar incidence (same order of magnitude) of mitochondrial abnormalities and 
DILI. For both conditions, the real number is probably higher 
• Age as a major risk factor for idiosyncratic DILI—both mtDNA abnormalities and 
oxidative injury increases with age 
• Estrogen protection against oxidative mitochondrial changes in skeletal muscle of 
young versus postmenopausal women, possibly in line with the increased 
preponderance of DILI in elderly women 
• Decreased activity of certain ETC complexes in susceptible DILI patients (e.g., 
valproic acid) has been documented as direct evidence 
• Genetic/acquired mitochondrial abnormalities in certain type 2 diabetes, Alzheimer, 
and Parkinson patient subsets have been consistently found. DILI has occurred in 
patients treated against these indications  
• In rare cases, mitochondrial mutations have been found in DILI patients 
Table taken from Toxicology and Applied Pharmacology (2007) 220: 92–107 
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Perhaps the most interesting clinical observation of idiosyncratic DILI is the 
higher occurrence in older women (Navarro & Senior, 2006), which is common across 
the heterogeneous variety of pharmacologically-unrelated drugs. While such information 
does suggest the convergence of estrogen as a cytoprotective hormone, it is difficult to 
elucidate any mechanisms in such diverse patient populations and drug types, and thus 
the scientific basis of this observation remains unanswered. However, experimental data 
suggest that estrogen and estradiol regulate mitochondrial function (Nilsen & Diaz 
Brinton, 2003, Stirone et al., 2005), increased expression of mitochondrial proteins 
(Nilsen et al., 2007) and enhanced mitochondrial antioxidant defence in the hippocampus 
(Nilsen, et al., 2007, Strehlow et al., 2003), neurons and vascular systems (Brinton, 2008, 
Duckles et al., 2006). Furthermore, a recent report has indicated that elderly 
postmenopausal women exhibited more significant markers of oxidative stress in muscle 
tissue than elderly men, suggesting a gender-differential mechanism in the redox 
regulation of aging muscles (Barreiro et al., 2006). However, the association of gender-
specific susceptibility, aging and estrogen-mediated mitochondrial liability to 
idiosyncratic DILI requires further investigation. 
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1.2.2. Mitochondria and idiosyncratic troglitazone DILI  
 
Continual usage of troglitazone was linked to cumulative risk of developing liver 
failure and this was not associated with diabetes (Figure 4) (Graham, et al., 2002). Type 2 
diabetes, which troglitazone was used to treat can arise from genetic mitochondrial 
dysfunctions in the OXPHOS or mitochondrial biogenesis (Mantena, et al., 2008, Mootha 
et al., 2003, Patti et al., 2003, Petersen, et al., 2004). These observations connotes that 
clinically latent, genetically acquired mitochondrial defects may be partially due to 
mtDNA heteroplasmy and could aid progression of troglitazone-induced hepatotoxicity.  
Experimental in vitro evidence demonstrated that troglitazone adversely affected a 
multitude of mitochondrial functions, such as (i) lowering of mitochondrial membrane 
potential (∆Ψm) and cellular ATP, (ii) inducing the mitochondrial outer membrane 
permeabilization (MOMP), (iii) enlargement of mitochondria with intramitochondrial 
myelin-like structures, (iv) elevation of H2O2, and O2•-, (v) uncoupling of State 2 and 
inhibition of State 3 respiration, (vi) inhibition of OXPHOS Complexes II + III, IV and V 
activities and sometimes (vii) inducing apoptosis (Lim et al., 2008, Masubuchi et al., 
2006, Nadanaciva et al., 2007, Shishido et al., 2003, Tirmenstein et al., 2002). 
Interestingly, troglitazone improved OXPHOS in patients with insulin resistance (Arioglu 
et al., 2000). However it is important to note that the doses of troglitazone used in these 
experiments are considerably several orders of magnitude higher (ranging from 50 to 150 
μM) than the therapeutic dose in humans. Furthermore, the cells were incubated with 
drugs in the absence of albumin, where albumin sequesters 95 to 99% of plasma 
troglitazone, thereby reducing the bioavailability (pharmacologically and toxicologically) 
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of the drug (Chojkier, 2005, Loi et al., 1999). Finally, some of the cell lines are 
transformed cell lines which make extrapolation to in vivo conditions unrealistic. Hence 
such information should be considered cautiously when interpreting and translating in 
vitro data to the more complex in vivo system. 
 
As noted earlier, mitochondria are sensitive to troglitazone exposure but 
mitochondrial dysfunction triggered by troglitazone alone is insufficient in explaining 
the idiosyncrasy of troglitazone-mediated liver injury. Rather, a “1st and 2nd hit” 
paradigm may explain why a small fraction of the patients seemingly suffer such sudden 
hepatic injuries while the rest does not develop overt liver injuries. In other words 
patients with underlying clinically silent mitochondrial abnormalities may be more 
predisposed to the mitochondrial toxic effects of troglitazone. This is more compatible 
with the idiosyncratic DILI nature of troglitazone toxicity. Such a model also explains 
the independence of correlation of drug dosage and toxicity in troglitazone and other 
idiosyncratic DILI incriminated with inflicting idiosyncratic DILI (Dykens & Will, 
2007). To summarize, a low degree of mitochondrial abnormality is insufficient to elicit 
any obvious phenotypic effects but provide a source for cumulative damage to act on, 
and by lowering the threshold required to maintain normal cellular functions. When this 
threshold is exceeded, presumably through overwhelming the system’s ability to 
mitigate exogenous stresses, there is a sudden, rapid onset of cellular and tissue injuries 
as shown in Figure 5.  
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Unfortunately, preclinical testing for mitochondrial toxicity has not gained wide 
acceptance in drug companies and is also hampered by a lack of an established suite of 
mitochondrial toxicity assays (Dykens & Will, 2007). Another complication is the 
difficulty in unmasking natural occurrences of uncommon genetic, silent mutations and 
toxicities during clinical trials. For instance, if a particular drug inflicts 0.1% of the 
patients, it will require more than 10000 patients in a Phase III clinical trial to even 
realistically uncover it. Therefore, outdated tools needs to be urgently replaced and it is 
incumbent for the innovative development and adoption of better tools for the rigorous 
identification of mitochondrial toxic drugs. In addition, the use of preclinical mutant 





Figure 4. Chart showing relationships between troglitazone exposure and risk of 
troglitazone-induced liver injury. 
Cumulative risk of liver failure in patients treated with troglitazone increases, together with 
decreases in the number of patients needed to harm, with longer durations of troglitazone 














Elderly? Post-menopausal females? 
Tolerance  
Threshold 
Figure 5. Clinically silent mitochondrial abnormality and threshold effect. 
Red circles represent hepatocytes with mitochondrial abnormality (due to heteroplasmy) that is silent but represents a susceptibility 
factor. This is observed in a small subset of individuals (second column from left), unlike the general populace (blue circles; left most 
column). Aged or post-menopausal women may also be more predisposed. Short-term exposure to the drug may result in a loss of 
hepatocytes but this is tolerated, given the regenerative abilities of the liver. However, with chronic drug exposure there is 
accumulating mitochondrial damage and hepatocytic death which upon crossing the tolerance threshold, triggers the abrupt progression 
of DILI. The number of cells needed to tolerate insults is indicated by the dash line.  
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1.3. Heterozygous Sod2+/- mouse  
 
During oxidative phosphorylation, it is inevitable that a small portion of the 
oxygen consumed within the ETC escapes to form superoxide anion (O2•-) as toxic by-
products of respiration. Approximately 0.4 to 4% of the oxygen is reduced to O2•- 
(Chance et al., 1979, Hansford et al., 1997) and it is generally accepted that the main sites 
of ROS production are Complex I and Complex III (Orrenius et al., 2007). In addition, 
Complex II which serves Complex I and III has been implicated in ROS genesis (Zhang 
et al., 1998). Therefore it has been suggested, and is widely accepted that the 
mitochondrion is the primary locus for free radical and other reactive oxidant species 
(ROS) generation. O2•- is a relatively short-lived species and is restricted to 
biomembranes, including the mitochondrial outer and inner membranes whereas H2O2 is 
freely diffusible. Although H2O2 reacts slowly with most biological molecules, its 
damaging effects stem from the production of hydroxyl radicals (•OH) via Fenton 
chemistry (Gutteridge & Halliwell, 2000). NO• is another poor oxidant but because it 
reacts with O2•- to form the highly reactive peroxynitrite (ONOO-) it is biologically 
important. ONOO- is a short-lived free radical formed from •NO and O2•- and is highly 
diffusible across biomembranes (Marla et al., 1997). In biological systems, ONOO- can 
react with carbon dioxide to form carbonate (CO3•-) and nitrogen dioxide (•NO2) radicals. 
There are clearly other secondary reactive products of ROS and RNS, but the 
physiologically more important ones (Winterbourn, 2008) and that are relevant to this 
study are O2•-, H2O2, •OH, CO3•-, •NO,  •NO2 and ONOO-  (Figure 6). Thus any further 








 Figure 6. Physiologically relevant ROS/RNS 
Most reactive free radical species that are physiologically important are featured in this figure. 
Although relatively poorer oxidants, hydrogen peroxide and nitric oxide (H2O2 and •NO) 
reacts readily with other oxidants, yielding other more biologically damaging ROS/RNS. 
Peroxynitrite chemistry is more complex, generating carbonate (CO3•-), nitrogen dioxide 
(•NO2) and hydroxyl (•OH) radicals. •OH has the highest oxidizing strength and can also be 
generated from H2O2 via Fenton chemistry with iron (Fe2+). Red, one-electron oxidants 
(radicals); blue, two-electron oxidants (non-radicals). Not included are hypochlorous acid 
(HOCI), phenoxyl radicals (PhO•) are produced from tyrosine and other phenolic metabolites 
and xenobiotics and gluthionyl radical (GS•) are generated from other thiols such as cysteine 
residues. Figure modified from Nature Chemical Biology (2008) 4: 278 - 286 
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To cope with the generation of ROS/RNS, cells have a pool of antioxidants to 
detoxify free radicals and maintain redox homeostasis, of which are three forms of 
superoxide dismutases (SOD) that are found in mammalian cells, viz., copper-zinc SOD 
(SOD1 or CuZnSOD), manganese SOD (SOD2 or MnSOD) and extracellular SOD 
(SOD3 or EcSOD). SOD2 is the predominant form of O2•- catalyzing enzyme within the 
mitochondrial matrix by dismutating O2•- (Equation 1). It should not be assumed that 
SOD-mediated dismutation of O2•- always lead to increased H2O2. This is because under 
different biological conditions, O2•- can be diverted to reactions generating ONOO- and/or 
oxidation of Fe-S clusters (which also produces H2O2 but is not a result of SOD 
detoxification of O2•-) (Winterbourn, 2008). Equations 2 and 3 show this.  
 
         (Eq. 1) 
           (Eq. 2) 
           (Eq. 3)  
 
While O2•- is a substrate of SOD2, this enzyme itself can be subjected to post-
translational modification via protein tyrosine nitration. Mass spectrometric analysis 
revealed that ONOO- reacts with the Mn center of SOD2, leading to its inactivation due 
to the nitration of Tyr34 which is critical for enzyme activity (Quijano et al., 2001, 
Yamakura et al., 1998). The inactivation of SOD2 would lead to an increase in O2•- and 
hence favour the formation of more ONOO-. Excessive ONOO- can then inhibit 
numerous mitochondrial proteins, including SOD2. This synergistic effect would in turn 
cause mitochondrial injury, initiating a vicious cycle leading to cellular demise (Brown & 
2O2•- + H+        H2O2 + O2 
SOD 
O2•- + •NO        ONOO- 
 
   O2•- + [4Fe-S]2+ + 2H+                              [4Fe-S]3+ + H2O2   
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Borutaite, 2002). The critical importance of this enzyme in maintaining mitochondrial 
redox status is highlighted by the early and high incidence of neo-natal and pre-natal 
fatalities in Sod2-null mice (Huang et al., 2001, Lebovitz et al., 1996, Li et al., 1995). 
This deleterious consequence of complete ablation of Sod2 gene indicated that the 
toxicity of the mitochondrial ROS is particularly deleterious to health. If the high and 
early incidence of death among Sod2-/- pups remained as technical limitations, then the 
exogenous, synthetic mimetics of SOD2 enzyme can be used to overcome such problems. 
The deleterious phenotypes of the Sod2 null mouse can be rescued and their life spans 
extended by pharmacological rescue of the SOD mimetic, Mn-TBAP and low molecular 
weight SOD and catalase mimetics, EUK8 and EUK189 (Doctrow et al., 2005, Melov et 
al., 2001). In contrast, HET mice do not share the same neo-natal fatal consequences as 
the homozygous knockouts and do not exhibit any gross phenotypic abnormalities. 
Therefore, their heterozygous mutations and intermediate phenotypes make them 
potentially valuable as murine models for studying the role of SOD2 in antioxidant 
protection and mitochondria-associated pathophysiological conditions. 
 
Mice lacking SOD2 enzyme have been generated in numerous genetic 
backgrounds (Table 3). Figure 7 shows the extensive research had been conducted using 
the Sod2 deficient mouse model for defining various oxidative stress-induced disorders 
including senescence, neurology, cardiology, ophthalmology, drug safety and oncology. 






Figure 7. Areas of research that utilizes the Sod2 mutant mouse. 
Both the heterozygous and homozygous Sod2 knock-out mouse model have been used in 
numerous scientific fields, namely aging, research, cardiology, drug safety assessment, 
hepatology, neurology, oncology and ophthalmology. Symbols represented: heat map, 
microarray studies; MS-spectrum, proteomics; -/-, studies using the Sod2-/- mouse; +/-, 
studies using the HET mouse 
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1.3.1. The utility of HET mouse in toxicological studies 
 
 
Idiosyncratic adverse drug reactions are inadvertently impossible to reproduce in 
vitro and usually slips detection during clinical testing (Dixit & Boelsterli, 2007). This 
problem is compounded by the fact that there are currently no ideal ‘normal’ animal 
models for the reproduction of idiosyncratic drug toxicity in the laboratory (Boelsterli, 
2003, Kaplowitz, 2005, Shenton et al., 2004). The impact of this is the huge economic, 
time and social loss associated with withdrawal of such normally-mild drugs (Figures 8 
and 9). The use of drugs at supra-therapeutic doses in healthy, laboratory animal during 
toxicity testing remains a question on the biological relevance to humans. There are 
genetic mouse models, for example, JNK-/- and ASK-/- mice used in the study of drug-
induced toxic effects of acetaminophen or doxorubicin-induced toxicity but they are 
limited to drugs with predictable or non-idiosyncratic toxic effects (Gunawan et al., 2006, 
Nakagawa et al., 2008, Oliveira & Wallace, 2006). Hence there is an urgent need for 
valid animal models to replicate the idiosyncratic DILI situation in humans for they are 
important and practical tools for drug safety assessments. A mutant murine model for 
drug toxicology research that has found application for the study of rare or idiosyncratic 
DILI is the HET mouse (Dykens & Will, 2007). The clinically silent phenotype of the 
HET mouse offers a novel alternative animal model to studying the mechanisms behind 




Figure 8. Change in investment of successful new drug launch over time.  
The Critical Path refers to the development process beyond the discovery phase and is the 
‘critical bottleneck’ to bring development of products into the clinic. Modified from Bain 
drug economics model, 2003 
 
 
Figure 9. Increase in cost, time and drug amounts with drug development 
progession 
Significant cost and time savings can be made if toxicity assessments are made earlier in 




Genetic mitochondrial abnormalities in the partial Sod2 knockout mouse generate 
a mitochondrial environment of cumulative endogenous ROS/RNS production which 
predisposes these mice to toxicants (Ong et al., 2007). They are morphologically normal 
but biochemically different from the WT mice, thus exhibiting a premature decline in 
mitochondrial functions and activities of some mitochondrial proteins including oxidative 
damage to mitochondrial biomolecules. For example, enzymatic assays revealed 
reductions in liver and heart mitochondrial aconitase and Complex I activities and 
increases in 8-OHdG levels in liver and skeletal muscle mtDNA (Mansouri et al., 2006, 
Van Remmen et al., 2001, Williams et al., 1998) (Table 3). The implication is that the 
chronic detrimental effect of cumulative oxidative stress over time can be simulated by 
sensitizing the HET mouse with mitochondria-targeting toxicants. The B6-Sod2tm1Leb+/- 
mouse has been shown to exhibit higher sensitivity towards the mitochondrial damaging 
effects of xenobiotics such as NSAID nimesulide, the nucleoside reverse transcriptase 
inhibitor stavudine or troglitazone and this aids in unmasking certain mechanistic 
pathways in rare drug-induced adverse reactions (Leitner et al., 2005, Ong et al., 2007, 
Ong et al., 2006). Thus the potentiality of this mouse model in toxicological studies has 
been demonstrated. 
 
 Various lines of evidence propose that genetic variability is an important genetic 
factor in the pathogenesis and increased risk of idiosyncratic DILI (Larrey & Pageaux, 
1997, Wilke et al., 2007). This is compatible with our hypothesis of acquired genetic 
mitochondrial abnormality as a risk factor for idiosyncratic DILI (Figure 5; also see 
above, Section 1.1.1 for discussion) and the low incidence of idiosyncratic reactions. It is 
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important to note that the Sod2 deficiency represents a generic model of mitochondrial 
abnormality for the testing of drugs with potential mitochondrial liabilities. For reasons 
stated in above (Section 1.2.2), it is attractive that at the preclinical stage, high-
throughput technologies, namely genomics, transcriptomics, proteomics and 
metabolomics can test and generate hypotheses at the global-scale of the impact of DILI-
causing drugs on biological systems such as the Sod2 mutant mouse. Information 
generated from such technologies may lead to the discovery of genetic risk factors that 
predispose certain groups of exposed patients to toxicants. Also, comparative studies can 
be performed using the different risk factors in large cohort of patients or animal models. 
At a time when drug-induced toxicities are a growing concern, the US. Food and 
Administration has initiated the Critical Path Activities to modernize the drug 
development process and drug safety evaluation, among which mechanisms underlying 
DILI and its prediction came under the priority topic of “Better Evaluation Tools” (FDA, 
2008, Hennessy & Strom, 2007). The use of proteomics on a mutant mouse model of 
acquired mitochondrial abnormality may therefore help to advance our understanding on 
the association of risk factors in the pathogenesis of idiosyncratic DILI. 
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Table 3. Summary of functional characterization studies in Sod2-/- and Sod2+/- 
deficient mice 
Abbreviations: Δψm, transmembrane potential; ACO1, cytosolic aconitase; ACO2, mitochondrial 
aconitase; AP-1, activator protein 1; CASP3, caspase-3; CATA, catalase; Cyt c; cytochrome c; 
GS, Glutamine synthase; GPX, glutathione peroxidise; HMG-CoA lyase, 3-hydroxy-3-
methylglutaryl CoA lyase; KDGH, ketoglutarate dehydrogenase; mPT, mitochondrial 
permeability transition; SOD1, CuZn Superoxide dismutase. † CD1-tm1Cje Sod2 mutant mouse 
produced on CD1 background. * B6D2F1-tm1Cje Sod2 mutant mouse generated from 
intercrossing C57BL/6J and DBA/2J. ‡ B6-tm1Cje Sod2 mutant mouse originally produced in 
CD1 strain but backcrossed to C57BL/6 background for 13-14 generations. # B6-Sod2tm1Leb 
Sod2 mutant mouse produced on C57BL/6 background. 
Genotype Strain Changes found Organ Reference 
Sod2-/- CD1-tm1Cje† Decreased  Complex I  
activity 
Brain, heart Melov et al., 1999, 
Hinerfeld et al., 2004 




Melov et al., 1999, 
Hinerfeld et al., 2004, 
Morten et al., 2006 
 CD1-tm1Cje,  
B6D2F1-
tm1Cje* 
Decreased ACO2 activity Brain, heart Melov et al., 1999, Lynn et 
al., 2005 
 CD1-tm1Cje Decreased  KGDH,  HMG-
CoA lyase activities 
Brain, liver Melov et al., 1999, 
Hinerfeld et al., 2004 
 CD1-tm1Cje Increased  mPT propensity Liver Kokoszka et al., 2001 
 B6D2F1-tm1Cje 
(5 days old) 
Increased  SOD1activity Brain, heart, lung, 
liver 
Huang et al., 2001 
 B6D2F1-tm1Cje 
(15 days old) 
Increased activity  (CATA, 
liver) 
Decreased activity (GPX,  
kidney & liver) 
Kidney, liver  Huang et al., 2001 
 D2- tm1Cje 
(5 days old) 
Increased SOD1 activity Heart Huang et al., 2001 
 D2-tm1Cje  
(5 days old) 
Increased activity (CATA) 
Decreased activity ( GPX) 
Kidney, liver Huang et al., 2001 
Sod2+/- B6-tm1Cje‡ Decreased  ACO2, Complex 
I, Complex V activities 
Liver, heart, 
skeletal muscle 
Williams et al., 1998, 
Mansouri et al., 2006, Van 
Remmen et al., 2001, Liang 
& Patel, 2004 
 B6-tm1Cje No change in  GS, ACO1, 






Williams et al., 1998,  
Van Remmen et al., 1999, 
Van Remmen et al., 2003 
 B6-tm1Cje,   
B6-tm1Leb #  
Increased  mitochondrial 
protein carbonyls 
Liver, skin Williams et al., 1998,  Zhao 
et al., 2002, Ong et al., 2006 
 B6-tm1Cje,   
CD1-tm1Cje 
Increased rate of  mPT 
induction 
Liver, heart Williams et al., 1998, 
Kokoszka et al., 2001, Van 
Remmen et al., 2001 
 CD1-tm1Cje Lowered  Δψm Liver Kokoszka et al., 2001 
 CD1-tm1Cje  
(20-25 mths old)  
Increased  Complex I, II, 
II+III, IV activities 
Liver Kokoszka et al., 2001 
 B6-tm1Cje Increased DNA binding 
activity 
Skin Zhao et al., 2002 
 B6-tm1Leb No change in Cyt c release,  
CASP3 activity  





Elucidation of gene-product function and regulation is a fundamental objective in 
biology. However the one gene-one product paradigm is out-dated, slow and luck-
dependent; hence systems-wide analyses have gained much interest recently. Profiling 
the genome and transcriptome can be readily done through the use of microarrays and 
sequencers. Yet, DNA and mRNA are proxy to proteins, the molecules truly reflecting a 
cell state. Aside from this, it is widely acknowledged that mRNA and protein abundance 
correlate modestly, or average at best (Kislinger et al., 2006). Therefore, proteomics 
bridges the gap between what is known at the genome level and what is translated and 
modified from the genome.  
 
Because proteins are biological molecules that directly related to physiological 
conditions, high-resolution proteomic technologies are in the best position to systemically 
probe complex biological systems and determine the roles of the protein complement in 
different biological states (Figure 10). Proteomics offers more complexity and potentially 
more specificity than examining genes and transcripts alone, fostering advances in 
understanding physiological and pathological conditions, development of biomarkers for 
diagnosis and prognosis of diseases, all for moving bench-top science to bed-side 




Figure 10. A schematic diagram of the level of complexity from genome to the 
proteome. 
The increase in complexity of biological molecules moving from genome to 
transcriptome to proteome level. The number of estimated analytes is in parentheses. 
Figure taken from Nature 451: 949 – 952. 
 
 
Proteomics can be broadly divided into three main platforms – (i) top-down 
approach which includes the classical two dimensional electrophoresis or 2DE, (ii) 
bottom-up approach, also known as shot-gun proteomics which encompasses chemical 
labelling and label-free mass-spectrometry-based proteomics and (iii) and protein-chip-
based arrays. There are advantages and disadvantages to both platforms and they are 
listed in Table 4. Due to the numerous facets of protein characteristics that make up a 
proteome, complementary proteomic technologies are believed to capture as much 
information as possible. The two main proteomics platforms used in this study will be 
discussed briefly. 
 
2DE is one of the central tools for proteomic analysis (Gorg et al., 2004). 
Separation of proteins is based first on isoelectric focusing (IEF) according to differences 
in net charge in the first dimension followed by molecular weight in the second 
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dimension using standard SDS-PAGE. Hundreds to thousands of proteins can be resolved 
on a single 2D gel that can then be identified by mass spectrometry (MS) and their 
relative abundances are determined. Hence, each well-resolved spot on a gel should, in 
principle, represent one protein species. A more recent technological innovation, two-
dimensional difference gel electrophoresis (2D-DIGE), incorporates the labelling of two 
pools of protein samples and an internal standard with fluorescent cyanine dyes (Cy2, 
Cy3 and Cy5) permitted the multiplexing of samples in a single 2D gel (Unlu et al., 
1997). The dyes are each composed of a peptide reactive group (N-hydroxysuccinimide 
ester; NHS) to derivitize the ε-amino groups of lysine residues. The molecular mass of 
each CyDye is approximately 450 Da and should not significantly alter the labelled 
proteins’ Mr, and even if they do, the labelled proteins should move in tandem. Therefore, 
the same protein found in both sample pools but labelled with different Cydyes will 
migrate to the same spot, minimising the gel-to-gel reproducibility problem of 
conventional 2DE gels.  Figure 11 shows a typical 2D-DIGE experimental setup. The gel 
can then be post-stained with silver (see Methods & Materials, sections 2.10 and 2.11 for 
further details) and the spot excised for protein identification (Figure 11). This 
multiplexing of samples in a single gel circumvents many technical limitations of 
conventional 2DE, including (i) improved intra and inter-gel reproducibility, (ii) a 
standard reference for eliminating experimental errors, (iii) less laborious, resource and 
time-saving by reducing the number of gels runs and (vi) increasing the confidence of 
spot quantification.  
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While conventional 2DE and 2D-DIGE have little problems identifying changes 
in the abundance of the hydrophilic proteins (for example, such as the mitochondrial 
matrix proteins, with respect to this study), membrane proteins are poorly resolved by the 
fact that many of these proteins precipitate at the basic end of the IEF strips (Eravci et al., 
2008, Hanson et al., 2001). Therefore, alternate protein separation techniques are required 
to define changes for membrane proteins. Shotgun or MS-based proteomics based on 
liquid chromatography (LC) separation is a gel-free method. It separates complex 
biological samples after proteolytic digestion and when combined with chemical labelling 
(such as isobaric Tag for Relative and Absolute Quantitation or iTRAQ™) allows the 
quantification of these peptides. In the multidimensional LC assay, which is more ideal 
for complex samples, a typical experiment involves the digestion of proteins into peptides 
prior to separation first by strong cation exchange, followed by C18 reversed-phase 
column chromatography. Multidimensional separation is useful in its orthogonal nature, 
defined as the lack of correlation between analyte retention in two modes (Slonecker et 
al., 1996), thereby increasing the coverage of peptides of different physiochemical 
characteristics. In other words, the separation mechanisms between the first and second 
LC dimensions should be as dissimilar (or correlated) as possible, analogous to the 
independence of right-angles in geometry. A strong-cation exchanger separates peptides 
based on their positive charges , that is, a stationary phase that contains ionic groups 
which interact with the cationic samples) while reversed-phase column separates on the 
basis of  hydrophobic differences, that is, the stationary phase is less polar than the 
mobile phase and the retention of samples is based on how polar (water-soluble) they are. 
This approach is termed Mulitdimensional Protein Identification Technology (MudPIT) 
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(Washburn et al., 2001), which is ideally suited for shotgun proteomics. The advantage of 
such an approach is that the resolved peptides from the C18 column can be directly 
introduced into a mass spectrometer. This is also known as online setup. In contrast, an 
offline 2D-LC setup allows less restriction on the compatibility of the mobile phase 
composition between the first and second LC dimension (Gilar et al., 2005, Peng et al., 
2003) while remaining fully automated. The flexibility offered by the offline 2D-LC 
setup is especially useful for this study, since the collected fractions cannot be injected 
directly in MALDI, but rather the collected fractions from the second dimensional 
separation can be evaporated or diluted and mixed with the matrix.   iTRAQ™ allows the 
multiplexing of four samples and recently, multiplexing up to eight samples is now 
possible (Wiese et al., 2007). Proteolytic peptides are chemically labelled with iTRAQ™ 
reagents of masses 113.1 – 119.1 Da and 121.1 Da. 120.1 Da was omitted to avoid 
contamination from phenylalanine immonium ion at m/z 120.08 (Pierce et al., 2008). 
Each label also exploits the NHS ester and an isobaric tag of 145 Da that consists of a 
balance group (carbonyl group) and a reporter group (based on N-methylpiperazine) via 
the formation of an amide bond. Due to the isobaric mass of the labels, digested peptides 
labelled with different iTRAQ™ channels do not differ in mass and appear as single 
peaks in MS scans. In  MS/MS fragment ion spectra of iTRAQ™ labelled peptides, 
additional peaks appear in the m/z range of 113 to 121, originating from the singly 
charged reporter group fragment of each iTRAQ™ label. Between the balance and the 
reporter group is a fragmentation site thereby liberating reporter ion as a neutral ion. The 
peptide reactive group attaches specifically to free primary amino groups – N-termini and 
ε-amino groups of lysine residues. Peptide quantification can be performed by 
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interpretation of these peaks. Using this approach, in combination with 2D-DIGE, 
changes in the expression levels of mitochondrial proteome that comprise the ETC 
complexes and others can be assessed. In summary, 2D-DIGE and iTRAQ™-coupled to 
LC enables the labelling and protein/peptide fractionation which can then be successfully 
detected and analyzed by Matrix-assisted laser desorption/ionization (MALDI). 
 38 
 
Table 4. Advantages and disadvantages of major proteomic platforms. 
 
Technique Advantages Disadvantages 
2D-DIGE1,3 Quantitative, retains information 
on pI and Mr and subsequently 
gives direct information on PTM. 
Because each resolved spot is in 
principle one protein, the 
information generated from this 
pool of peptides is often more 
reliable. 
Time-consuming technique, lack of 
automation for spot picking from gels, 
low throughput (~only 25–30 samples 
can be analysed per day). Biases 
against high- and low- molecular 
proteins and hydrophobic proteins 
MS-based 
proteomics2 
Excellent for differentially 
expressed proteins, measures the 
relative abundance of labelled 
peptides. Increased ability to 
detect hydrophobic proteins. 
Expensive equipment and processing 
costs. Proteins digested into peptides 
are generally not uniform and 
generates various redundant peptides 
which makes it a challenge for 




Extremely sensitive (femtomolar 
range), high throughput (more 
than 100 samples can be analysed 
per day). Less complicated to use, 
offers convenience to the clinics 
Not quantitative to semi-quantitative, 
antibodies used arrays are incomplete 
for entire protein complement, 
epitopes lie in different segments of a 
peptide and may not be represented on 
the array 
 
1, 2 The two platforms used in this study. 3 2D-DIGE is an improvement over the classical 
2DE for its ability to multiplex and increase in reproducibility which is one of the major 
technical concerns for 2DE. 2DE, two-dimensional gel electrophoresis; DIGE, 
differential gel electrophoresis; MS, mass spectrometry; pI, isoelectric point; Mr, 








Figure 11. Experimental setup of a typical 2D-DIGE experiment 
Protein extracted from biological samples (cells, medium, tissues) are labelled with Cydyes 
prior to 2D separation. The internal standard, labelled with Cy2 contains equal aliquots of 
the two sample pools. Spots that are detected to be differential on DIGE gels are matched 
with the post-stained gels, excised and identified by mass spectrometry.  
 40 




Toxicology focus on the study of adverse effects of chemicals on living 
organisms, and has traditionally been evaluated by the dosing of animals to measure their 
effects of chemicals and drugs on the cytology, physiology, metabolism, and 
morphology. Biochemical endpoints, histology and clinical chemistry have 
conventionally been used to assess the toxicity of exogenous stressors and in 
understanding the mechanisms by which these agents elicit their effects. Toxicology has 
progressively developed from studies predominantly based on individual chemicals to a 
knowledge-based science involving ‘omics’ and bioinformatics (Iannaccone, 2001). The 
effects of structurally and functionally similar agents can be characterized to a greater 
depth by assessing information of high-throughput data from databases. This will 
facilitate the rapid assessment of toxicant-related effects on diseases as well as gaining an 
understanding of the underlying mechanisms. 
 
In drug discovery and development, preclinical drug safety assessments typically 
involve low-to-intermediate throughput and sometimes high-throughput in vitro and in 
vivo toxicity testing (Kramer et al., 2007). As toxicity continues to be a primary cause for 
compound attrition and long development cycle times, drug companies in the past 5–10 
years have increasingly initiated and integrated new technologies for toxicity prediction 
(Walgren & Thompson, 2004). The rapid development of new drug candidates and 
subsequent screening for leads can be tightened and aligned by the use of high-
throughput technologies for the early selection of leads with acceptable safety profiles, 
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which in turn gives important information to continue or discontinue the development of 
drug candidates before entry into the more expensive clinical development. Increasingly, 
new technologies, such as ‘omics’, stem cells and mutant animals have emerged to 
interpret and reinforce information gleaned from the more traditional mechanistic 
toxicology studies, and possibly save time and resources to achieve higher drug safety 
(Heijne et al., 2005, Ulrich & Friend, 2002). In Singapore, pharmaceutical companies like 
Eli Lilly and Schering-Plough has set up research programs aimed at supporting drug 
discovery/development that harness novel technologies to guide drug safety assessment.  
 
One of the main goals of toxicoproteomics, besides the advancement of 
understanding of exogenous stressor associated with disease susceptibility and 
elucidating the mechanisms underlying toxicity is the identification of biomarkers of 
toxicity (Waters & Fostel, 2004). Biomarkers can be generally grouped into three major 
classes: diagnostic, prognostic, and predictive. The use of proteomics for predictive 
toxicity markers and toxicity profiling is especially informative given the simultaneous 
measure of a large number of proteins. Predictive markers can not only foretell the course 
of a drug-induced adverse effect but also help in understanding its route of toxicological 
mechanism. The larger implication will be the prediction and/or discerning of the type of 
toxicity judging from certain patterns of proteome changes. Toxicoproteomics can pave 
the way for reducing drug candidates with potential toxic effects by the early prediction 
of the modes of toxicity and managing the risks appropriately (Guengerich & 
MacDonald, 2007, Waters & Fostel, 2004, Wetmore & Merrick, 2004). Changes in the 
proteome profile induced by a candidate can be compared to profiles of known toxicants 
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and classified or discarded early in the development phase (Guengerich & MacDonald, 
2007). In addition, toxicoproteomics may provide the framework for the extrapolation of 
toxicological data between species (Aardema & MacGregor, 2002, Stierum et al., 2005). 
Another advantage of toxicoproteomics is the extrapolation of in vitro cytotoxicity results 
to in vivo toxic results at the molecular level (Aardema & MacGregor, 2002). The use of 
extant clinical data may also help to correlate laboratory model toxicity profiles with that 
of human toxicity profiles in a similar fashion. The contribution of numerous indirect and 
direct pathways that has been hypothesized from in vivo, in vitro and clinical data that 
could aggravate or lead to troglitazone-induced DILI can be better explored and even 
reconciled through the application of highly accurate and objective assays such as 
proteomics.  
 
Hitherto, one toxicoproteomic analysis of troglitazone-induced cytotoxicity has 
been described (Maniratanachote et al., 2005). Using 2D-DIGE analysis on HepG2 cells 
incubated with troglitazone versus similar doses of the less-toxic rosiglitazone, the 
authors showed that 78 kDa glucose-regulated protein (GRP78) and protein disulfide 
isomerase-related protein (ERp72) increased in a dose-dependent manner and suggested 
the involvement of chaperones in troglitazone-induced cytotoxicity (Maniratanachote, et 
al., 2005). However, such results have to be taken cautiously with the following 
considerations. The lethality of in vitro troglitazone toxicity depends very much on the 
dose and duration of the drug exposure to the cells. The dose used in the study was four 
to twenty fold greater than maximum plasma concentration (Cmax of 3.6 to 6.3 μM) 
achieved in humans after 7 days of troglitazone exposure (Loi et al., 1999). Further to this 
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is the non-reproducibility of troglitazone-induced idiosyncratic and delayed toxicity in 
the petri dish. Hence it is our objective to extract information from the proteome at doses 
that is therapeutically used and in a complex in vivo biological system, by achieving as 
much relevance as possible to the clinical manifestation of troglitazone-induced 
idiosyncratic DILI.  
 
Given the importance and complications of troglitazone mediation of 
mitochondrial dysfunction and its role and interplay with ROS / RNS production, our 
understanding of free radical-induced mitochondrial-associated pathologies can be 
advanced by studying protein expression dynamics under a genetically compromised 
condition. The mitochondrial abnormalities in the HET mutant mouse are associated with 
discreet mitochondria redox imbalance. This presents an interesting phenotype that is 
clinically silent, but represents a model for oxidative stress at the same time. Subtle yet 
chronic elevated production of endogenous free radical influences gene expression and 
post-translational modifications of proteins extensively (Bailey et al., 2005, Pryor et al., 
2006). Assessing such alterations on a global-scale has been facilitated by advances in 
proteomic technologies using gel and MS-based platforms (Hamdan & Righetti, 2002). 
So far limited proteomic studies have been performed on the Sod2 deficient mouse. 
Incidentally, and not surprisingly, published works have been directed at the analysis of 
the mitochondrial proteome where perturbations should occur most prominently at the 
site of free radical production and also where there is lowered antioxidant defence 
(Chang et al., 2004, Hinerfeld et al., 2004). From the standpoint of large-scale, global 
studies, using quantitative proteomics on HET mutant mouse will provide unbiased 
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information about the involvement of mitochondrial ROS on a proteome. Furthermore, 
the administration of drugs onto this susceptible mouse model can uncover the often 
obscure off-target (or toxic) ROS-inducing effects of drugs. In this sense, functional 
proteomics may help to illuminate the interaction of a proteome with a mitochondria-




The main aims of this study are three-fold –  
(1) To investigate to what degree is the HET hepatic mitoproteome different from the 
WT mouse. This will address its suitability as a preclinical surrogate model for 
assessing idiosyncratic DILI associated with discreet mitochondrial abnormalities.  
(2) Secondly, building on the hypothesis of acquired abnormal or dysfunctional 
mitochondria as a susceptibility factor of troglitazone-induced toxicity, 
toxicoproteomics will be employed to analyze the dynamics of mitochondrial 
proteome and more clearly define the mechanisms and time course of troglitazone 
hepatotoxicity in the HET mouse. 
(3) Finally, to understand the relationship between hepatic mitochondria oxidative 
stress on the mitoproteome and how it may lead to hepatic injury in the HET 
mouse. 
 
Specifically, the unique properties of the HET mutant mouse will be exploited. 
Integrating unbiased, sensitive and comprehensive quantitative proteomics with 
conventional toxicological endpoints will provide complementary views on the ensemble 
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of mitochondrial proteins in which the adverse effects manifested with chronic 
troglitazone exposure. This approach may aid in deriving new understanding of 










The cyanine dyes, Cy2, Cy3, and Cy5, and Immobiline pH gradient (IPG) strips 
and two-dimensional electrophoresis reagents were purchased from GE Healthcare 
(Uppsala, Sweden). iTRAQ™ reagents were purchased from Applied Biosystems (Foster 
City, CA, USA). All other chemicals were of the highest purity grade and were purchased 




Gene symbols are italicized and begin with an uppercase letter, followed by all 
lowercase letters. Protein symbols are at upper case and not italicized. Genes coded by 
the mitochondrial genome have a prefix “mt-”, lowercase mt followed by a hyphen.  
The WT allele of a gene is indicated by “+” as superscript to the gene symbol and the 
deficiency (due to knock-out or mutation) is denoted by “-” as superscript to the gene 
symbol. For example, a wildtype mouse carrying two copies of Sod2 alleles will be 
designated as WT, a heterozygous knock-out as HET (Sod2+/-) and a homozygous mutant 
as Sod2-/-.  
 
With regards to proteomics, in the context of 2DE, the terms “protein abundance” 
and “differentially modulated” are used to reflect the variations in protein levels, 
including transcription (up-regulation and down-regulation), post-translational 
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modifications, translocation, degradation, accumulation and trafficking (Cohen et al., 
2008, Godovac-Zimmermann et al., 2005, Nesvizhskii & Aebersold, 2005) that occur 
when proteomes are perturbed in various conditions especially. In contrast, the term 
“differentially expressed” is more tractable and suitable for describing detected protein 
from MS-based proteomics. 
 
2.3. Animals, drug treatment and experimental design 
 
All protocols involving animals were in compliance with the Institutional Animal 
Care and Use Committee, Singapore and in accordance with the guidelines of the 
National Advisory Committee for Laboratory Animal Care and Research, Singapore. 
Heterozygous Sod2tm1Leb/J mice (breeding pairs), congenic in the C57BL/6 background, 
were obtained from Jackson Laboratory (Bar Harbor, ME, USA). A breeding colony was 
established by crossing male HET with female WT mice. The F1 littermates were 
genotyped and subsequently used for the experiments. Genotyping of all mice was 
performed prior to weaning. The assays were performed by polymerase chain reaction 
(PCR) analysis according to the protocol provided by The Jackson Laboratory. Briefly, 
the DNA was extracted from a <4 mm tail piece using a DNA tissue kit (Promega, 
Madison, WI). PCR was performed with a Taq polymerase kit (Promega). The primers 
for the HPRT minigene (240 bp) were 5’-TgT TCT CCT CTT CCT CAT CTC C-3’, 
oIMR0781, and 5’-ACC CTT TCC AAA TCC TCA gC-3’, oIMR0782, synthesized by 
Research Biolabs (Singapore). As internal standard, the Sod1 gene was used; primers for 
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the 123 bp product were 5’-TgA ACC AgT TgT gTT gTC Agg-3’, and 5’-TCC ATC 
ACT ggT CAC Tag CC-3’. 
 
Three WT C57BL/6 mice and three HET mice, 8 weeks old at the start of the 
experiment were used in the mitoproteome characterisation. The studies were conducted 
with a small number of laboratory mice because the tight, constant environmental 
conditions and due to inbreeding implies that their genetic variation should remain low. 
Following the characterisation study, a total of 15 HET mice were doused with either 
solutol or troglitazone for the toxicoproteomic analysis. Troglitazone ((±)-5-[4-(6-
hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-thioazolidine-2,4-dione 
(Cayman Chemical, Ann Arbor, MI, USA) was dissolved in 9% (w/v) solutol HS-15 in 
phosphate buffered saline, a nontoxic solvent used for parenteral administration of water-
insoluble compounds. Solutol HS-15 (BASF, Ludwigshafen, Germany) is composed of 
polyglycol mono- and di-esters of 12-hydroxystearic acid and 30% free polyethylene 
glycol served as the vehicle control. All animals used in this study were females and 
between 8 weeks to 14 weeks old at the start of the experiments. All mice kept under 
specified pathogen-free (SPF) conditions under controlled environmental conditions 
(22±2ºC, 75±5% relative humidity, 12-12 hr dark-light cycle) and had free access to 
standard rodent chow (Specialty Feeds Pte Ltd, Glen Forrest, Australia) and water ad 
libitum.  
 
In the toxicological study, HET mice were randomly divided in four groups 
according to different treatments and duration of study. Groups 1 and 2 were injected 
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daily intraperitoneally with vehicle (10 μL/g body weight) or troglitazone (30 mg/kg 
body weight) for 14 days (assigned as VEH for vehicle administered mice and TRG for 
troglitazone administered mice, n = 3 per group). Groups 3 (n = 3) and 4 (n = 6) were 
injected intraperitoneally daily for 28 days (Table 5). In group 4, the allocation of six 
mice is to account for any unforeseen deaths from prolonged troglitazone administration 
(Ong et al., 2007). The troglitazone dose used here in mice is similar to the previously 
used therapeutic human dose (200 mg) (Loi, et al., 1999) if corrected for interspecies 
dose scaling factors (Kirman et al., 2005). Pharmacokinetic studies using UPLC-MS/MS 
showed that systemic exposure was also comparable to humans, as the plasma levels 
(Cmax) and systemic exposure (AUC) in mice after a single dose of 30 mg/kg troglitazone 
were approximately 20 μM and 18.1 mgh/L respectively (New et al., 2007 ). The 
intraperitoneal route was selected in an attempt to target the drug to the liver and to 
guarantee maximal absorption. After 14 or 28 days of treatment, the mice were 
anesthetized with pentobarbital (60 mg/kg). Immediately after necropsy, the liver was 
excised and weighed; one portion of liver sample for histopathological evaluation was 
fixed in 4% neutral buffered formalin, another portion lysed in lysis buffer consisting of 7 
M urea (USB, Cleveland, OH), 2 M thiourea (Fluka, Buchs, Switzerland), 4% (w/v) 
CHAPS (USB), 1 × Halt protease inhibitor cocktail (Pierce, Rockford, IL), 1 × PhosStop 
phosphatase inhibitor, 50 μg/mL DNase 1 and RNase A (Roche Applied Science, 
Mannheim, Germany) and the remaining used to prepare mitochondrial fractions. Blood 
was collected by cardiac puncture and serum prepared by allowing the blood allowed to 
stand at 25ºC for 30 min. After the blood has clotted, the tube was centrifuged at 1500 × 
g for 10 min at 20ºC and stored at 4ºC until further analysis.  
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Table 5. Experimental design of vehicle and drug-treatments of HET mice.  
Fifteen HET mice were randomly assigned to four groups administered with either 9% 
solutol or 30 mg/kg troglitazone. Two weeks study comprises groups 1 and 2; four weeks 
study comprises groups 3 and 4. 
 
 Vehicle-administered Troglitazone-administered 
2 weeks Group 1: Group 2: 
VEH1, 2, 3 TRG1, 2, 3 
4 weeks Group 3: Group 4 ‡: 
VEH4, 5, 6 TRG4¶, 5¶, 6¶, 7, 8, 9 
 
¶ Randomly-assigned troglitazone-treated mice used for proteomics analysis. 
‡ Larger sample size were used for the 4 weeks troglitazone-treated mice due to possible 
unforeseen deaths (Ong, et al., 2007). 
 
 
2.4. Assessment of liver injury 
 
Serum activity of ALT and AST was determined spectrophotometrically using 
Cobas Diagnoistics machine (Roche). For histopathological analysis, small pieces of liver 
were fixed in 4% phosphate-buffered formalin. The fixed tissues were subsequently 
processed with an automatic tissue processor (Leica TP 1020, Germany) and embedded 
in paraffin blocks. Tissue sections (2 - 5 μm) were stained with hematoxylin and eosin (H 
& E) and analyzed by light microscopy. 
 
2.5. Isolation of liver mitochondria 
 
All overnight food-deprieved mice were euthanized with CO2. At all stages of 
preparation 1% protease inhibitor (Roche Complete) was added and all procedures 
conducted at 4°C unless stated. Liver tissue were quickly removed and rinsed with two 
washes of ice-cold isolation buffer (20 mM Hepes, 10 mM KCl, 1.5 mM MgCl2, 1 mM 
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EDTA, 1 mM EGTA, 1 mM dithiothreitol (DTT) (Bio-Rad, Hercules, CA), 250 mM 
sucrose, pH 7.4). The washed livers were finely minced and homogenized with a Dounce 
homogenizer in 10 mL isolation buffer. Unbroken cells and cell debris were removed by 
centrifugation at 800 × g for 10 min. The resultant supernatant was centrifuged at 8,000 × 
g for 10 min. The crude mitochondria pellet (CM) were resuspended and washed twice in 
wash buffer (210 mM mannitol, 70 mM sucrose, 5 mM Hepes, 1 mM EGTA, pH 7.4), 
and centrifuged at 8,000 × g for 10 min. The supernatants from the first and second 8, 000 
× g spins were collected for western blotting and were designated S1 and S2 respectively. 
To remove the contamination by endoplasmic reticulum, lysosomes or peroxisomes, the 
enriched mitochondrial pellet was resuspended in 5 mL of wash buffer and gently layered 
onto a modified discontinuous Percoll (GE Healthcare) gradient (Meisinger et al., 2000). 
A Percoll gradient was generated in place of sucrose in 38.5 mL polycarbonate tubes. By 
carefully layering stepwise, the discontinuous Percoll gradient consists of 1.5 mL of 60%, 
4 mL of 32%, 1.5 mL of 23% and 1.5 mL of 15% (v/v) Percoll in wash buffer. Gradients 
were prepared on ice and used within 15 min of preparation. After centrifugation at 
134,000 × g, 1 h in a Beckman SW41 Ti70 fixed-bucket rotor the purified mitochondria 
were recovered from the 32/60% interface. The mitochondria were then diluted with 4 
volumes of wash buffer and sedimented at 12,000 × g. Thereafter the purified 
mitochondria (PM) were resuspended in lysis buffer, vortexed and sonicated. The 
suspension was centrifuged at 20,800 × g for 1.5 h at 15°C. Samples were stored at -80°C 
until use. Protein amount was determined using a modified Coomassie Plus protein assay 





Figure 12. Schematic of discontinuous Percoll gradient. 
The crude mitochondrial fraction (CM) is carefully layered onto a preformed 
discontinuous Percoll gradient (4ºC). This multi-step purification process resulted in 





2.6. Determination of mitochondrial GSH 
 
Mitochondrial glutathione (mGSH) was determined in isolated mitochondria 
using monochlorobimane (MCB) as fluorochrome. MCB features a high selectivity for 
GSH and is conjugated to GSH by a glutathione-S-transferase (GST)–catalyzed reaction. 
Mitochondrial samples were incubated with MCB for 1 hr at 37ºC. The fluorescence was 
determined at 380/460 nm, and GSH levels were calculated from a standard curve formed 










2.7. Determination of nitrite/nitrate levels 
 
NO production was indirectly determined by measuring liver homogenate total 
nitrate/ nitrite (NOx-) levels with a fluorometric assay kit (Cayman Chemical, Ann 
Harbor, MI). Samples were ultra-filtered through a 10 kDa molecular weight cut-off 
centrifugal filter (Millipore, MA, USA) prior to the assay. Briefly, 20 μL of samples were 
incubated for 2 hr with nitrate reductase to convert nitrate to nitrite, followed by the 
addition of 2, 3-diaminonaphthalene and sodium hydroxide to enhance fluorescence. 
Fluorescence was measured using a fluorometer at excitation wavelengths of 365 nm and 
emission wavelengths of 430 nm.  
 
2.8. Detection of total mitochondrial protein carbonyls and 3-nitrotyrosine 
adducts 
 
To detect and quantify irreversible oxidative modification of total mitochondrial 
proteins, a protein carbonyl ELISA (Cell Biolab, San Diego, CA, USA) was used for its 
higher sensitivity and discrimination than the colorimetric assay (Buss et al., 1997) and 
according to the manufacturer’s instructions. Briefly, the samples were compared with a 
standard curve generated from predetermined reduced and oxidized BSA standards. This 
assay was adapted from a protocol described by Buss and co-workers (Buss, et al., 1997) 
and subsequently modified for smaller sample volumes (Alamdari et al., 2005).  
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All samples were adjusted to 10 μg/mL protein concentration and incubated 
overnight in wells of a Nunc Maxisorp immunoplate (Nalge Nunc International) at 4°C. 
Similarly, reduced/oxidized BSA standards were incubated overnight. The samples and 
standards were washed three times with 1 × PBS and derivatized with 0.04 mg/mL 
DNPH diluted in 2 M HCl for 45 minutes at room temperature in the dark, and were 
subsequently washed 5 times with PBS: ethanol (1:1 v/v) and twice with PBS. The wells 
were blocked with 5 % BSA in 1 × PBS for 1.5 hour at room temperature and washed 
thrice with 1 × wash solution (100 mM Tris, pH 7.5, 1.5 M NaCl, 0.5% Tween-20 
containing 0.02% thimerosal). Thereafter rabbit anti-DNP antibody (1: 1000) in 5% 
blocking solution was added to each well for 1 hour followed by HRP conjugated goat 
anti-rabbit secondary antibody (1: 1000) for another 1 hour and finally washed thrice 
with wash solution. The chromogen substrate, 3,3,5,5-tetramethylbenzidine (TMB) was 
added and incubated for 15 min at room temperature and the reaction stopped by adding 
0.5 M H2SO4. Absorbance was quickly measured at 450 nm. Carbonyl content was 
expressed as nmol/mg protein using a fully reduced BSA standard as absorbance blank 
(Reznick & Packer, 1994). To quantify 3-nitrotyrosine (3-NT) levels, sandwich-based 
ELISA was used (Kamiya Biomedical, Seattle, WA). Diluted samples (20 × dilution) 
were pipetted into anti-nitrotyrosine coated wells, incubated with biotinylated second 
antibody for 1 hour. The wells were then flushed 4 times with wash solution, followed by 
streptavidin-peroxidase conjugate substrate for 1 hour before washing again with wash 
solution (4 times). Finally TMB was added to the wells for 30 min and the colour 
developed proportionally to the amount of 3-NT present in the sample.The enzyme 
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reaction was stopped by the addition of citric and absorbance was finally measured at 450 
nm. 3-NT levels were expressed as nmol/mg protein using a calibration curve.  
 
2.9. Two-dimensional Difference Gel Electrophoresis 
 
2.9.1. Labelling with cyanine dyes 
 
To prepare for CyDye labeling, 50 mM sodium hydroxide was first added to 
adjust the samples to pH 8.5. In the characterisation study, mitochondrial protein samples 
(40 μg) from WT and HET mice were labelled separately with 320 pmol Cy3 and Cy5, 
respectively (Table 6), and incubated for 30 min in the dark. An internal standard 
consisting of a mix of equal amounts of mitochondrial proteins from all WT and HET 
animals was prepared by labelling with Cy2. After 30 min, the labelling was stopped with 
10 mM lysine. To check for labelling efficiency, 1.5 μg and 3 μg labelled proteins were 
subjected to 1D SDS-PAGE analysis, and the gels were scanned with a Typhoon 9400 
scanner (GE Healthcare) at the wavelengths corresponding to Cy3 (532 nm). The same 
gel was stained after scanning to check for equal loading after pH adjustment.  
 
In the toxicological study, 40 μg mitochondrial proteins from vehicle-
administered and troglitazone-treated HET mice were labelled with 320 pmol Cy3 and 
Cy5, respectively (Table 7). An internal standard was generated using equal portions 
(3.33 μg) of all 12 samples and labelled with Cy2. Subsequent steps were followed 
essentially the same as above. 
 56 
Table 6. Gel setup for 2D-DIGE experiments for HET hepatic mitochondrial 
proteome characterisation.  
For each sample pair, there were duplicate gels and a dye swap for the third. 
 
 Cy2 standard Cy3 Cy5 
Gel 1 – 2  WT1 HET 1 
Gel 3 (Dye swap)  HET 1 WT1 
Gel 4 - 5 Pooled WT1-3, WT2 HET 2 
Gel 6 (Dye swap) HET 1-3 HET 2 WT2 
Gel 7 - 8  WT3 HET 3 




Table 7. Gel setup for 2D-DIGE experiments for analysis of troglitazone-induced 
changes in HET hepatic mitochondrial proteome.  
VEH1 - 3, HET mice dosed with solutol (9%/day. i.p. for 2 weeks) and TRG1 - 3, HET 
mice dosed with troglitazone (30 mg/kg/day, i.p. for 2 weeks).  VEH4 - 6, HET mice 
dosed with solutol (9%/day. i.p. for 4 weeks) and TRG4 -6, HET mice dosed with 
troglitazone (30 mg/kg/day, i.p. for 4 weeks). For each sample pair, there were duplicate 
gels and a dye swap for the third. 
 
 Cy2 standard Cy3 Cy5 
Gel 1 – 2  VEH1 TRG 1 
Gel 3 (Dye swap)  TRG 1 VEH 1 
Gel 4 - 5  VEH 2 TRG 2 
Gel 6 (Dye swap)  TRG 2 VEH 2 
Gel 7 - 8  VEH 3 TRG 3 
Gel 9 (Dye swap) Pooled VEH1-3, 
TRG1-3, 
TRG 3 VEH 3 
Gel 10 – 11 VEH4-6, TRG4-6 VEH 4 TRG 4 
Gel 12 (Dye swap)  TRG 4 VEH 4 
Gel 13 – 14  VEH 5 TRG 5 
Gel 15 (Dye swap)  TRG 5 VEH 5 
Gel 16 – 17  VEH 6 TRG 6 
Gel 18 (Dye swap)  TRG 6 VEH 6 
 57 
2.9.2. Isoelectric focusing and two-dimensional gel electrophoresis 
 
Isoelectric focusing was conducted as described (Lee et al., 2008a). Briefly, a 40 
μg portion of each Cy3-, Cy5- or Cy2- labelled samples were combined and subjected to 
isoelectric focusing using an IPGphor isoelectric focusing unit (GE Healthcare). IPG 
strips were rehydrated overnight using rehydration buffer, consisting of 7 M urea, 2 M 
thiourea, 4% (w/v) CHAPS, 2 M DTT, 0.2% (v/v) pH 3-10 non-linear (NL) IPG buffer or 
pH 3-11 NL IPG buffer, trace amounts of bromophenol blue (Merck). IPG strips used 
were 18 cm, pH 3-10 NL for drug-treatment study and pH 3-11 NL for mitochondrial 
proteome characterization. For analytical gels, approximately 50 µg of sample was 
loaded into the strip using the cup-loading method. The rehydrated strips were subjected 
to focusing at 200 V for 400 Vh, 500 V for 250 Vh, 1 kV for 500 Vh, gradient ramp from 
1 kV to 8 kV for 2250 Vh, 8 kV for 36 kVh at 20°C at a maximum of 50 µA per strip. 
 
Equilibration of strips was done prior to SDS-PAGE gel electrophoresis as 
described (Lee, et al., 2008a). Briefly, the strips were equilibrated for 15 min in 
equilibration buffer, consisting of 6 M urea, 50 mM Tris-Cl, 30% (v/v) glycerol, 2% 
(w/v) SDS, 1% (w/v) DTT, trace of bromophenol blue, pH 6.8, then re-equilibrated for 
15 min in the same equilibration buffer containing 2.5% iodoacetamide (Fluka, Buchs, 
Switzerland), pH 8.8 in place of DTT pH 6.8. Subsequently, for characterization studies 
the equilibrated strips were loaded onto a 13% Laemmli SDS-PAGE polyacrylamide gel 
(20 × 20 cm) using a Protean II XL (Bio-Rad) cell and ran at 10°C, 15 mA per gel, for 20 
min followed by 30 mA per gel. To observe differential protein modulation in high to 
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moderate molecular weights proteins, 11% SDS-PAGE polyacrylamide gels were used in 
the troglitazone-treated studies. Duplicate gels were run per study group. To avoid Cy3- 
or Cy5-specific effects, a dye swap was run for a third gel. 
 
2.10. Image visualization and analysis 
 
Fluorescent images of the 2D DIGE gels were obtained using a Typhoon Variable 
Mode Imager 9410 (GE Healthcare). Determination of protein spot abundance and 
analysis of the 2D DIGE gels were performed using DeCyder v5.02 software (GE 
Healthcare) as described in the Ettan DIGE User Manual. Normalization and quantitative 
profiling of proteins in the 2-DE gels were performed using the Differential In-gel 
Analysis (DIA) module and Biological Variance Analysis (BVA) module of the DeCyder 
software. The spots were also manually screened to ensure correct matching across gels. 
For the first DIGE experiment, significant alteration in ratio relative to WT mouse was 
defined as equal or more than a 1.5-fold (≥ 1.5 or 33.3%) difference in spots that were 
present in at least 6 of the 9 gels run for each experiment. For the second DIGE 
experiment, significant alteration in ratio relative to vehicle-dosed HET mouse was 
defined as ≥ 1.45-fold (31%) difference in spots that were present in all gels run for the 
troglitazone study. The fold change criterion was lowered to expand on the possibility of 
capturing proteins that may fit into a particular pathway. Student’s t-test at 99% statistical 
confidence (P < 0.01) was set for both experiments. A 1% false discovery rate was 
applied in the BVA module to control false positives. Together they increase the 
stringency of matching gel spots and lower variability of gels, thereby generating high 
 59 
statistical confidence of the proteomic data. For visualization,  gels were silver-stained 
using the Vorum protocol (Mortz et al., 2001) and followed by in-gel tryptic digestion of 
the selected spots.  
 
2.11. Protein identification by MALDI-TOF/TOF MS/MS 
 
Gel pieces were excised from silver stained 2D-DIGE gels and washed twice with 
150 μL of 2.5 mM NH4HCO3 in 50% v/v acetonitrile (ACN) and incubated at 37°C for 
15 min. After drying, gel pieces underwent reduction with 10 mM DTT for 1 h at 56°C 
with constant shaking. This was followed by alkylation with 55 mM IAA for 45 min at 
room temperature in the dark. Trypsin (Promega) in 25 mM NH4HCO3. Five μg/μL was 
added to intense spots, while 2.5 μg/μL trypsin was added to faint spots, and incubated at 
37°C for 16 h. Upon sonication, peptides were extracted in 20 μL 0.1% v/v trifluoroacetic 
acid (TFA) in 50% ACN and dried in a speedvac evaporator. Peptide digests from each 
gel spot were spotted onto a 100-well MALDI sample plate and mixed with an equal 
volume of CHCA matrix solution (5 mg/mL α−cyano-4-hydroxy-cinnamic acid in 0.1% 
TFA, 50% ACN). MS and MS/MS spectra were obtained using the ABI 4800 Proteomics 
Analyzer MALDI-TOF/TOF Mass Spectrometer (Applied Biosystems) operating in a 
result-dependent acquisition mode. For MS analysis, 2,000 shots were accumulated for 
each well of sample. Peptide digests from each gel spot were spotted onto a 384-well 
MALDI sample plate and mixed with an equal volume of CHCA matrix solution (5 
mg/mL α−cyano-4-hydroxy-cinnamic acid in 0.1% TFA, 50% ACN). MS and MS/MS 
spectra were obtained using the ABI 4800 Proteomics Analyzer MALDI-TOF/TOF Mass 
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Spectrometer (Applied Biosystems) operating in a result-dependent acquisition mode. For 
MS analysis, 2,000 shots were accumulated for each well of sample.  Six external 
standards (mass standard kit for the 4700 Proteomics Analyzer, Applied Biosystems) 
were used to calibrate each spectrum to a mass accuracy within 50 ppm.  Peaks were 
detected without smoothing.  Peaks were deisotoped and only the peaks with s/n ≥ 10 
were submitted for database search.  Common keratin contamination peaks (804.4097, 
973.5313, 1179.6, 1234.68, 1320.583, 1475.785, 1707.773, 1791.728, 1993.977, 
2705.161) and trypsin autolytic peaks (842.51, 1045.56, 1940.95, 2211.10, 2225.12, 
2239.13, 2283.18, 2299.17, 2807.30) were excluded with a mass tolerance of 200 ppm.  
Peak density filter was implemented with a limit of 50 peaks per 200 Da, and the 
maximum number of peaks was set to 65.  The ten most intense ions from each sample 
excluding trypsin autolytic and keratin tryptic peptides were selected for MS/MS. The 
MS/MS analyses were performed at collision energy of 2 kV and a collision gas pressure 
~ 1 × 10-6 Torr, using air as the collision gas. Stop conditions were implemented so that 
2,000 to 3,000 shots were accumulated depending on the quality of the spectra.  No 
smoothing was applied before peak detection.  Only the peaks from 60 Da to 20 Da 
below each precursor mass, and with s/n ≥ 10 were picked.  Peak density was limited to 
30 peaks per 200 Da, and the maximum number of peaks was set to 125.  GPS explorerTM 
software Version 3.6 (Applied Biosystems) was used to create and search files with 
MASCOT search engine (Version 2.1; Matrix Science) for peptide and protein 
identification.  Both MS and MS/MS spectra were combined for database search.  
International Protein Index (IPI) (Kersey et al., 2004) mouse database Version 3.23 
(51536 entries) or Version 3.25 (52407 entries) was used for the search and was restricted 
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to tryptic peptides. N-terminal acetylation, cysteine carbamidomethylation, and 
methionine oxidation were selected as variable modifications. One missing cleavage was 
allowed. Peptide mass tolerance and fragment mass tolerance were set at 150 ppm and 
0.4 Da, respectively. Maximum peptide rank was set to 2 and the minimum ion score C. 
I. % (peptide) was set to 50.  Expectation values for protein and best peptide 
identification were ≤ 0.0.5 except for ECHM, 3HIDH and HMCS2 (expectation values 
can be found in Appendix). If more than one database entries were matched to the same 
set of MS data, the entry first entered on the database was reported in the table with the 
exception of 3HIDH / HMCS2.  
 
2.12. iTRAQ™ labelling  
 
Labelling of samples was performed according to manufacturer’s protocols 
(Applied Biosystems). This study comprised of two iTRAQ™ experiments done in 
duplicates, the 4-plex system for the heterozygous versus WT mouse comparison study 
and the 8-plex system for the toxicological study (Figure 13).  
 
4-plex iTRAQ™ labelling was performed as followed: iTRAQ™ label reagents 
114 and 116 (1st replicate) – a pool of three WT mice and iTRAQ™ label reagents 115 
and 117 (2nd replicate) – a pool of three HET mice. Duplication provided two advantages, 
firstly to eliminate label reagent-specific bias and secondly, to ensure quantification 
reproducibility. After extraction and purification of the mitochondrial proteins, the 
samples were precipitated using the 2D-clean up kit (GE Healthcare) and reconstituted in 
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0.5 M triethylammonium bicarbonate, 1.0% SDS (w/v). A total of 90 μg hepatic 
mitochondrial proteins, comprising of a pool of 30 μg portions from the 3 mice of each 
genotype were reduced, alkylated and digested. Following this, the samples were 
incubated with their corresponding labels for 1 h. The four labelled samples were then 
combined and pass through a strong cation exchange cartridge (Applied Biosystems) and 
the eluate desalted via a SepPak cartridge (Millipore). The iTRAQ™-labelled mixture 
was then vacuum dried and stored at -80°C until further use.  
 
8-plex iTRAQ™ labelling was also performed according to manufacturer’s 
instructions. With the exception of 50 μL isopropanol and the additional labels, the rest of 
the protocol remains the same as the 4-plex system. Similarly, the experimental design 
consists of two technical replicates. For the 2-weeks study, the vehicle-dosed mice 
(Groups 1 and 2) were labelled with iTRAQ™ label reagents 113 and 115 (replicate) and 
troglitazone-treated mice with reagents 114 and 116 (replicate). For the 4-weeks study, 
the vehicle-dosed mice (Groups 3 and 4) were labelled with iTRAQ™ label reagents 117 
and 119 (replicate) and troglitazone-treated mice with reagents 118 and 121 (replicate). A 
schematic diagram of the experimental design can be found in Figure 13B. 
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Figure 13. A flow-chart summary of the iTRAQ™ experiment design of 4-plex and 8-plex systems.  
(A) The quantification of proteins differentially expressed in the WT and HET hepatic mitochondria using 4-plex 
iTRAQ™. (B) Quantitative shotgun proteomics using 8-plex iTRAQ™ to elucidate and identify mitoproteome 
dynamics over two periods of daily vehicle (VEH) or troglitazone (TRG) dosing. See text for details to experimental 
design. NC, no change; NS, not significant; S, significant; SCX, strong cation exchange; RP, reverse phase. 
A B 
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2.12.1. Two-dimensional Liquid Chromatography-MS/MS of iTRAQ™ samples 
 
Each of the iTRAQ™-labeled peptide mixtures was separated using an 
Ultimate™ dual gradient LC system (Dionex-LC Packings) equipped with a Probot™ 
MALDI spotting device. A 2D-LC separation was performed as follows. The labeled 
peptide mixture was dissolved in 2% ACN with 0.05% TFA and injected into a 0.3 × 
150-mm strong cation exchange column (SCX300 Å, NanoEase Trap Column 0.50 × 47 
mm; Waters) for the first dimensional separation. The flow rate was 6 μL/min. Five 
fractions were obtained using step gradients of Mobile phase B (5 mM KH2PO4 buffer, 
5% ACN, 125 mM KCl, pH3) for the HET comparative study: unbound, 0–17, 17–26, 
26–36, 36–50, 50–100% and eight fractions for the toxicoproteomics study were obtained 
using step gradients of Mobile phase B: unbound, 0–10, 10–20, 20–40, 40–50, 50–75, 
75–100 and 100% of Mobile C (5 mM KH2PO4 buffer, pH 3, 5% ACN, 500 mM KCl). 
Mobile A was 5 mM KH2PO4 buffer, 5% ACN, pH 3. The eluting fractions were 
captured alternatively onto two 0.18 × 23.5 mm trap columns (5 μm C18 Symmetry 300; 
Waters) and washed with 0.05% TFA followed by gradient elution in a 300 μm × 150 
mm reverse phase column (Symmetry C18; Waters). The mobile phases used for this 
second dimensional separation were 2% ACN with 0.05% TFA (A) and 100% ACN with 
0.04% TFA (B). The gradient elution step was 0–45% B in 40 min at a flow rate of 2.7 
μL/min. The LC fractions were mixed directly with MALDI matrix solution (7 mg/ml α-
cyano-4-hydroxycinnamic acid and 130 μg/mL ammonium citrate in 75% ACN) at a flow 
rate of 5.4 μL /min via a 25-nL mixing tee (Upchurch Scientific) before they were spotted 
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onto a 192-well stainless steel MALDI target plate (Applied Biosystems) using a Probot 
Micro Precision Fraction Collector (Dionex-LC Packings) at a speed of 5 s/well.  
 
2.12.2. Mass Spectrometry for iTRAQ™ 
 
The samples on the MALDI target plates were analyzed using a 4700 Proteomics 
Analyzer mass spectrometer (Applied Biosystems). MS/MS analyses were performed 
using nitrogen at a collision energy of 1 kV and a collision gas pressure of 1 × 10-6 torr. 
One thousand shots were accumulated for each MS spectrum. For MS/MS, 6,000 shots 
were combined for each precursor ion with signal to noise (S/N) ratio greater or equal to 
100. For precursors with S/N ratio between 50 and 100, 10,000 shots were acquired. The 
resolution used to select the parent ion was 200. No smoothing was applied before peak 
detection for both MS and MS/MS, and the peaks were deisotoped. For MS/MS, only the 
peaks from 60 to 20 Da below each precursor mass and with S/N ≥ 10 were selected. 
Peak density was limited to 30 peaks per 200 Da, and the maximum number of peaks was 
set to 125. Cysteine methanethiolation, N-terminal iTRAQ™ labeling, and iTRAQ™ 
labeled lysine were selected as fixed modifications; methionine oxidation was considered 
as a variable modification. One missed cleavage was allowed. Precursor error tolerance 
was set to 100 ppm; MS/MS fragment error tolerance was set to 0.4 Da. Maximum 







In order to show mitochondrial enrichment during the isolation process, 
immunoblot analysis was performed using standard methods. Polyvinylidene difluoride 
membrane blots (PVDF, Bio-Rad) were developed with primary antibodies directed 
against either cytochrome oxidase subunit IV or COX IV (Molecular Probes, Invitrogen, 
CA, USA) or SOD2 (Abcam, Cambridge, UK). Blots were incubated against antibodies 
in 0.1% Tween 20 (Duchefa, Netherlands), 5% blocking non-fat milk (Bio-Rad) in PBST 
(20 mM Tris, 150 mM NaCl, pH7.5, 0.2% Tween 20) or 2.5% BSA in TBST. Primary 
antibodies were incubated overnight at 4°C, while secondary antibodies were incubated 
for 1 h at room temperature. Primary antibody binding was visualized utilizing 
horseradish peroxidase-conjugated secondary antibody and appropriate chemiluminescent 
substrate (ECL or ECL plus, GE Healthcare, Uppsala, Sweden). All quantifications were 
done by scanning the blots with a GS-800 densitometer (Bio-Rad). COX IV was used as 
a loading control. 
 
To validate the mass spectrometry results in HET mitoproteome profiling, a range 
of mitochondrial antibodies were selected with respect to their molecular weights and 
sub-mitochondrial localizations via 1D or 2D immunoblotting. Antibodies against 
NDUFS3 (MitoSciences, Invitrogen), COX IV, succinate dehydrogenase [Fe-S] subunit 
(Molecular Probes, Invitrogen), medium-chain acyl-CoA dehydrogenase (ACADM), 
methionine sulfoxide reductase, SOD2, thiosulfate sulfurtransferase, hydroxyacyl-
coenzyme A dehydrogenase, (Abcam) and cytochrome c (BD Pharmingen, San Jose, CA) 
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were used. In 2D-immunoblots, 20 μg of mitochondrial proteins were separated on first 
dimension using 7-cm IPG strips (pH3-10 non-linear), followed by second dimension 
separation on 13% polyacrylamide minigels and subsequently incubated with antibodies 
against SOD1 (Santa Cruz Biotechnology), SOD2 or GPX1 (Abcam). 2D-PAGE 
immunoblotting was also performed to ascertain that aconitase-2 (Abnova) and 
thioredoxin-2 (Abcam) were not altered in their abundance levels in the HET mouse.  
 
For the toxicological studies, equal amounts of mitochondrial protein (5 μg) were 
loaded onto acrylamide gels, resolved, transferred to PVDF and incubated with primary 
antibodies directed against LAMP-1 (Santa Cruz Biotechnology), calnexin (Chemicon), 
PEX-19 (Santa Cruz Biotechnology), or cytochrome c oxidase subunit IV (Molecular 
Probes, Invitrogen) to demonstrate the level of purity of the mitochondrial fractions. As a 
confirmatory step to our mass spectrometry results, we performed 1D and 2D-
immunoblotting (pH3-10 non-linear and pH6-11 linear; 11% and 14% gels respectively) 
as above. Antibodies against ACO2 (Abnova), ornithine transcarboxylase, medium-chain 
specific acyl-CoA dehydrogenase, methionine sulfoxide reductase, SOD2, thiosulfate 
sulfurtransferase, hydroxyacyl-coenzyme A dehydrogenase, (Abcam), VDAC1 
(Calbiochem, CA, USA), NDUFS3 (MitoSciences, Invitrogen), cytochrome c oxidase 
subunit IV, succinate dehydrogenase [Fe-S] subunit (Invitrogen), cytochrome c (BD 
Pharmingen, San Jose, CA, USA) in 5% non-fat milk or 2.5% BSA in TBST. Total 
cytochrome c levels were determined from liver extracts.  
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To detect activation of MAPK and AKT signalling cascade, liver lysates were 
immunoblotted. Equal amounts of proteins were separated and subjected to 
immunblotting with antibodies as follows. Antibodies specific for ASK1, phospho-
ASK1Serine 83, phospho-ASK1Threonine 845, JNK, phospho-JNKThreonine183/Tyrosine185, p38 
MAPK, phospho-p38 MAPKThreonine180/Tyrosine182, AKT, phosphor-AKTSerine 473 (Cell 
Signaling Technology, Beverly, MA) and visualized using peroxidase-conjugated 
secondary antibodies and advanced chemiluminescence (GE Healthcare). To assess the 
transcriptional regulatory circuits leading to expression of mitochondria gene products, 
liver lysates were immunoblotted using antibodies against NRF-1, ERRα, (Abcam), 
PGC-1β (Santa Cruz Biotechnology), PGC-1α (Aviva Systems Biology, San Diego, CA), 
PPARγ, pFOXO3aSerine 253 and FOXO3a (Cell Signalling Technology) to check for levels 
and/or activation of such transcription factors or transcriptional co-activators. 
 
All blots were checked for equal loading by post-colloidal silver staining. After 
development with chemiluminescent substrate, the membrane blots were washed with 
three times with fresh changes of ddH2O and rocked with colloidal silver solution (40% 
NaNO3, 20% FeSO4, 20% AgNO3; w/v) for 15 to 30 min until the colour develop. The 
colloidal silver solution was discarded and the membrane washed with ddH2O for 15 min 






2.14. Aconitase-2 aggregation and degradation study 
 
Polyclonal antibodies against residues 767 to 780 of the C-terminus of aconitase 2 
(ACO2) were raised in rabbits (generously provided by Dr. Bi Xuezhi, National 
University of Singapore, Singapore) and cross-reacted with murine aconitase 2 (Bota et 
al., 2002). This antibody recognises murine ACO2 in the non-oxidized, intact form 
(corresponding to bands of ~85 kDa) and oxidized, degraded form (corresponding to 
bands detectable at ~43 kDa). Additional ACO2 antibodies were bought from Abnova 
(Taipei, Taiwan), and were used for the detection of aggregates which formed an 
extended smear of >100 kDa.  
 
For isolation of ACO2 aggregates and proteins bigger than 100 kDa, mitochondria 
samples were diluted 20 × and filtered through Ultracel YM-50 centrifugal filters 
(Millipore) at 14,000 × g at 10°C. The 50, 000 Da nominal molecular weight cut-off was 
chosen according to the manufacturer’s recommendation of using a cut-off two times 
smaller than the molecular weight of the protein to be concentrated, i.e. proteins above 
the molecular weight of 100 kDa will be retained as the retentive and proteins below 100 
kDa, including non-aggregated ACO2 will pass through the membrane as filtrate. Lyses 
buffer was used as a negative control. To test for aggregation (>100 kDa), 25 μg of 
protein from the retentate fraction was loaded onto 8% SDS-PAGE gels (3% stacking 
gel), allowed to run beyond the dye front for an additional 30 min and immunoblotting 
was performed by transferring to PVDF membrane blots and incubated with ACO2 
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antibodies. Detection was by ECL Plus. Another replicate gel was stopped when the dye 
front reaches the edge of the gel and was immunoblotted for the analysis of intact ACO2.  
 
To study the degradation of ACO2, the filtrate fraction was analyzed by 
immunblotting. 20 μg per lane from the filtrate samples were loaded onto 13% SDS-
PAGE gels and the gel was stopped when the dye front reached the end of the gel. 





Dewaxed paraffin-embedded liver sections (2 μm) were rehydrated and antigen 
retrieval was by heating in 0.01 M sodium citrate buffer for 20 min. Endogenous 
peroxidase activity was blocked using 0.3% hydrogen peroxide for 10 min. Sections were 
then blocked and immunostained using Envision + System-HRP Labelled Polymer Kit 
(Dako, Denmark). Anti-pFOXO3aSerine 253 antibodies (Cell Signalling Technology) were 
incubated overnight, 4°C. After that the sections were rinsed thrice with PBS, incubated 
with secondary antibody for 1 hr at room temperature, washed thrice with PBS and 
immunoreactivity detected using 3, 3-diaminobenzidine. The sections were 
counterstained using Lillie’s modified Mayers Hematoxylin, dehydrated, mounted and 




2.16. In silico analysis 
 
2.16.1. Mass spectra analysis – ProteinPilot™  
 
The data analysis for 8-plex iTRAQ™ was performed using ProteinPilot™ (Applied 
Biosystems/MDS-Sciex) by searching the spectra against either species-specific subset 
(mouse in this case) concatenated with a reversed "decoy" version of itself. The decoy 
database is constructed by reversing all the protein sequences in the database (IPI mouse 
database) and appending these reversed sequences to the original database. The list of 
identifications obtained by searching of the concatenated target and a randomized decoy 
database is ordered from highest confidence to lowest confidence (or sorted from highest 
score to lowest score).  
 
The data analysis for 4-plex and 8-plex iTRAQ™ was performed using 
ProteinPilot™ (Applied Biosystems/MDS-Sciex) by searching the spectra against mouse 
database (IPI mouse version 3.48) concatenated with a randomized "decoy" version of 
itself (Feng et al., 2007). “Instantaneous” false discovery rate (FDR) estimation of 5%, as 
calculated from the slope of the accumulated Decoy database hits by the PSPEP 
algorithm were applied (Tang et al., 2008). As a further refinement, proteins have to meet 
the criteria of (i) ProteinPilot™ Unused ProtScore of ≥ 2.0 (99% C.I.) and (ii) two or 
more tryptic peptides of which at least one unique peptide of high confidence (> 99%) 
(Shilov et al., 2007) before proteins were accepted for further analysis. The software 
calculates a percentage confidence which reflects the probability that the hit is a false 
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positive, so that at the 99% confidence level, there is a false positive identification rate of 
1%. Low confidence peptides do not identify a protein by themselves, but support the 
identification of the protein and hence is the true indicator of a protein (Shilov, et al., 
2007). The Unused ProtScore is a measure of all the peptides evidence specific for a 
protein and prevents reuse of the same unique peptide to support the identification of 
another protein. Manual bias correction was applied to account for any experimental error 
that may arise from unequal sample mixing during combination of the differently labelled 
samples (seven potential biases due to the 8-plex system).  
 
Confidently-identified proteins passing the global 5% FDR, and the micro-level 
criteria were selected for relative protein quantification using the Pro Group algorithm™ 
(Kapp et al., 2005, Sadygov et al., 2004). Because the iTRAQ™ experiments were 
performed in pairs (technical replicates; Figure 13), the denominator of the reagent 
corresponding to the first reagent pair was swapped to the other reagent pair, thereby 
generating four independent fold change ratios. For example, 114 of the 115/114 pair was 
swapped with 116 to form 117/114 fold change ratio. Fold changes, FC was defined as 
1.2 ≤ FC ≤ 0.83 (reciprocal of 1.2). For quantification purposes, MS and MS/MS spectra 
were manually examined and detected sequences rejected based on one or more of the 
following criteria – (i) C.I. ≥ 99, (ii) partially cleaved tryptic sequences or internal 
miscleavages, except proline is C-terminus of lysine or arginine (sequences cleaved by 
trypsin should end with arginine or lysine at its C-terminus), (iii) within a window of ±5 
Da around the main precursor peak, “crowding” of one or more adjacent peaks whose 
intensity is half or more than the matched experimental precursor, (iv) unlabeled 
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iTRAQ™, (v) non-specific iTRAQ™ labelling, (vi) plausible PTMs, (vii) weak absolute 
quantification peaks for iTRAQ™ reporter labels (<3500 relative intensity for 4-plex and 
<2000 for 8-plex, based on 5th percentile cut-off; Figure 14) and main precursor peak 
(Keil, 1992, Nesvizhskii & Aebersold, 2005, Olsen, et al., 2004). Keratin was considered 
as contamination during processing and was disregarded. 
 







2.16.2. Gene Ontology over-representation and pathway analysis 
 
 
Gene Ontology (GO) over-representation analysis was performed using Ontologizer 
2.0 (http://compbio.charite.de/index.php/ontologizer2.html). GO is a widely used 
classification system of gene functions and other gene attributes that uses a controlled 
Figure 14. Histogram of mean signal area (intensity) of reporter channels.  




vocabulary. Statistically enrichment of GO terms were tested using “Term-for-Term” 
analysis and enrichment of GO “biological process” terms was defined at adjusted P < 
0.05 after using Bonferroni correction for multiple testing against 18080 gene products 
(filtered Mus musculus database, 
http://www.geneontology.org/GO.current.annotations.shtml) that forms the population 
sample accessed 26 Jan 2008 (Bauer et al., 2008). GO terms “Metabolic process, cellular 
metabolic process and primary metabolic process” were considered broad terms and were 
not included in the analysis. KEGG and GO enrichment of 2-weeks and 4-weeks 
intersecting and non-overlapping “biological process” was performed using Database 
for Annotation, Visualization and Integrated Discovery (DAVID; version 6) (Dennis et 
al., 2003).  Ingenuity Pathway analysis (IPA; version 7.1) was used for the analysis of 
over-represented biological pathways. The information is obtained from Ingenuity’s 
Knowledge Base, a manually curated database. Right-tailed Fisher’s Exact test (P < 0.05) 
is used for multiple testing of over-represented pathways.  
 
2.17. Statistical evaluation 
 
The mean ± SD was calculated for each treatment group. For biochemical 
analyses, all assays were performed in triplicate, and the mean was taken as 1 data point. 
Linear regression (Pearson correlation) analysis and agglomerative hierarchical clustering 
were performed using Microsoft Excel and XLSTAT (Addinsoft, New York, USA). 
Significant differences between means were determined by ANOVA and Newman-Keuls 
multiple comparison or Tukey post-tests (InStat, GraphPad software, San Diego, CA, 
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USA). P values of < 0.05 were considered significant. Mean centroid value (MCV) is 
simply the ratio of averaged fold change of a group of functionally-related proteins, that 
is proteins of the same distribution (statistical population), treated fold-change as a 
function to vehicle fold-change. By letting i be the expression for proteins 1, 2, 3, …n, of 





xm =  
           (Eq. 4) 
where m is the shrunken centroid value, ikx  is the class average of functional cluster ik in 
week 2, iky  is the class average of functional cluster ik in week 4 
 
 
To do so, proteins were first determined if they are mitochondrially-localized 
through the use of Bioinformatic Harvester IV (http://harvester.fzk.de/harvester/). 
Bioinformatic Harvester is a meta-search engine that collects information from various 
scientifically curated proteins and genes databases. For each mitochondrial-localized 
protein entry, the description and associated literature was examined for its GO and/or 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) annotated function as well as its 
interactions with other proteins; the latter being able to provide additional information 
about its functions. This is based on the presumption that the association of proteins 
would suggest their common involvement in a biological function or pathway, analogous 
to the ‘guilt-by-association’ concept. On top of this, published literature was manually 
curated to further assess a protein’s function so as not to miss out additional lines of 
experimental evidence that was left out due to reasons such as recent publications (not 
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updated on databases) or just not included in the databases for other reasons. For 
example, it was shown very recently that thioesterase superfamily member 2 (also known 
as acyl-CoA thioesterase 13) is involved with mitochondrial fatty acid metabolism (Wei 
et al., 2009). Often there is a time-lag in the annotation of new information and given the 
above example, such recent information would not be captured on the databases and 
escape further analysis. Some proteins have promiscuous functions and hence may 
overlap in different functional clusters. The proteins are then included under a functional 
class with focus for biological functions and pathways associated with the mitochondrion. 
Finally, the MCV is a value of 4-weeks averaged fold change relative to 2-weeks. Of 
note, the functional cluster ‘Apoptosis’ was listed but expression values of associated 
proteins do not dictate an up- or down-regulation of this pathway; additionally, the 
incomplete detection of proteins such as Bax, Bcl-2 and caspases implies that the MCV 




3.1. High level of mitochondrial purity  
 
Prior to proteomics investigation, the genotypes of the mice were validated 
(Figure 15A). Having confirmed the genotypes, liver mitochondria from the HET and 
WT mice were isolated and enriched. Purity assessment of the mitochondria-enriched 
fractions is important to establish the level of contamination of other cellular 
compartments. As shown in Figure 15B (CM fraction), an enrichment of mitochondrial 
proteins can be observed using simple density differential centrifugation.  
 
To further purify this fraction, density differential centrifugation followed by 
ultracentrifugation with discontinuous Percoll™ gradient was employed, which separates 
molecules purely by its density and not by particle size. This Percoll™-purified 
mitochondrial fraction demonstrated a high abundance of cytochrome c oxidase subunit 
IV (COX IV), and an apparent lack of lysosomal, endoplasmic reticulum, or peroxisomal 
markers, indicating a high degree of purification of mitochondria (PM fraction, Figure 
15B). 
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3.1.1. Comparative proteomics of HET liver mitoproteome by 2D-DIGE 
 
To detect a large range of proteins including low molecular weight proteins, 2-D 
DIGE analysis was conducted on 13% polyacrylamide gels using a pI range of 3 to 11. A 
total of approximately 1500 protein spots were found on the 2D-DIGE gels (Figure 16B). 
In 2D-DIGE, WT and HET mouse hepatic mitochondria lysate were labelled with three 








Figure 15. Assessment of genotype and mitochondria purification 
(A) Genotyping of mice used for proteomic analysis. Hypoxanthine 
phosphoribosyltransferase minigene (HPRT) was used to replace part of exon 1 of Sod2.  
 (B) Immunoblots demonstrating a high degree of purification of hepatic mitochondria 
used for proteomics analysis. At each step of the Percoll purification, fractions were 
collected and the proteins probed with antibodies against markers of lysosomes (LAMP-
1), endoplasmic reticulum (calnexin), peroxisomes (PEX-19), and mitochondria (COX 
IV). LH, liver homogenate; S1 and S2, first and second-spin supernatants; CM, crude 
mitochondria; PM, purified mitochondria. 
 





Protein spots that exhibited an average fold change of ≥ 1.5 as determined by 
DeCyder software were selected for further analysis. It must be stressed that in order to 
preserve biologically meaningful interpretations, a number of differentially expressed 
proteins that fell below the average fold change cut-off threshold were not accepted. On 
this basis, 57 proteins were found to be differentially modulated in the HET mouse as 
compared to the WT (Student’s t-test P < 0.01). Among these, 57 proteins (46 unique 
spots and 11 redundant spots) were identified, while two failed to be identified by MS 
(Supplemental Table 1; Figure 16). However, about three-quarters of these proteins were 
affected mildly, with only one being highly modulated (Figure 20A). The proteins 
identified above are involved in a wide range of pathways and biological processes 
(Figure 20B). Also, of the 54 proteins, a large number (58%) increased in abundance. 
Collectively, this has led to the proposition that the extent of oxidative stress within the 
HET mitochondria has not reached a critical threshold that would adversely impact the 
mitoproteome. Most of the proteins identified have expectation values ≤ 0.05 and at least 
one MS/ MS expectation value ≤ 0.05. Although enoyl-CoA hydratase has a protein 
expectation value > 0.05, its best MS/MS score is 33 (expectation value = 0.088) with a 
relatively good y-ion series assignment (Figure 17; Appendix Figure 45). Thus it was 
included as a positive identification. Another spot was identified as 3-hydroxyisobutyrate 
dehydrogenase and hydroxymethylglutaryl-CoA synthase. 3HIDH has a protein 
expectation value of 0.0071 and best peptide score of 32 (expectation value = 0.13), with 
a relatively good b-ion-series assignment. Hydroxymethylglutaryl-CoA synthase has a 
protein expectation value of 0.11 and best peptide score of 33 (expectation value = 0.069) 
with a relatively good b-ion-series assignment. Together, both 3-hydroxyisobutyrate 
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dehydrogenase and hydroxymethylglutaryl-CoA synthase were therefore included as 
positive identifications (Appendix Figure 44 and Figure 46). However, which of these 
two proteins contributed to the calculated fold change could not be determined.  
 
First, there was confirmation of lower SOD2 expression in the HET mice (FC = 
2.17 versus WT) as a result to the partial ablation of the Sod2 allele (Figure 18). This is 
consistent with a 50–55% decrease in SOD2 activity and a decrease immunoreactivity of 
immunoblots found in other studies (Li et al., 1995, Ong, et al., 2006, Van Remmen et 
al., 1999). Subsequently, SOD2 was used as an internal control, supporting the use of 2D-
DIGE/MS as a valuable tool in quantifying changes in protein expression. Interestingly, 
mitochondrial SOD1 abundance level was also decreased by 1.77-fold (Figure 18). In 
contrast, other redox-sensitive proteins with antioxidant activity were up-regulated or 
increased in abundance; GPX1 and catalase levels increased by 2.01- and 1.73-fold 
respectively (Figure 18), thus indicating a mildly pro-oxidant environment in the liver 
mitochondria of the heterozygous mutants. To further validate the observed differences in 
protein expression from 2D-DIGE/MS, the levels of three crucial enzymes (SOD1, 
SOD2, and GPX1) by 2D immunoblotting was examined. The results clearly show that 
both SOD1 and SOD2 amounts were decreased in the HETmice, whereas GPX1 amounts 
increased, corroborating our MS analysis (Figure 18). 
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Figure 16. Representative proteome map of mouse liver mitochondria. 
Mitochondrial proteins were separated on a 13% gel and identified using MALDI 
TOF/TOF-MS/MS. Annotations of differentially modulated proteins indicated on the 
silver-stained proteome map are shown in Supplemental Table 2. − correspond to 
proteins level that decreased in abundance in the HET mouse while + correspond to 
proteins that increased. 
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Figure 17.Tandem mass spectrum of enoyl-CoA hydratase generated from MALDI- 
TOF/TOF MS/MS. 
The relatively good y-ions series (bold red) and a good match of a majority of intense peaks 
make it a reliable assignment despite a low protein and ion score in (A) the MS/MS 




Figure 18. Comparison of SOD1, SOD2, and GPX1 abundance levels by DIGE, silver-
staining of DIGE gel, and immunoblotting.  
(A) Decreased abundance of SOD1 and SOD2 (green spots) and increased abundance of 
GPX1 (red spot) by DIGE imaging. (B & C) Silver staining; the arrows correspond to the 
gel spots on DIGE gel. (D & E) Verification by immunoblotting of selected spots was used 
to validate the MS results. 






















Interestingly, other proteins that are normally considered to be very sensitive to 
oxidative stress were unaltered in their expressions/abundances. For example, Complex I 
and ACO2 are sensitive to oxidative damage due to their [4Fe-4S] clusters (Gardner et 
al., 1995), yet ACO2 and thioredoxin-2 abundance levels were not altered within the 
defined 1.5-fold threshold. This was determined by 2D immunoblot analysis with 
antibodies directed against these proteins, which showed no significant difference 
between their amounts in mitochondria isolated from HET or WT liver (Figure 19). 
Certain mitochondrial enzymes involved in energy metabolism were also altered in the 
HET mice. For example, succinyl-CoA ligase (β-chain) and E1k and E2k components of 
a-ketoglutarate dehydrogenase (KGDH) were also affected. Furthermore, the decreased 
abundance of long-chain fatty acid-CoA ligase 1 and inorganic pyrophosphatase 2, the 
first and second enzymes of the β-oxidation cascade, points toward a down-regulation of 

















Figure 19. Immunoblotting of thioredoxin-2 and aconitase-2 
(A) To ascertain effects of oxidative stress-sensitive ACO2 (Mr = 85 kDa, pI = 8.08) and 
thioredoxin-2 (TRX2; Mr = 18 kDa, pI = 7.73) in HET mouse, immunoblot analysis was used. 
(B) Densitometric analysis demonstrated that both mitochondrial proteins were insignificantly 
















































Figure 20. 2D-DIGE observations of HET hepatic mitochondrial proteome.  
(A) Pie chart depicting the proportion of mildly, moderately or highly differentially 
modulated HET mitochondrial proteins relative to WT mouse. The low percentage of 
highly differentially modulated proteins versus a large majority of proteins that were 
mildly differentially modulated suggests a subtle pro-oxidant status within the 
mitochondria. (B) Classification of differentially modulated proteins identified by 2D-





3.1.2. Quantitative proteomics HET liver mitoproteome by 4-plex iTRAQ™  
 
The 4-plex iTRAQ™ chemical labelling methodology coupled to 2DLC-MS/MS 
permitted the running of duplicate experiments to control for reagent bias as well as to 
increase statistical confidence. In the absence of IEF, membrane and hydrophobic 
proteins are expected to be better represented using chemically-labelled, MS-based 
proteomics. A large number of proteins from the inner and outer mitochondrial 
membranes were obtained using iTRAQ™ coupled LC-MS/MS approach (Figure 21A). 
A total of 321 proteins was identified positively with high confidence using a stringent 
set of criteria of Unused ProtScore ≥ 2 (C.I. = 99%) and identification was based on two 
tryptic peptides of which at least one unique peptide is of high confidence (>99%) and 
5% “instantaneous” FDR at protein level. At a less stringent selection criterion of 5% 
“aggregate” FDR, 416 proteins were identified from the same set of data. Although 
“aggregate” FDR estimations generated a higher number of protein identifications, this 
set of proteins are more likely to contain more false positives than the more conservative 
“instantaneous” FDR (Tang, et al., 2008). Low reporter ion intensity resulted in less 
robust quantification whereas higher ion intensities contributed to more accurate and 
reliable quantification; hence one-tailed cut-off at the 5th percentile to restrict peptides of 
low reporter ion signals was applied (Figure 14A). The reproducibility of the proteome-
wide quantification analysis to detect Sod2 haplodeficiency was tested (Pearson r = 0.69, 
P = 1.33 × 10-36; Figure 21B). Next the robustness and specificity of the MS-based 
analysis was verified by confirmation of the HET heterozygosity (FC = 0.527, Figure 
22A). Following this, the extent to which the proteins were responsive to the partial loss 
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of the Sod2 allele was quantified (Supplemental Table 4). To ascertain the accuracy of 
MS quantification, selected mitochondrial proteins were validated by immunoblotting. 
The fold changes of 9 out of 9 selected proteins were confirmed which was consistent 
with MS results (Figure 22B). This also demonstrated the critical need for manual 
filtering that underpinned the accuracy of MS analysis. 
 
Next the question of whether the apparent homeostatic maintenance of the HET 
hepatic mitoproteome was maintained in part by the antioxidant enzymes housed within 
the mitochondria to curtail redox imbalance was assessed. Glutathione (GSH; L-γ-
glutamyl-L-cysteinylglycine), one of the major protective molecules against elevated free 
radicals is regulated by a network of enzymes and oxidoreductases (Fernandez-Checa & 
Kaplowitz, 2005). From the mass spectrometric survey, the amounts of glutathione S-
transferase kappa 1 (GSTK1) and microsomal glutathione S-transferase increased 
(MGST is also found in the mitochondria; FC = 0.71 and 0.70 respectively), thus 
suggesting increased recycling of mGSH to restore redox equilibrium. Consistent with 
2D-DIGE results, GPX 1 was up-regulated (Figure 18). Mitochondrial GSH (mGSH) 
depletion is a hallmark of oxidative stress. Subsequently, endogenous mGSH levels of 
WT and HET mice were determined and there was no significant difference between both 
genotypes (Figure 22C). 
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Figure 21. Global analysis HET mouse hepatic mitochondrial proteome by 4-plex iTRAQ™.  
(A) Improvement in number of detected membrane proteins using iTRAQ™/LC-MS/MS. (B) Reproducibility of 4-plex 
iTRAQ™ (Pearson r = 0.69, P = 1.33 × 10-36). (C) Duplicate analysis of the same samples labelled with different iTRAQ™ 
reagents demonstrate high degree of reproducibility in detecting fold change and low level of regent-specific biasness. Random 
mitochondrial proteins were selected for the comparison. ACADM, medium-chain specific acyl-CoA dehydrogenase; ACO2, 
aconitate hydratase; ASS, argininosuccinate synthase; CPSI, carbamoyl-phosphate synthase; COX VI, cytochrome c oxidase 
subunit VIb; HMGCS2, hydroxymethylglutaryl-CoA synthase; UQCRFS1, ubiquinol-cytochrome c reductase core protein 1. 
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    WT   HET- Figure 22. Enrichment of function 
of proteins responsive to Sod2 
haplodeficiency.  
 (A) Immunblot agrees with 
iTRAQ™ quantification of SOD2. 
Note that channels 114/115 and 
116/117 form a pair of replicates. 
(B) Validation of selected detected 
mitochondrial proteins by 
immunoblotting demonstrates 
accuracy of mass-spectrometry 
results. (C) Mitochondrial GSH 
levels isolated from WT and HET 
mice (n = 4, two-tailed Student’s t-
test).  (D) The 134 hit proteins from 
the 2D-DIGE and iTRAQ™ 
analysis were classified into 
molecular function categories for 
mouse genes according to the Gene 
Ontology classification system. 
Proteins for which no annotations 
could be assigned were excluded 
from the analysis for both the hits 
and the global set. The number of 
proteins assigned to each category 
and enrichment adjusted P values (P 
< 0.01) are shown in brackets.  
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To fully describe the mitoproteome changes, DIGE and iTRAQ™ fold change 
values are to be transformed before they can be combined and analyzed together. Because 
measures of fold change were different in the two methods as shown below (Equations 5-
7), the fold change values were standardised and expressed as percentage fold change.  
 
2D-DIGE fold change: 
 if 
x
y  > 1,   E = (R -1) × 100     (Eq.5) 
if  
x
y  < 1,   E = (1+
R
1 ) × 100     (Eq.6) 
iTRAQ™ fold change:      
E = (1-R) × 100     (Eq.7) 
where:  
 y is the normalized spot volume to the HET mouse, 
 x is the normalized spot volume to the WT mouse,  
 E is the percentage expression ratio and  





3.1.3. Combined proteomic analysis using 2D-DIGE and iTRAQ™ labelling 
 
Using two independent and technologically different proteomic platforms is a 
formidable way of comprehensively describing the mitochondrial proteome in a global 
view by minimising individual technological shortcomings, complementing each other so 
as to potentiate the total proteome profile. By combining the number of proteins detected 
by the two unbiased proteomic screens, the HET liver mitochondria profile of 
differentially modulated proteins (detected with high statistical confidence) was 
expanded. 
 
Gene Ontology or GO over-representation analysis of detected proteins revealed 
‘oxidation reduction’ as the top biological process in terms of gene products number and 
confidence level for total and positively modulated proteins (32 proteins, P = 6 × 10-17; 
Figure 23). Biologically, this is not unexpected as the singular loss of the Sod2 allele will 
result in fluctuations of proteins that are involved in redox activities. It was surprising, 
however, to see lipid metabolism ranking high in the GO analysis (12 proteins) – 
ACADM, acyl-Coenzyme A oxidase 1, acyl-CoA synthetase family member 2, acyl-CoA 
synthetase long-chain family member 1, acyl-coenzyme A synthetase isoform 2, ATP 
synthase subunit beta, catalase, carnitine O-palmitoyltransferase 2, delta(3,5)-Delta(2,4)-
dienoyl-CoA isomerase, enoyl-CoA hydratase, GPX1, hydroxymethylglutaryl-CoA 
synthase. Further evidence of altered glutathione cycling (P = 1.19 × 10-5) was also 
demonstrated in this over-representation analysis (Figure 23). Proteins under negative 
modulation were classified into classes that are predominantly involved in maintaining 
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homeostasis, including redox homeostasis. Apart from SOD1 and SOD2, thioredoxin 
domain-containing protein 4, thioredoxin domain-containing protein 5, protein disulfide 
isomerase associated 4 and PDIA 5 were listed under ‘redox homeostasis’. While these 
proteins are generally not annotated to the mitochondrion (Pagliarini et al., 2008), the 
mitochondria form interacting networks with the endoplasmic reticulum to facilitate Ca2+ 
uptake and mitochondrial lipid synthesis (de Brito & Scorrano, 2008, Rizzuto & Pozzan, 
2006), and these proteins might be mitochondrial-associated proteins, or could be just 
contaminants.  
 
Taken together, these results imply that despite an increase in the level of ROS 
within the HET mouse mitochondria, it is insufficient to elicit major perturbations in the 
mitoproteome, possibly attenuated by adjustments made in the mitochondria. This is 
compatible with the alternative hypothesis of using a phenotypically normal mouse 
model but with clinically silent redox abnormalities for picking up mitochondrial toxic 
effects (Dixit & Boelsterli, 2007). 
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Figure 23. Classification of HET hepatic mitochondrial proteins based on GO 
annotation 






3.2. Prolonged troglitazone administration causes oxidative stress in 
mitochondria and moderate liver injury in HET mice 
 
Genotyping verified Sod2 haplodeficiency in all the mice used for the toxicity 
study (Figure 24A). Histopathological evaluation revealed the presence of small areas of 
hepatic necrosis (4/6 mice) in the 4-week troglitazone-treated group (Figure 24B), while 
no such alterations were seen in the 2-week drug-treated or in all vehicle controls (Table 
8). This indicates that the small repeated doses of troglitazone cause a delayed-type 
moderate hepatocellular injury which is not yet manifested after 2 weeks. Although no 
significant increases in serum ALT activity was observed between 4 weeks troglitazone-
treated mice and the vehicle controls (P = 0.4 and P = 0.66 respectively; Table 9), a 
general trend of increase in ALT activity was observed (47.73 U/L in 4-weeks TRG 
group versus approximately 33 U/L in the controls).  
 
To quantify the depletion of mGSH with troglitazone administration, MCB was 
used as fluorochrome for sensitive detection of GSH. As shown in Figure 25A, in isolated 
HET hepatic mitochondria, mGSH levels were significantly depleted after 4 weeks of 
troglitazone administration (P < 0.05). By comparison, vehicle administration did not 
deplete mGSH levels, demonstrating the minimal adverse biological effects of 9% solutol 
and that mGSH depletion was a result of prolonged troglitazone treatment. Further, 2 
weeks of troglitazone treatment did not significantly altered mGSH levels versus vehicle 
control (Figure 25A). 
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Figure 24. Liver histopathology in troglitazone-treated HET mice. 
(A) Genotyping of WT and HET mice by PCR analysis before drug treatment showed 
the partial loss of Sod2 allele. Sod1 gene was used as a control. (B) Representative 
micrographs (H & E staining) showing areas of hepatocellular necrosis in 4 weeks 
troglitazone-exposed (original (black arrows), but not in 4 weeks vehicle-treated or 2 
weeks-troglitazone treated mice (original magnification × 200) 
















Table 8. Hepatotoxicity score of HET mice treated with troglitazone for 2 or 4 
weeks.  
 
Histological sections were obtained from livers of mice treated daily with i.p. injections of 
troglitazone in 9% solutol. Mice were sacrificed after 14 or 28 days. Slides stained with 
H&E were reviewed under low and high power by two individuals.  
 
 Histopathology types and scores 
Treatment 
Necrosis  
(Inflammation) Apoptotic cells Foci of infarction 
2 weeks                   
Vehicle control  
(n = 3) 0 1 0 - - - 0 0 0 - - - 0 0 0 - - - 
Troglitazone,  
30 mg/kg/day  
(n = 3) 1 0 0 - - - 0 0 2 - - - 0 0 0 - - - 
                   
4 weeks                   
Vehicle control  
(n = 3) 1 1 0 - - - 1 0 0 - - - 0 0 0 - - - 
Troglitazone,  
30 mg/kg/day  





Hepatocellular degeneration was graded based on frequency of occurrence regardless 
of extent of damage i.e. 0 (no occurence); 1 (stated degeneration occurring once) and 
so on. Values are total number of animals featuring the indicated score. † A larger 
number of mice were administered with 30 mg/kg troglitazone to account for any 
potential deaths resulting from the hepatotoxic effects of troglitazone. 
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Table 9. Biochemical and clinical chemistry properties of female HET mice 
      
    
2 weeks, 
VEH 






n   3 3 3 6 
      
Age (weeks) 12.3±2.52 11.3±3.06 10.7±2.08 11.7±3.27 
      
Weight (g)         
 Week 0 21.2±1.31 19.6±0.80 20.33±1.67 20.95±1.77 
 Week of Sacrifice* 18.3±1.11 17.3±1.04 19.5±2.15 18.165±1.06 
      
ALT (U/L) 40.47±1.29 33±7.79 33.67±5.78 47.73±23.1 
      
AST (U/L) 160.4±40 121.4±28.9 126.5±40.7 139.9±41.8 
      




* Mice from Groups 1 and 2 were sacrificed after 2 weeks and mice from Groups 3 
and 4 were sacrificed after 4 weeks. All differences across groups were statistically 




A hallmark of ROS-induced protein modification is the addition of carbonyl 
groups to the amino acid side chains of proteins. The stability, early formation and 
irreversibility make protein carbonyls an excellent biomarker of protein oxidation 
(Alamdari et al., 2005, Nystrom, 2005). Total hepatic mitochondrial protein carbonyls 
increased significantly in HET mice treated with troglitazone for 4 weeks as compared to 
2 weeks (41%, Student’s t-test, P < 0.05; Figure 25B). Prolonged troglitazone treatment 
in HET mice resulted in increased production of NO levels, determined by liver 
homogenate levels of its metabolites nitrate and nitrite (Figure 25C; Student’s t-test, P < 
0.01). 3-NT is a relevant biomarker of NO•-dependent oxidative stress, arising from 
unregulated increased •NO production and its secondary intermediates such as ONOO- 
and •NO2 (Abello et al., 2009, Radi, 2004, Souza et al., 2008). To investigate for protein 
tyrosine nitration, total hepatic mitochondrial proteins were assayed for 3-NT and were 
found to significantly increased in HET mice administrated for 4-weeks with troglitazone 
(Student’s t-test, P < 0.01; Figure 25D). No significant increase in 3-NT was observed in 
the solutol-administered mice and mice administered with troglitazone for 2-weeks. 
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Figure 25. Prolonged troglitazone exposure leads to elevated •NO and mitochondrial 
oxidative stress. 
(A) Mitochondrial GSH (mGSH) was depleted by two-fold after 4 weeks of administrating 
troglitazone to HET mice (Student’s t-test, n = 4). The resultant loss of mGSH left the 
mitochondria less protected from the oxidation damaging effects of free radicals. (B) Protein 
carbonyls and (D) nitrotyrosine adducts (3-NT), established markers of oxidative damage to 
proteins were significantly increased after 4 weeks of troglitazone treatment. (C) The increase 
in 3-NT is due to •NO-dependent oxidative stress stemming from increased hepatic 
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3.3. HET Mitochondrial Proteome Dynamics induced by prolonged 
troglitazone treatment 
 
3.3.1. 2D-DIGE Analysis of Troglitazone-induced HET Mitoproteome  
 
To better understand the underlying mechanisms of this delayed toxicity and to 
identify potential early biomarkers of liver injury, the proteomics profiles after 2 and 4 
weeks of treatment were analyzed. Using 2D-DIGE coupled with MALDI-TOF/TOF 
MS/MS analysis, the 2-weeks group showed that 24 proteins were differentially 
modulated relative to the corresponding vehicle controls, and that the vast majority 
(~80%) showed an increase in abundance (FC ≥1.45, P < 0.01) (Figure 26, Supplemental 
Table 1). Specifically, a number of heat shock proteins, catalase, and Lon protease 
exhibited increased abundance levels which are commensurate with an adaptive response 
against mild oxidative stress (Douette et al., 2006, Maniratanachote, et al., 2005, 
Rabilloud et al., 2001). Among the proteins with decreased abundance, ACO2 was 
conspicuous, suggesting that a mild oxidant stress had actually lowered the levels of this 
exquisitely redox sensitive protein.  
 
In contrast, the 4-week treatment with troglitazone affected a much larger number 
of mitochondrial proteins, and with a distinct proteome profile (Figure 26B). Specifically, 
among the 46 differentially expressed proteins, ~65% exhibited reduced levels as 
compared to vehicle controls (FC ≤ −1.45, P < 0.01). For example, besides ACO2, 
catalase and the ATP synthase β-subunit (Complex V) also exhibited decreased 
abundance. It is likely that these changes have inflictions for mitochondrial function and 
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energy homeostasis. Some of these proteins, exhibiting decreased expression levels, may 
reflect decreases in the amounts due to more severe and sustained oxidant stress. It is also 
possible that a number of these proteins underwent modifications that were then 
selectively directed towards proteolytic degradation (Grune et al., 2003). On the other 
hand, a number of proteins exhibited increased expression levels. For example, VDAC, a 
component of Complex III, and SOD2. This likely points toward a compensatory up-
regulation of critical (yet sensitive) components of the mitochondrial ATP biosynthesis 
machinery and antioxidant defence to cope with increased oxidative stress. Another 
important oxidoreductive stress-regulated mitochondrial protein is the redox sensor and 
antioxidant TRX2. TRX2 was not detected in 2D-DIGE, probably due to its small 
molecular mass (18 kDa). However, in a separate immunoblotting experiment using a 
high-percentage polyacrylamide gel, TRX2 abundance was positively modulated after 4 
weeks, but not after 2 weeks.  
 
The number of DIGE-detected overlapping proteins between 2-weeks and 4-
weeks of troglitazone treated mice showed only 6 proteins (Supplemental Tables 2 and 
3). This low number of overlapping proteins between the two time-points strongly 
suggested that the early effects on the liver, and also the toxic response, may be different 
from the latter effects. For some proteins, several distinct spots were identified on the 
gels, representing the same protein but featuring different isoelectric points or molecular 
weights (corresponding to the multiple entries in Supplemental Tables 2 and 3). These 
multiple spots suggested the occurrence of either different protein isoforms or post-
translationally modified proteins. To validate the results from the MALDI-TOF/TOF 
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MS/MS analysis, 2D immunoblotting for selected proteins spanning a wide range of 
molecular weights were performed. Specifically, the abundance levels of five proteins: 
ACO2, CATA, OTC, SOD2, and VDAC1 (Figure 27) were examined. For the 2-week 
treated samples, the immunoblot for ACO2 exhibited a decrease in abundance, 
concordant with the MALDI-TOF results. Furthermore, the identity of HADH was 
confirmed, but not HIBCH due to a lack of commercially available antibody. As for 4-
week treated samples, the identity of all five proteins and their relative change in 
expression levels were confirmed by immunoblotting. 
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3.3.2. Analysis of different ACO2 fates under different oxidative stress 
conditions 
 
2D-DIGE was able to partially demonstrate the changes occurring in ACO2 
protein modification and abundance (Figure 26, Supplemental Tables 1 and 2). In the 2-
weeks study, the HET mouse was mildly sensitized to oxidative stress stemming from the 
toxicant, troglitazone. We observed a decrease in ACO2 abundance levels (~80 kDa), 
which becomes a substrate for Lon protease degradation under mild prooxidant 
conditions (Bota & Davies, 2002). Immunoblotting against ACO2 confirmed the 40 kDa 
band as cleaved ACO2 (Figure 28). This correlated well with the observation of increased 
Lon abundance. With prolonged troglitazone treatment and an increase in ROS, ACO2 
should form aggregates. However, aggregated ACO2 (beyond the upper separation range 
of 2D gels of ~ 220 kDa) and Lon were not detected on the 2D-DIGE gels. By using a 
different approach, we were able to observe the aggregation of ACO2 after extended 
troglitazone administration (Figure 28). This is consistent with the three different fates of 
ACO2 under varying stages of oxidative stress (Bota & Davies, 2002, Delaval et al., 
2004).  
 
From these integrative proteomics results, the two-stage mitochondrial and 
cellular response complemented the potential of ACO2 as a potential biomarker for 
distinguishing varying degrees of mitochondrial redox status effects. While further in-
depth studies are still required, ACO2 can be a promising oxidative stress marker for 
early detection as well as for diagnosing a biological system’s redox status in response to 






















Figure 26. 2DE profile of HET mouse hepatic mitochondrial protein expression with 
solutol or troglitazone treatment. 
Representation silver-stained (A, B) and DIGE profiles (C, D) of HET mouse hepatic 
mitochondrial protein expression after 2 weeks (A, C) or 4 weeks (B, D) treatment with 
troglitazone (30 mg/kg/day). +, increased amounts of protein relative to vehicle control; 
−, decreased amounts of protein relative to vehicle control. ACO2, aconitase-2; VDAC1, 
voltage-dependent anion channel-1. For numbering of proteins see Supplemental Tables 








Figure 27. Validation using 2D immunoblotting.  
Confirmation of MS results using 2D immunoblots on the differential expression of 
selected mitochondrial proteins after 2 weeks (A) or 4 weeks (B) troglitazone treatment. 
Note that while ACO2 and SOD2 isoforms and/or post-translational modifications were 
found to be differentially expressed on the immunoblots, 2D-DIGE only detected spots 
that were within the ≥1.45 fold change cut-off. ACO2, aconitase-2; CATA, catalase; 
HADH, hydroxyacyl-coenzyme A dehydrogenase; OTC, ornithine carbamoyltransferase; 








Figure 28. Varying fates of ACO2 
ACO2 undertakes different forms with prolonged troglitazone administration and 
accompanying ROS levels in the HET mouse. Early administration with troglitazone 
already starts to induce ACO2 aggregation (> 100 kDa) and partial cleavage (~40 kDa; 2nd 
lane). With extended troglitazone treatment (4 weeks), large aggregation of ACO2 can be 
observed, in tandem with small amounts of non-aggregated and cleaved ACO2. (5th and 6th 
lanes). Arrowhead denotes the reduced amounts of ACO2 monomers and cleaved ACO2;  
∗ denotes ACO2 aggregation. V, vehicle; T, troglitazone. 
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3.3.3. 8-plex iTRAQ™ Analysis of Troglitazone-induced HET Mitoproteome  
 
The biasness of 2D-DIGE against certain classes of proteins is well-recognized 
(Hamdan & Righetti, 2002)) and the use of complementary  proteomic approaches is an 
attractive way to adequately cover the proteome of any cell or organelle in depth 
(Andersen & Mann, 2006, Cox & Mann, 2007). Specifically, two main objectives were 
sought: (1) to gather a comprehensive proteome profile of the HET hepatic mitochondria 
upon challenge with therapeutic doses of troglitazone and (2) to determine which 
mitochondrial functional clusters were more sensitive to troglitazone-induced toxicity. 8-
plex iTRAQ™ technology became available at a later part of this study and we adapted 
its multiplex chemical labelling for labelling the larger number of samples in this drug-
treatment study. 
 
Through quantitative MS analysis and post-MS acquisition filtering, 
approximately 277 proteins with high confidence (39 unquantified, total 314 detected 
proteins; Supplemental Tables 5 and 6) were quantified and a very good correlation 
between each set of technical replicates was found (channels 114/113 versus channels 
116/115, Pearson r = 0.79, P = 1.19 × 10-57; channels 118/117 versus channels 121/119, 
Pearson r = 0.91, P = 9.36 × 10-111; Figures 33A and B). Identification of proteins was 
based on a stringent criteria which included that identification be based on the 
requirement of two tryptic peptides with at least one peptide unique to the protein 
sequence and not shared with any other database entry, 5% instantaneous FDR at protein 
level and finally Unused ProtScore ≥ 2 (99% C.I.).  
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An evaluation of the protein attributes of the detected proteins against the most 
complete list of mitochondrial proteins (Pagliarini, et al., 2008) revealed an 
undersampling of very basic proteins, low molecular weights and hydrophobic proteins 
(Figure 30). Nevertheless, the detected proteins followed the distribution of annotated 
mitochondrial proteins. In terms of functionality, the selection of detected proteins had 
the tendency to describe their functional clusters substantially, covering 44 out of 48 GO 
Slim terms annotated to the mitochondrial “Biological Process” (Figure 31).This 
permitted the investigation of which functional clusters were more susceptible to 
troglitazone mitotoxic effects and if these proteome changes correlated with alterations 
observed at the tissue level. 
 
MS-based quantitative proteomics revealed 55 proteins (20.52%) that increased in 
abundance (FC ≥ 1.2) as compared to 17 proteins (6.34%) that decreased in abundance 
(FC ≤ 0.833 ) after 2-weeks of troglitazone administration (Supplemental Table 5;  
Figure 29C). In contrast, after 4-weeks of daily troglitazone administration, the 
proportion of mitochondrial proteins that increased versus those that decreased was 
markedly different, 22 proteins (8.21%) increased whereas 53 proteins (19.78%) 
decreased in abundance (Supplemental Table 6; Figure 29C). These results were 
therefore similar to the DIGE experiment. This therefore connoted a two-stage toxic 
phase: an early phase denoted by adaptory response to maintain mitoproteome 
homeostasis and a latter, sustained phase of mitoproteome changes that contributed to 
liver injury, as exemplified by confluent areas of hepatocytic death (Figure 24 and Figure 
29D).
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Figure 29. Sod2 haplodeficiency delays troglitazone hepatotoxicity as revealed by 
quantitative proteomics. 
 (A and B) Linear regression of technical replicates show high levels of correlation and 
hence reproducibility of 8-plex iTRAQ™. (C) Pie charts showing the proportion of 
proteins that increased or decreased in abundance following 2 or 4 weeks of troglitazone 
treatment based on a threshold of 1.2 and 0.83. (D) Box plot of quantified proteins by 
iTRAQ™ for 2 weeks and 4 weeks study groups. Median - vertical line in box, 
interquartile range – box from end to end show 25% and 75% quartiles, minimum and 






Figure 30. Bias analysis of protein attributes. 
The detected proteins were classified according to their (A) molecular weight, (B) isoelectric 
point; pI, (C) hydrophobicity; the GRand AVerage hydropathicity or GRAVY score (a 
prediction of the hydrophobicity of a hypothetical translated gene product) and (D) length and 
compared against the 1098 annotated mouse mitochondrial genes fromMitoCarta (Pagliarini et 
al., 2008). Note that the detected proteins followed the distribution of annotated mitochondrial 
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Figure 31. Pie charts of GO slim analysis. 
GO slim analysis of detected mitochondrial proteins demonstrates substantial 
representation of functions annotated to the mitochondrion. Annotated GO terms not 










Missing Molecular Functions 
terms:  
1) carbohydrate binding,  
2) chromatin binding, 
3) cytoskeletal protein binding,  
4) motor activity,  
5) oxygen binding,  
6) phosphoprotein phosphatase 
activity,  
7) transcription factor activity 
Terms not included:  
1) translation factor activity,  
2) nucleic acid binding,  




Missing Biological Processes 
terms:  
1) cell growth,  
2) regulation of gene expression,  
3) epigenetic response to 
endogenous stimulus,  
4) viral reproduction  
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Using DAVID (Dennis, et al., 2003), we analyzed non-intersecting enriched 
biological functions as well as intersecting ones from the proteome dataset. Among the 
top-ranking and overlapping enriched KEGG functions, there was fatty acid metabolism 
(P = 1.1×107) and expectedly, PPAR signalling (P = 5.2×105) in both 2 and 4 weeks of 
troglitazone administration. Functions exhibiting over-representation in 2 weeks included 
OXPHOS and ATP generation (Figure 32). In general, GO analysis suggested the 
absence of a stress response and a normal functioning liver that is refractory to short-term 
troglitazone-induced toxicity. This is in agreement with histopathological analysis at 2 
weeks (Figure 24). By comparison, which is unique to 4 weeks treatment, there was a 
marked enrichment of a number of stress responses, including apoptosis, oxidative stress 
(H2O2, O2•-) response, GSH metabolism and cell death (Figure 32). There was also a 
chemical stimulus response, consistent with the toxicity arising from extended 
troglitazone administration. When viewed together with toxicological/biochemical 
endpoints and liver histopathology, it is apparent that after 4-weeks of troglitazone 
treatment, the liver of the HET mouse was subjected to considerable chemical insults in a 
pro-oxidant environment. Cellular (mitochondrial) compensatory responses were 
insufficient, which resulted in mitochondrial protein oxidation and liver injury.  
 
IPA analysis revealed ‘toxic’ pathways manifested with long-term troglitazone 
administration, which included mitochondrial dysfunction, fatty acid metabolism and 
oxidative stress (Figure 33 and Figure 34). These altered pathways, which were affected 
with troglitazone-induced toxicity, were concordant with our 2D-DIGE results and 
biochemical endpoints reported here and elsewhere. This confirmed the importance of 
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mitochondria and oxidative stress in troglitazone hepatotoxicity (Smith, 2003). By 
agglomerative hierarchical clustering and simple scatterplot analysis, a large number of 
mitochondrial proteins displayed bimodal modulation and that they tended to group 
together by their functions (Figure 35).  However, automated hierarchical clustering by 
statistical measures did not reveal GO biological process over-representation specific to 
any cluster. This is likely due to several reasons, such that hierarchical clustering was 
devoid of functional information and as a result the clustering was not thorough, or was it 
sufficiently biologically meaningful.  This prompted us to cluster the mitochondrial 
proteins by their functions and to investigate which functional clusters were more 






















Figure 32.  Non-intersecting GO terms of proteins in 2 and 4 weeks treatment 
Significantly enriched GO biological process terms within the 321 protein dataset. 
Enriched GO terms are listed together with p values and the number of proteins sorted in 
by statistical rank (A) 2 weeks and (B) 4 weeks. ATP, adenosine triphosphate; RNT, 




























oxidative phosphorylation 5.5E-03 
transport 8.3E-03 
coenzyme biosynthetic process 9.9E-03 
establishment of localization 9.9E-03 
cofactor biosynthetic process 1.3E-02 
localization 2.1E-02 
apoptotic nuclear changes 2.2E-02 
carboxylic acid metabolic process 3.7E-02 
organic acid metabolic process 3.7E-02 
negative regulation of cell growth 3.8E-02 
nuclear organization and biogenesis 4.5E-02 
negative regulation of cell size 4.6E-02 
mitochondrial transport 4.7E-02 
negative regulation of growth 5.7E-02 
ATP synthesis coupled proton 
 
6.5E-02 
ATP biosynthetic process 7.2E-02 
nucleoside phosphate metabolism 7.2E-02 
ATP metabolic process 8.1E-02 
purine RNT biosynthesis process 8.9E-02 
purine NTP biosynthesis  process 8.9E-02 
RNT biosynthesis 9.0E-02 
apoptotic program 9.0E-02 
nucleoside triphosphate biosynthesis 9.4E-02 
purine RNT metabolism process 9.7E-02 
purine NTP metabolism 9.9E-02 
RNT metabolism 9.9E-02 
phosphorylation 1.0E-01 
   
response to superoxide 0.009581 
response to oxidative stress 0.010007 
negative regulation of apoptosis 0.010402 
negative regulation of programmed cell death 0.010854 
response to oxygen radical 0.011962 
glycine catabolic process 0.014338 
catabolic process 0.015101 
serine family amino acid catabolic process 0.019073 
glycine metabolic process 0.021432 
regulation of apoptosis 0.023981 
electron transport 0.024318 
regulation of programmed cell death 0.025003 
response to hydrogen peroxide 0.028476 
response to chemical stimulus 0.0327 
acyl-CoA metabolic process 0.037792 
response to reactive oxygen species 0.044722 
serine family amino acid metabolic process 0.047021 
response to stress 0.048717 
generation of precursor metabolites & energy 0.04903 
cellular response to stress 0.049315 
glutathione metabolic process 0.049315 
superoxide metabolic process 0.051603 
double-strand break repair 0.056164 
cellular response to stimulus 0.067472 
apoptosis 0.081196 
isoprenoid metabolic process 0.083083 
programmed cell death 0.085302 
oxygen & ROS metabolic process 0.087496 
protein folding 0.091121 
cell death 0.094547 
death 0.095278 
Figure 32. Figure legend can be 
found on page 122. 
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Figure 33. Schematic diagram of 
mitochondrial dysfunction after 4 –
weeks of troglitazone administration.  
Multiple points of elevated ROS levels 
(yellow) by troglitazone contributed to 
the up-regulation (red) and down-
regulation (green) of mitochondrial 








































Figure 34. Histogram of “Toxic Pathways” affected by troglitazone treatment 
The top 6 canonical pathways are shown due to space limitation. Mitochondrial 
dysfunction was also ranked highest under “Canonical Pathways” (Figure 33). This is 
likely due to the large proportion of detected ETC components which form part of 
annotated pathway. Of note, RXR activation and function were ranked highly in the 
analysis. Troglitazone activates PPAR, which in turns heterodimerize with RXR for 
transcriptional regulation. These chars provide an overview of affect pathways but may 
not be ideal for viewing the complex biological pathways as a whole. Significantly 
















































Figure 35. Cluster analysis of detected of proteins show bimodal expression 
(A) Scatterplot shows biomodal expression can be seen for a large number of proteins at 
the extremes of the scatterplot. Proteins were sorted according the magnitude of 
expression difference (x-axis). (B) Agglomerative hierarchical clustering of quantified 
mitochondrial proteins with heatmap. The different colors on the side bars represent the 
three major clusters (red, blue and violet). Fold change is the variable attribute. Two 

























2 weeks    4 weeks 
 119 
3.3.3.1. ETC components show bimodal response to acute and chronic 
troglitazone treatment 
 
The ETC forms the defining and critical components for the ATP-generating 
capability of the mitochondria. MS analysis demonstrated that troglitazone has non-
equitable effects on components of the OXPHOS both over short-term and long-term 
administration (Figure 36). Short-term treatment with troglitazone led to general down-
regulation of the five ETC complexes. In particular, mitochondrially-encoded subunits of 
cytochrome c oxidase (mt-COX1 and mt-COX2) were up-regulated. Despite the 
exclusion of mt-COX1 based on FDR thresholds (Unused ProtScore= 2), manual 
inspection of the MS/MS spectrum revealed a highly confident fragmentation (99% 
confidence and complete y series for best scoring peptide sequence), mt-COX1 was 
deemed a positive identification (Figure 37A). To substantiate the claim, immunoblotting 
was performed. Indeed, mt-COX1 was up-regulated with 2-weeks treatment and was 
down-regulated with 4-weeks troglitazone treatment (Figure 36). It is interesting to note 
that mt-COX1, mt-COX2 and mt-COX3 form the catalytic and structural core of the 
functional complex while mt-COX1 and mt-COX2 constituted the catalytic core which 
contained the redox cofactors (Taanman, 1997). There could also be early ETC instability 
as suggested by a decreased in LETM1 levels (FC2weeks = 0.91) (Tamai et al., 2008). 
Conversely, low ProtScores do not necessarily translate into accurate protein 
quantification. For example, NDFUS3 MS-quantified fold change did not agree with 




The observation that prolonged troglitazone treatment adversely affected the HET 
liver (Figure 24) suggested that a mitotoxicant-mediated increase in oxidative stress 
should potentiate the damage done on the ETC. Intriguingly, the hepatic injury at the 
tissue level was not associated with adverse changes on the ETC proteins which 
unexpectedly increased in abundance. With the exception of three ETC subunits 
including mt-COX1 (FC4 weeks = 0.27), NDUFS4 (FC4 weeks = 0.87) and ATP5F1 (FC4 weeks 
= 0.91), most ETC members were up-regulated or at basal levels (Figure 36A and B). 
Because the majority of detected ETC members were at homeostatic levels or up-
regulated (MCV = 1.07), this suggested that sustaining ATP generation remained an 
important cellular process during chronic toxicity events, and was unlikely a cause for 
hepatocyte death. In addition, there were instances of ETC subunits (~54%) showing 
bimodal differential expression (Student’s t-test, P < 0.05) in the two study groups 
(Figure 36A and B). It is apparent that the bimodal dynamics of 54% of these ETC 
members were modulated in a concerted manner. Using immunoblotting, the MS-
quantified abundance differences of selected components of the ETC and other 






























Figure 36. Impact of troglitazone on HET electron transport chain complexes 
(A) Heatmap of quantified subunits of the ETC complexes. Fold change were centred to mean 0 
and standard deviation 1 for better graphical presentation. (B) Histogram showing bimodal 
expression of most ETC components. Statistically significant differences of the same 
protein/subunit from 2 weeks to 4 weeks of troglitazone administration are marked with red 
borders (Student’s t-test, P < 0.05). (C) Immunoblotted ratios are in agreement with MS-






Figure 37. Mass spectrometric quantification of mt-COX1 and NDUFS3.  
(A). MS/MS of best scoring peptide of mt-COX1 (99% C.I., ProtScore Unused =2) 
demonstrates a complete y-ion series (green boxes). Insert shows a zoomed-in area of low m/z 
which gives information on the iTRAQ™ reporter ions intensity and hence mt-COX1 
quantification. (B). Peptide summary of NDUFS3 obtained from ProteinPilot software. Red 
arrow denotes the highest scoring unique peptide assigned to NDUFS3 which did not attain 







3.3.3.2. Modulation of PPAR-agonist targets 
 
Thiazolidinediones are known to transcriptionally induce expression of genes 
belonging to the β-oxidation pathway (Bogacka et al., 2005) and this motivated us to test 
if β-oxidation was affected. Short-term administration with troglitazone in HET mice 
brought about increases in ACAA1, CPT I and CAC (Slc25a20) levels. These changes 
are specific to the PPAR-agonist’s mechanism of action to normalize glucose and lipids 
levels and are also consistent with no observable hepatic damage at this point. Prolonged 
troglitazone administration however, brought about the down-regulation of several β-
oxidation enzymes such as CISD1, ECH1, ACAT1 and ACAA1 and suppressed the 
overall β-oxidation cluster (Figure 11).  
 
Pioglitazone, a weaker PPARγ-agonist was discovered to bind to MitoNEET or 
CISD1 (Colca et al., 2004) and later it was found that pioglitazone stabilized its 2[Fe-S] 
cluster (Paddock et al., 2007). At different dosing regimens, CISD1 abundance varied 
(FC2weeks = 1.23 and FC4weeks = 0.83). CISD1 has been implicated as a redox sensor 
and/or in the formation of [Fe-S] clusters. Not much is known if and how binding to 
CISD1 has mediated PPAR-ligand specific actions. While it is tempting to speculate that 
troglitazone may also bind to CISD1, interactions with troglitazone, if any remained 
unknown.  
 
Significantly, drugs intended for therapeutic indications often have inadvertent 
‘off-target’ effects that cause drug-induced toxicities. Interestingly, there was IPA-
qualified association of IL-1-mediated inhibition of RXR with troglitazone administration 
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(Figure 34). Mitochondrial dysfunction, apoptosis and oxidative stress can trigger 
inflammatory responses (Jaeschke, 2002, Smith, 2003, Uetrecht, 2008, Uetrecht, 2009) 
and while troglitazone has been shown to down-regulate IL-1 and IL-6 (Maggi et al., 
2000a, Sigrist et al., 2000), the biological and toxicological consequences of such 
repression remain circumstantial (Desmet et al., 2005). To test for the potentiality of 
troglitazone-mediated PPAR-toxicity, we analyzed the fold change of differentially-
regulated proteins with experimentally-verified PPAR-inducible genes (Nakachi et al., 
2008, Tachibana, et al., 2005) in relation to the duration of the PPAR-agonist 
administration. The list included 186 genes, including those with established functional 
PPRE sites (true positives) such as catalase (Girnun et al., 2002), acyl-CoA oxidase 
(Varanasi et al., 1996), ACADM (Gulick et al., 1994), diazepam binding inhibitor 
isoform 1 (Helledie et al., 2002), HMG-CoA synthase (Rodriguez et al., 1994). Such an 
analysis revealed that after 2-weeks of troglitazone administration, PPAR-responsive 
proteins remained at basal levels (Wilcoxon rank sum test, P = 0.2572; Figure 38A). By 
contrast, after 4-weeks, down-regulation of PPAR-responsive proteins was observed 










Figure 38. Boxplots of PPAR-responsive proteins with differential expression upon 
troglitazone administration 
Boxplots showings the fold changes of proteins that are PPAR-responsive that changed with 
(A) 2 weeks and (B) 4 weeks of troglitazone adminstration. (A) At 2 weeks, there was no 
significant difference between the groups (Wilcoxon P > 0.05) (B) Signifcant differences 
(Wilcoxon P <0.01) at 4 weeks implied that the presence of PPREs, and by extension, 
prolonged troglitazone treatment may play a role in troglitazone-induced toxicity under 
increased mitochondrial oxidative stress. Outliers were represented as dots (defined as 1.5 × 
interquantile range) 
B A 
2 weeks 4 weeks 
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3.3.3.3. Parallel proteome shift suggests ROS-induced mitochondrial stress 
 
Another important functional cluster to explore would be redox homeostasis. 
Despite the intrinsic partial loss of Sod2 allele, the prolonged sensitization of the HET 
liver with troglitazone induced the up-regulation of SOD2 (FC4 weeks = 1.23), and this 
occurred with troglitazone treatment (Figure 24A). Notably, two proteins involved in 
reducing protein disulfides and maintaining redox homeostasis, peroxiredoxin3 and 
glutaredoxin-related protein 5 exhibited an increase in their fold changes. Consistent with 
this, mitochondrial 3-NT protein adducts and protein carbonyls were significantly 
increased after 4 weeks of troglitazone administration (Figure 25B and C). Together, 
these data strongly illustrated an increasing redox imbalance in the HET mouse that 
required additional SOD2 and other ROS-detoxifying enzymes to overcome the elevated 
O2•- that stemmed from chronic administration of a PPARγ-agonist (Ong, et al., 2007).  
 
In contrast to the redox homeostasis cluster, the mGSH transport cluster proved to 
be the most perturbed among the mitochondrial functional clusters, showing a highly 
reconfigured profile with prolonged troglitazone administration (MCV = 0.92). Anion 
transporters, dicarboxylate carrier (DIC; Slc25a10) and oxoglutarate carrier (OGC; 
Slc25a11), which mediated electroneutral exchange of dicarboxylates for inorganic 
phosphate and 2-oxoglutarate for other dicarboxylates, respectively have been suggested 
as GSH transporters (Fernandez-Checa & Kaplowitz, 2005, Lash, 2006). Mitochondrial 
uptake of GSH is essential for the maintenance of mGSH levels against elevated ROS 
levels. The impairment of GSH transport into the mitochondria will result in inadequate 
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mGSH to attenuate elevated ROS, as shown in Figure 25A. One adverse consequences of 
hepatic mGSH depletion is the potentiating of acetaminophen and usnic acid toxicity 
(Han et al., 2004, Zhao et al., 2002), thus highlighting the critical role of mGSH depletion 
in enhancing the toxicity of drugs. Noticeably, constituents of mGSH transport cluster, 
GPX1 and OGC were markedly up-regulated which suggested a compensatory response 
to an already compromised mGSH transport and protection. In summary, the results 
showed that troglitazone hit several mitochondrial functional clusters and in particular, 
exploited a compromised antioxidant environment due to Sod2 haplodeficiency, and 
acted through disrupted mGSH cycling to propagate damage to the mitochondria and 
liver.
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Table 10. Functional clustering of detected mitochondrial proteins. 
 
 
No. Functional Cluster MCV 
   
1 GSH homeostasis  0.9226491 
2 Transporters 0.9255224 
3 β-oxidation 0.9264068 
4 Fatty acid metabolism 0.9375569 
5 Detoxification 0.9545206 
6 Redox homeostasis 0.9647358 
7 Morphology and structure 0.9816671 
8 Ca2+ 0.9834463 
9 Bile salt biosynthesis 1.0398769 
10 Nucleobase, nucleoside, nucleotide and nucleic acid metabolic 
process 
1.0424324 
11 Electron Transport Chain 1.0719918 
12 Urea cycle 1.0769769 
13 Mito translation/transcription 1.0789724 
14 Tricarboxylic acid 1.1031997 
15 Stress response 1.1094348 
16 Amino acid metabolism 1.1094898 
17 Protein import machinery 1.1470873 
 
Only established mitochondrially-localized proteins were used for the Mean Centroid 
Value (MCV) calculations of 17 functional clusters. Probable proteins that are localized 
(or potentially organelle-promiscuous but not established) to the mitochondrion were 
excluded. Other mitochondrial functional clusters such as heme synthesis, ubiquinone 
biosynthesis and amino sugars metabolism were excluded due to insufficient data to 
calculate a feasible MCV. Functional clustering were manually curated from GO 









3.3.4. Prolonged troglitazone treatment activates FOXO3a through oxidative 
stress-mediated signals 
 
In vertebrates and C. elegans, Forkhead box-containing, O3a subfamily 
(FOXO3a) has been implicated as a transcriptional activator in the up-regulation of 
SOD2 as a form of oxidative-stress defence (Honda & Honda, 1999, Kops et al., 2002). 
As shown in Figure 39A, endogenous FOXO3a was activated in the HET mouse liver 
(indicated by moderate dephosphorylation at Ser253), while FOXO3a remained 
phosphorylated in the WT mouse. Treatment with troglitazone for 4 weeks in HET mice 
caused the dephosphorylation of p-FOXO3aSer253 (Figure 39B). By 
immunohistochemistry, control studies confirmed the sustained deactivation of FOXO3a 
(monitored by p-FOXO3aSer253; Figure 39B and C). Significantly, in areas of confluent 
hepatocytic degeneration of troglitazone-exposed HET livers, activation of FOXO3a 
occurred in a dephosphorylation-dependent manner and was translocated into the 
nucleus. In contrast, in the neighbouring surviving areas, FOXO3a remained 
phosphorylated at Ser253 and was retained in the cytoplasm (Figure 39D). Direct 
phosphorylation of Ser253, which is located at the nuclear localization signal domain of 
FOXO3a, is regulated by AKT/protein kinase B (AKT/PKB)-survival signalling which 
negatively regulates FOXO3a by promoting its interaction with 14-3-3 proteins and 
retention in the cytosol (Biggs et al., 1999). Subsequently, AKT/PKB activation was 
tested. In the control mice, FOXO3a inactivity and nuclear export was mediated by 
activated AKT/PKB (Figure 39E). Interestingly, AKT/PKB remained activated after 4 
weeks of troglitazone treatment. The presence of activated AKT/PKB induces the 
phosphorylation, nuclear export and transcriptional inactivation of FOXO3a but this was 
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not observed (Figure 39D). This suggested that there was an interference of AKT/PKB-
survival signalling by a competing signalling mechanism under increased oxidative stress 
and mGSH depletion that led to cell death.  
 
ROS are potent stressors to activating stress kinases including JNK and p38, 
which form part of the mitogen-activated protein kinase (MAPK) pathway. Indeed, JNK 
has been implicated in its antagonistic action against AKT/PKB-mediated FOXO3a- 
(Sunayama et al., 2005) and FOXO4-inactivation (Essers et al., 2004). More notably, 
JNK and p38-dependent in troglitazone-induced cytotoxicity has been observed 
previously (Bae & Song, 2003, Lim et al., 2008). Apoptosis signal-regulating kinase 1 
(ASK1) is the upstream kinase of JNK and p38 (Takeda et al., 2008).  We observed that 
after 4 weeks of daily administration, troglitazone activated ASK1 (phosphorylation of 
Thr845 and dephosphoryation of inhibitory residue Ser83; Figure 39E). This resulted in 
the activation of JNK but not p38 (Figure 39E). By contrast, minimal levels of 
phosphorylated JNK were observed for control groups and a slight increase in 2-weeks 
treated group (Figure 39E). The phosphorylated form of p38 was minimal in all study 
groups. Therefore, increased troglitazone-mediated mitochondrial oxidative stress and 
this led to ASK1-JNK activation in vivo and to the delay in observed hepatotoxicity. This 
indicated, in agreement with other reports (Bae & Song, 2003, Lim, et al., 2008), that 
troglitazone-induced hepatotoxicity proceeded through mitochondrial ROS-activated 
JNK. In the HET mouse, however, this occurred irrespective of p38. Further, this is 
consistent with reports of antagonism between JNK and AKT/PKB in the regulation of 
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FOXO3a nuclear import and transcriptional activation when the balance was tipped 
towards stress-signalling (Sunayama, et al., 2005).  
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Figure 39. Prolonged troglitazone exposure causes ASK1-dependent JNK and p38 
MAPK activation. 
(A & B) Immunoblot analysis of FOXO3a in WT and HET mice and in HET mice treated 
with vehicle or troglitazone over a period of 2 or 4 weeks. (C & D) 
Immunohistochemistry of vehicle-administered HET mouse and troglitazone-
administered HET mouse. Extended troglitazone administration caused FOXO3a 
dephosphorylation and nuclear translocation. Liver sections were incubated with anti-p-
FOXO3aSer253 antibody and counterstained. In areas with hepatocytic degeneration, 
FOXO3a was dephosphorylated and nuclearly imported (original magnification × 100). 
Insert illustrates the cytosolic localization of pFOXO3a (original magnification × 400). 
(E) The expression of pAKT at Ser453, AKT, pASK1 at Thr845 (activation pASK1Thr845) 
or Ser83 (inhibitory pASK1Ser83), pJNK at Thr183/Tyr185, JNK, p-p38 at 
Thr180/Tyr182, p38, were determined using immunoblot analysis. The relative ratios of 







3.3.5. Transcriptional regulation of SOD2 and the HET hepatic mitoproteome 
 
SOD2 expression and other mitochondrial proteins are also regulated by 
transcription factors or activators other than FOXO3a. Given that PGC-1α, a co-activator 
of PPARγ,  drove the gene expression of Sod2 under pro-oxidant status (St-Pierre et al., 
2006, Valle et al., 2005) and that troglitazone restored PGC-1α levels in the skeletal 
muscle of Zucker diabetic fatty rats (Jove et al., 2004), we investigated if prolonged 
troglitazone-induction of SOD2 was PGC-1α/PGC-1β-dependent. Unexpectedly, PGC-1α 
and PGC-1β levels remained at similar levels throughout the study and were independent 
of the form of treatment (Figure 40A). This is consistent with the lack of increase of 
LRPPRC levels which up-regulated PGC-1α and PGC-1β expression (Cooper et al., 
2006). NO has been implicated in modulating PGC-1α expression and in parallel, 
affected mitochondrial ROS defense (Borniquel et al., 2006). Interestingly, increased NO 
did not translate into higher PGC-1α levels (Figure 25A).  
 
However, in HET liver as compared to WT liver, PGC-1α but not PGC-1β may 
play a major role in orchestrating the mitoproteome profile under compromised 
mitochondrial antioxidant defense (Figure 40B). Other workers have reported that PGC-
1α and PGC-1β share the induction of several mitochondrial genes such as ATP synthase 
β subunit, ACADM, cytochrome c and COX IV. This was in agreement with our 
proteomics profiling results as these proteins were found to be differentially expressed in 
the HET liver relative to WT mice (Figure 40C, Supplemental Table 4). PPARγ 
expression has been reported to increase with troglitazone treatment in hepatocytes 
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(Davies et al., 1999), and we ask if the HET mitoproteome might be influenced by 
PPARγ given its role as a transcriptional regulator. Immunoblot analysis of liver extracts 
of vehicle and troglitazone-treated HET mice revealed no significant differences in 
PPARγ amounts across the time-course study (Figure 40A). This is consistent with 
another proteomic study in which treatment with a PPARγ agonist did not increase 
PPARγ mRNA levels (Lanne et al., 2006). Taken together, this indicated that 
troglitazone-induced SOD2 up-regulation and mitoproteome dynamics was independent 
of PGC-1α, PGC-1β, NO and PPARγ but regulated by FOXO3a. In addition, no 
significant difference was observed with duration or drug-treatment for two other well-
established transcriptional regulators of nuclear-encoded mitochondrial proteins, NRF-1 
and ERR-α (Figure 40A). Of note, PGC-1α, PGC-1β, NRF-1 and ERR-α are part of the 
nuclear regulatory program for mitochondrial biogenesis, indicating that troglitazone-
induced modification of the HET mitoproteome was not accompanied with mitochondrial 














































Figure 40. Transcriptional regulation over mitoproteome under elevated oxidative 
stress and troglitazone administration 
(A) Immunoblot analysis of transcriptional regulators and co-activators involved in 
regulating nuclear-encoded mitochondrial proteins upon short and long-term troglitazone 
administration in the HET mouse.  (B) Immunoblot analysis of transcriptional regulators 
and co-activators involved in regulating nuclear-encoded mitochondrial proteins in the 
HET mouse. (C) Bar graph showing the densitometric readings of several proteins 






HET WT  –      +      –     +      TGZ: 
















One of the aims of this study is to characterize the hepatic mitochondrial 
proteome of the heterozygous HET mouse, an increasingly used murine model in 
neurobiology, cardiovascular biology, aging research, and toxicology, to address is 
suitability as a preclinical mouse model of drug toxicity. Although the HET mouse has 
been characterized with respect to mitochondrial function and transcript expression of 
certain individual genes, the effects of the singular loss of the Sod2 allele on the global 
expression of hepatic mitochondrial proteins remains unknown. Specifically, we focused 
on the hepatic mitochondria because the partial reduction in SOD2 activity is likely to 
produce alterations in many of the important hepatic mitochondrial functions. This will 
address the suitability of the HET mouse as a surrogate animal model for studying DILI 
that arise as a result of clinically silent mitochondrial abnormalities.  
 
4.1.2. Purity of mitochondria preparation 
 
In this study we described an approach that uses discontinuous Percoll™ gradient 
to obtain a highly pure mitochondrial fraction. Preparation of highly pure mitochondrial 
fractions is critical to subcellular proteome research (Dunkley et al., 2006, Yates et al., 
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2005).  Based on immunoblotting against markers of ER, lysosomes and peroxisomes, we 
were able to confirm the lack of contaminating organelles. While we identified several 
nuclear, ER, lysosomal and peroxisomal proteins, they may represent minor 
contaminants, mitochondrial-associating proteins or multi-localized proteins. Sometimes 
their associations may even reflect a physiological condition. It is noteworthy that the 
mitochondria and the ER are spatially connected and organised, forming networks of 
interconnecting organelles (de Brito & Scorrano, 2008, Rizzuto & Pozzan, 2006). Such 
juxapositioning of the mitochondria and ER may facilitate the dual localization of 
proteins such as detoxifying cytochrome P450s (Omura, 2006) and phospholipid 
biosynthetic enzymes (Vance, 1990).  We also identified cathepsins A, B, C, D, H and Z 
in the proteomics profiles. Cathepsins are proteases found mainly in the lysosome. Under 
stress, defective or mutant mitochondria may be degraded by engulfing autphagic 
machinery such as lysosomes (Yu et al., 2008). Our findings may suggest an ongoing 
dynamic degradation of the HET mitochondria for the maintainence of homeostasis. The 
biological significance of such non-mitochondrial-associations remained to be 
determined. Nevertheless, the level of mitochondrial purity gave us the confidence to 
conduct proteomic analyses of the hepatic HET mitoproteome. 
 
4.1.3. The HET liver mitoproteome 
 
The vast majority of mitochondrial proteins, estimated at approximately 1000–
1500 (Pagliarini, et al., 2008, Taylor et al., 2003), are encoded by the nuclear genome, 
while 13 subunits of ETC complexes I, III, IV, and V (and the transfer RNA and 
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ribosomal RNA genes for protein synthesis) are encoded by the mtDNA. Proteomics 
analysis is a powerful method to assess the status of mitochondrial damage under 
pathological conditions of oxidative stress (Bailey, et al., 2005, Gibson, 2005). As a first 
step, 2D-DIGE coupled with MALDI-TOF/TOF MS/MS was used to resolve and identify 
these proteins. Because of the complexity of the mitochondrial proteome, additional 
proteomics methodologies would be required to reveal this protein complement. To 
increase proteome coverage, the mitochondrial samples were additionally profiled using a 
complementary MS-based proteomic approach. This approach has several merits, 
including no apparent biasness against proteins of any characteristics, higher dynamic 
range sensitivity as well as high level of reproducibility. Comparative proteomics by 4-
plex iTRAQ™ and 2D-DIGE coupled to with MALDI-TOF/TOF MS/MS  of HET mice 
versus WT mice revealed a mild redox perturbation in the mitochondrial proteome and 
demonstrated that mitochondrial proteins could cope with the mild pro-oxidant challenge. 
Overall, there was a good correlation between our findings and the functional or 
biochemical changes that have been described for this mouse model was observed 
(Huang et al., 1999, Kokoszka, et al., 2001, Lebovitz, et al., 1996, Liang & Patel, 2004, 
Ong, et al., 2006, Van Remmen et al., 2003, Van Remmen, et al., 1999, Van Remmen, et 
al., 2001, Williams, et al., 1998). Two features were particularly obvious. First, the 
changes in protein expression were mild and in the vast majority of proteins did not 
exceed two-fold changes. Although it is difficult to extrapolate from the observed change 
in abundance of a given protein to the possible consequences in a cell, these changes 
seemed relatively small when compared to other studies that have measured changes in 
protein expression after treatment with toxicants. Second, with the exception of SOD1 
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and 2, and thioredoxin domain-containing protein 4 and 5 (TXNDC4 and 5), most of the 
proteins involved in oxidant stress were up-regulated, rather than exhibiting decreased 
expression levels. Again, this is in contrast to other studies where rodents were treated 
with hepatotoxicants, including acetaminophen and bromobenzene, and where there was 
a bias towards lower protein levels (Fountoulakis et al., 2000, Fountoulakis et al., 2002). 
The reason for this is not entirely clear but it seems inviting to speculate that these 
changes are adaptive responses, likely compensatory mechanisms involved in 
counteracting the oxidative stress in mitochondria, rather than toxic responses leading to 
protein degradation. 
 
While it is expected that certain ROS-sensitive proteins ought to be hit or 
damaged by the cumulative oxidative stress in the HET mice, and hence would exhibit a 
lower expression level, but the contrary is true. Importantly, the expression levels of 
enzymes with [Fe-S] clusters such as ACO2, Complexes I and II which have been shown 
to be exquisitely sensitive to oxidative stress do not seem to be affected by the pro-
oxidant conditions and this was experimentally confirmed using iTRAQ™ quantitation 
analysis. This could be due to the constant signal feedback from mitochondria to the 
nucleus known as retrograde response (Poyton, 1996), resulting in compensatory 
homeostatic regulation of certain proteins. Another reason for this observation could be 
an up-regulation of the overall antioxidant defense systems, possibly via the nuclear 
transcriptional co-activator PGC-1α (St-Pierre, et al., 2006, Valle, et al., 2005) or it could 
be that the threshold for oxidative damage has not been attained (refer to Figure 5 for 
graphical explanation on the concept of thresholds). Thus, in the HET mouse, the partial 
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loss of SOD2 activity resulted in a pro-oxidant environment, whereby some form of 
compensatory mechanism is activated to achieve a new homeostatic condition. This 
implies that the singular loss of the Sod2 allele results in a subtle redox imbalance. 
 
4.1.3.1. Redox proteins 
 
SOD2 (MnSOD) is one of the major mitochondrial antioxidant enzymes and is 
involved in the enzymatic dismutation of O2•- toH2O2. A lowered expression of SOD2 
correlates with an increased redox imbalance in the mitochondria. It is therefore inviting 
to speculate that a number of the observed changes in the expression of the mitoproteome 
were a consequence of increased oxidant stress that is aimed at compensating the 
increases in superoxide levels. SOD1 (CuZnSOD) is primarily localized in the cytosol 
but can also be found in the intermembrane space in rat liver mitochondria (Okado-
Matsumoto & Fridovich, 2001). In contrast to previous reports (Lebovitz, et al., 1996, 
Williams et al., 1998) we show for the first time there is a decrease in the expression of 
SOD1 in the HET mouse. This decrease in SOD1 expression suggests a coordinated 
effect of SOD2 levels on SOD1 expression under conditions of increased ROS. In heart 
tissue of a different transgenic HET model (Strassburger et al., 2005), it was shown that 
SOD1 activity was decreased by 50% in the absence of a decrease in Sod1 mRNA and 
protein levels. The apparent discrepancy among several reports and the present data can 
be attributed in part that cytosolic SOD1 was measured while we focused entirely on 
mitochondria-associated SOD1. The reason for the decreased expression of mitochondrial 
intermembrane SOD1 is currently unknown. 
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Mitochondria are a key source of H2O2 generated either spontaneously or via 
enzymatic dismutation of O2•-. In addition to the endogenous production of O2•- and 
H2O2, the partial deletion of Sod2 adds further oxidative stress to the mitochondria and 
hepatocytes. The concomitant decrease in abundance of SOD2 and SOD1 would imply 
an accumulation of O2•- coupled with reduced amounts of H2O2. However, the general 
increased oxidative stress in mitochondria may induce compensatory feedback 
mechanisms resulting in upregulation of antioxidant enzymes including GPX1, GSTK1, 
MGST1 and catalase. This could explain the differentially increase expressed in levels of 
both H2O2-degrading enzymes. The up-regulation of GSTK1 and MGST1 suggested the 
increased recycling of mGSH to restore redox equilibrium with the partial ablation of 
Sod2. Depletion of mGSH is a hallmark to endogenous and chemically-induced oxidative 
stress. In the absence of intra-mitochondrial GSH synthesis, maintenance of the mGSH 
pool is crucial to ensure mitochondrial redox balance (Fernandez-Checa & Kaplowitz, 
2005). Although GPX is the most important H2O2-degrading enzyme in liver, we found 
that catalase was also upregulated. Catalase is generally contained in the peroxisomal 
matrix; however, previous reports indicate that catalase can also be found in rat cardiac 
mitochondria (Radi et al., 1991). More recently, a combined proteomics and 
bioinformatics prediction strategy has indicated that catalase is localized in rat liver 






Several members of the ETC proteins were detected in our proteomic profiling. 
Subunits of the ATP synthase were the most commonly-detected ETC proteins. An 
interesting observation is that while the ATP synthase α-subunit was downregulated, the 
β-subunit was upregulated in an almost compensatory manner. Both form the F1 catalytic 
portion necessary for phosphorylating ADP to ATP. The changes in α and β-subunits of 
ATP synthase probably reflect adaptive changes in the energy production as a result of 
mitochondrial oxidant stress. In contrast to these findings, other studies using protoxicant 
drugs that induce massive oxidant stress in mitochondria (e.g., acetaminophen) found a 
decrease in the ATP synthase β-subunit, which is a consequence of oxidative damage to 
the ATP synthase (Ruepp et al., 2002). ATP synthase subunit δ was observed to be 
upregulated, possibly reflecting the sustained generation of ATP. We also identified the 
down-regulation of cytochrome b-c1 complex subunit 7 (UQCRB) and cytochrome c 




4.1.3.3. Urea cycle 
 
Both carbamoyl phosphate synthase (CPS) and ornithine carbamoyltransferase 
(OTC) proteins are confined to the mitochondrial matrix. In particular CPS1 is one of the 
most abundant enzymes and rate limiting in catalyzing the first step of ureagenesis. The 
reason why both proteins are up-regulated in the HET mice is not entirely clear. 
However, besides playing a major role in the urea cycle, both CPS1 and OTC1 are 
involved in the synthesis and regulation of arginine, respectively. Arginine is a common 
substrate for arginase 1 and nitric oxide synthase. While arginase 1 is a known 
peroxisomal protein, close association of this enzyme with mitochondria is likely due to 
the functional link with the urea cycle enzymes OTC and CPS. More importantly, the 
decrease of arginase 1-like protein (Q3UEL0), a competitor of nitric oxide synthase for 
arginine, suggests that increased superoxide levels in the liver deplete NO (Aslan et al., 
2001). Thus, a pool of arginine may be required to restore a physiological amount of 
beneficial nitric oxide to attenuate oxidative stress already present (Dasgupta et al., 
2006). In contrast, ONOO- can be formed from excessive NO and a fine balanced NO 
production is mandatory. The decrease in arginine could signal both the upregulation of 
OTC and CPS to compensate for the generation of carbomyl phosphate and citrulline to 
ultimately regenerate arginine through the urea cycle. Thus, it is possible, that the 
increased levels reflect a response to altered NO synthesis from arginine as a 
consequence of accumulating O2•-, and is indicative of an adaptive mechanism as part of 





The decreased expression of the first two enzymes involved in fatty acid β-
oxidation (long-chain fatty acid-CoA ligase 1 and inorganic pyrophosphatase 2 may be a 
protective mechanism to reduce excessive NADH and FADH2 formation from the β-
oxidation process. Accumulation of reducing equivalents may pose a reductive stress and 
promote the formation of ROS (Adam-Vizi & Chinopoulos, 2006). Hence, down-
regulation of both proteins suggests a reaction to balance the NAD+/NADH ratio under 
the oxidative mitochondrial environment (Dawson et al., 1993). Consequently, the 
elevated expression of enoyl-CoA hydratase corresponds to the need to counteract further 
decreases in β-oxidation of fatty acids which yields acetyl-CoA that enters into the Krebs 
cycle. 
 
4.1.3.5. α-ketoglutarate dehydrogenase (KGDH) 
 
This mitochondrial matrix protein, also called 2-oxoglutarate dehydrogenase, is a 
TCA cycle enzyme catalyzing the oxidative decarboxylation of α-ketogluratate to 
succinyl-CoA, generating NADH. This protein complex comprises three protein subunits, 
KGDH (E1k), dihydrolipoamide succinyltransferase (E2k), and dihydrolipoyl 
dehydrogenase (E3). Mechanistic studies have revealed that KGDH is sensitive to 
oxidative stress and that it can be reversibly inactivated by ROS, suggesting that KGDH 
may serve an antioxidant function, limiting oxygen radical formation where H2O2 levels 
are high, and thus preventing further damage to mitochondria (Nulton-Persson & 
Szweda, 2001, Tretter & Adam-Vizi, 2005) In particular, the lipoic acid sulfhydryl group 
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of the E2k subunit make the protein exceptionally vulnerable to oxidative stress 
(Humphries & Szweda, 1998). Interestingly, the E1k subunit, which exhibited 
significantly increased protein expression in our study, was shown to be decreased 
approximately two-fold in the Sod2-/- mice (Hinerfeld et al., 2004) The reasons for the 
discrepancy are not known. However, it is possible that this protein which is highly 
sensitive to redox environment changes was up-regulated upon mild oxidant stress, while 
it becomes oxidatively damaged by extensive oxidative stress. The increase in E1k 
subunit could be reflective of a compensatory up-regulation, as it was found that the 
integrity of KGDH is extremely critical for NADH generation, especially in the early 
period of oxidative stress (Tretter, 2000). 
 
Collectively, we found that apart from an obvious 50% reduction in SOD2, a 
number of oxidative stress-sensitive proteins were differentially regulated, but that the 
overall changes were minimal. However, the consequences of these subtle changes in 
mitochondrial redox status in vivo are not known; they could affect the function of 
OXPHOS, the TCA cycle, β-oxidation, the urea cycle, and other enzymes that form part 
of the mitochondrial antioxidant defense system. 
 
 
Genetic mitochondrial abnormalities in the partial Sod2 knockout mouse generate 
a mitochondrial environment of cumulative endogenous ROS production which is latent. 
Because the HET mouse is sensitized to the adverse effects of sustained mitochondrial 
oxidant stress, they hold the potential to unmask toxic effects of drugs otherwise not seen 
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in healthy mice. In fact, a genetic polymorphism (47T > C mutation) in Sod24
 
 has been 
reported to predispose patients to a higher risk of DILI; that is, patients with C/C and C/T 




Our proteomics analysis of HET mouse liver mitochondria demonstrated that the 
overall changes in protein expression were quantitatively minor, and that most of the 
differentially expressed proteins were up-regulated. Part of this study (2D-DIGE) has 
already been published (Lee, et al., 2008a) and the iTRAQ™ work, which substantiated 
and extended the DIGE results will be published soon. The lack of a large number of 
down-regulated proteins suggested that the extent of oxidative stress had not attained a 
critical threshold that would adversely modify proteins. This implied that the singular 
loss of the Sod2 allele resulted in a subtle redox imbalance, representing a “1st hit”. The 
data confirmed biochemical and functional findings from earlier studies and are 
compatible with the hypothesis that the HET mouse is a suitable animal model for 
clinically silent mitochondrial abnormalities that can result in mild oxidative stress in 
mitochondria (Boelsterli & Lee, 2008). It has been generally recognized that 
heterozygous mutants could lead to interesting and novel genetic mouse models beyond 
knockout mice because such mice display partial-intermediate phenotypes. Heterozygous 
                                                 
4 Thymine for cytosine substitution at nucleotide 47 results in an alanine for valine substitution which may 
augment import into the mitochondrial matrix (Shimoda-Matsubayashi et al., 1996, Sutton et al., 2003). It 
is arguable why more SOD2 leads to liver injury but may be explained by the higher production of H2O2 
that overwhelms the system (Nahon et al., 2005, Sutton et al., 2006).  
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mice retain in part the function of the deleted gene, and compensatory mechanisms can 
ameliorate the mutation-evoked deficits (Kalueff et al., 2007). Importantly, this clinical 
scenario further supports the use of this murine model as a surrogate model for drug 








Mitochondrial dysfunction is a common feature of troglitazone-induced toxic 
events (Bova et al., 2005, Haskins et al., 2001, Lim, et al., 2008, Masubuchi et al., 2006, 
Nadanaciva et al., 2007, Narayanan et al., 2003, Shishido et al., 2003, Tirmenstein et al., 
2002) and that the underlying diminished redox defence of the HET mouse is a useful 
characteristic for the evaluation of mitochondrial toxic effects induced by hepatotropic 
drug challenges (Boelsterli & Hsiao, 2008, Boelsterli & Lee, 2008). However, the 
determinants of susceptibility to troglitazone-induced idiosyncratic liver injury have not 
yet been determined. Hence, the other major goal of this study is to obtain a global 
picture of the changes in the mitoproteome upon daily short- and long-term 
administration with troglitazone. We correlated molecular changes to histological and 
biochemical parameters. Figure 41 shows the toxicoproteomics workflow for this study. 
By doing so, it would allow a better understanding of the underlying molecular 
mechanisms and time-course of troglitazone hepatotoxicity, and that would facilitate the 
identification of potential early biomarkers of mitochondrial toxicity in vivo.  
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Figure 41. Workflow of toxicoproteomics 
2D-DIGE and iTRAQ™ were the main tools used for increasing coverage of the 
mitochondrial proteome. Various toxicological and biochemical endpoints were 
integrated and correlated with proteomic data termed as ‘phenotypic anchoring’ to 





4.2.2. Mitochondrial proteome expression dynamics induced by prolonged 
troglitazone treatment 
 
Two separate proteomic platforms were performed to study the time-course of 
troglitazone-induced liver toxicity in the HET mouse. Using 2D-DIGE, we found 70 
mitochondrial proteins that were differentially-modulated in the two time-points. To 
deepen our mechanistic understanding and increase the coverage of membraneous 
proteins, 8-plex iTRAQ™ in combination to MALDI TOF/TOF MS/MS was used. A 
total of 277 differentially-expressed proteins were revealed using this non-gel based 
method. For the 8-plex iTRAQ™ reporter structures have larger mass compared to the 4-
plex iTRAQ™ reagents (Pierce, et al., 2008), the 8-plex iTRAQ™-labelled peptides 
cannot be fragmented as efficiently with the same set of MS parameters used in 4-plex. 
Using Glu-fibrinopeptide B, at different collision gas pressures (6.2 × 10-8, 1.4 × 10-6 and 
3.5 × 10-6 Torr), the intensity of the reporter ion is markedly reduced in the 8-plex system 
(Figure 42; compare Figures 42F and 42I). Low reporter ion intensity tends to suffer from 
poor ion statistics. To obtain efficient MS/MS fragmentation and subsequent reliable fold 
change values, initial optimization of the collision gas pressure to suit the 8-plex system 
was required. At high collision gas pressure (3.5 × 10-6 Torr), high quantification 
accuracy was achieved (Figure 42J) but at a cost in protein identification sensitivity, as 
indicated by a drop of ~55% in the fragment ion intensity (Figure 42K). Having 
established the optimal collision gas pressure for 8-plex iTRAQ™, the mitochondrial 
samples were detected and quantifed by MS. 
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Off (6.2×10-8 Torr)            Medium (1.4×10-6 Torr)    High (3.5×10-6 Torr) 
Mass (m/z) 
Glu-Fib with no labelling 
Glu-Fib labelled with 4-plex iTRAQ™ 114 









































2 5 10 
Medium gas 2.4 ± 0.66 4.70 ± 0.84 8.01 ± 2.36 
High gas 2.14 ± 0.41 5.14 ± 0.84 9.44 ± 1.76 
J 
   
 
   
  
Figure 42.  Optimising of collision energy for 8-plex iTRAQ™.  
(A – I, K) Glu-fibrinopeptide B, labelled with channel 114 was used to optimise collision 
energy for a compromise between accurate and sensitive quantification of the peptide versus the 
iTRAQ™ reporter ion. (J & K) Quantification accuracy can be achieved with high collision gas 




The list of detected mitochondrial proteins was substantially physicochemically 
and functionally diverse; although the two combined proteomic methodology was not 
optimal for detecting certain classes of proteins such as the highly hydrophobic and small 
ones. This could partially stem from the intrinsic properties of MALDI that included the 
poorer ionization of hydrophobic peptides and the tendency to detect larger peptides 
(Lubec & Afjehi-Sadat, 2007) or insufficient solubilization of hydrophobic proteins.  
 
In our analysis, we found the occurrence of a two-stage mitoproteome response 
after a short- or long-term administration of troglitazone. This was observed by 
proteomic shifts across the time-course in terms of (i) the ratio of up-regulated versus 
down-regulated proteins, (ii) the absolute number of differentially-expressed proteins, 
(iii) the functional classes of the differentially-expressed proteins and (iv) the minimal 
overlap in the proteins in the two groups. From 2D-DIGE, the modest number of 
differentially-modulated proteins (24) and that 83% of them increased in abundance 
suggested that troglitazone-induced early changes in the mitochondrial proteome were 
adaptive. Such greater proportion of up-regulated proteins was similarly reflected in the 
8-plex iTRAQ™ study. An adaptive response to potential protoxicants typically involves 
transcriptional up-regulation of genes, changes to post-translational modifications and 
translocation of proteins into the mitochondria whose actions include eliminating the 
drug more efficiently and/or detoxifying reactive metabolites or ROS (antioxidant 
response), thus protecting the cell from initial damage (Ulrich & Friend, 2002). This was 
followed by a second phase where distinct proteome expression changes occurred that 
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were indicative of oxidative damage to a number of proteins as evidenced by decreased 
abundance of certain target proteins at 4 weeks. The small number of proteins common to 
both time-points (3 out of 70 proteins) reflected distinct and possibly stark changes that 
occurred at the molecular level.  
 
This study confirms and extends previous data obtained with this model (Ong, et 
al., 2007) where we had found that 2-week treatment with troglitazone did not cause any 
apparent liver injury, while 4-week treatment caused decreased mitochondrial function 
(complex I activity) and oxidative injury to hepatic mitochondria. Furthermore, this study 
confirms that troglitazone, administered to HET mice at doses that resulted in systemic 
exposure levels similar to the clinical situation, caused, in some animals, overt hepatic 
necrosis. 
 
4.2.2.1. Functional clustering of mitochondrial proteome 
 
A logical and common step in analyzing genomic or proteomic data will be to 
examine the extremes of the data set (Lescuyer et al., 2007, Ransohoff, 2005). This 
simple yet efficient method is useful in the discovery of biomarkers, in selecting those 
that are most or least altered in terms of abundance given a biological state. However 
such analyses do not address the full potential of proteome-wide experiments; they also 
place assumptions that the most modulated proteins represent the functionally most 
important proteins or that they correlate specifically to the biological state of interest. In 
addition, automated generation of annotated pathways can present a few issues in 
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interpreting proteomic data. For example, IPA canonical pathways software considers 
individual protein fold-change but not overall directionality. Secondly, with respect to 
protein fold-change thresholds, it establishes limits that constraints the inclusion of low-
to-moderately modulated proteins. Low-to-moderately modulated proteins are not 
necessarily functionally unimportant. By contrast, by capitalizing on the wider proteome 
coverage of MS-based proteomics, we took into account the entire range of differentially-
expressed proteins, from mild to drastic fold changes and derived the mean centroid value 
or MCV of functional clusters. On doing so, one could faithfully index the overall 
modulation of a pathway, recapitulate the complexity of robust biological pathways and 
also maximise the real potential of global-scale technologies. Results from this approach 
demonstrated that there were several functional clusters which were more susceptible to 
troglitazone-toxic effects than others. For example, with prolonged troglitazone 
administration, the mitochondrial GSH transport system, ion transporters and β-oxidation 
were more likely to influence the phenotypic changes on the HET liver than components 
of ETC, urea cycle and TCA cycle.  
 
4.2.2.2. Mitochondrial glutathione transport 
 
Significantly, one fragile functional cluster is the mGSH cycling/transport system. 
The mGSH cycling/transport system was the most negatively-affected mitochondrial 
functional cluster with prolonged troglitazone administration. The mGSH is intrinsically 
perturbed by a compromised mitochondrial ROS defence in the HET mouse (Figure 23) 
and this fragile cluster could confer a point of sensitization for troglitazone to expose its 
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toxic effects. This suggests that the mGSH cluster is intolerant of unregulated elevated 
levels of ROS, even in the subtle redox imbalance of the HET mouse. This may stem 
from the lack of de novo GSH synthesis in the mitochondria (Griffith & Meister, 1985, 
Martensson et al., 1990) and the mitochondrion must replenish its pool of GSH by 
importing cytosolic GSH. Numerous studies have highlighted the importance of mGSH 
depletion and the association of hepatotoxicities (Das & Vasudevan, 2007, Fernandez-
Checa & Kaplowitz, 2005, Zhao, et al., 2002).  
 
The transport of GSH into the mitochondria is ATP-dependent and can be 
inhibited by a collapse of  ∆Ψm (Martensson, et al., 1990). In addition, mGSH is an 
organic anion. Together, this suggest that GSH import cannot diffuse passively through 
the inner mitochondria membrane but require its active transport or exchange with 
another anion to reach the mitochondrial matrix (Lash, 2006). DIC, an anion carrier 
located on the inner mitochondrial membrane has been shown to function as a GSH 
transporter (Chen & Lash, 1998, Lluis et al., 2005, Zhong et al., 2008). The 
overexpression of rat kidney DIC, showing a two- to ten-fold increase in mGSH, 
confirmed the role of this carrier in the mitochondrial import of GSH in exchange for 
inorganic phosphate (Lash et al., 2002). In particular, DIC has three features that makes it 
a plausible target of troglitazone: (i) its temporal-based differential expression – up-
regulation followed by down-regulation, fits well with the two-stage changes observed at 
tissue level, (ii) knockdown of DIC in C. elegans increases ROS production that could 
result in further oxidative damage (Lee et al., 2009) and (iii) the apparent compensatory 
response of OGC, the other mGSH transporter in isolated rat liver mitochondria (Zhong, 
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et al., 2008) to counteract the deleterious effect of DIC damage. Therefore, the data 
suggests that troglitazone exploited a diminished antioxidant environment due to Sod2 
haplodeficiency, and then apparently acting through a disrupted mGSH cluster to elicit 
damage via downstream mechanisms on the liver. Independent clinical studies support 
and extend this hypothesis further (Huang, et al., 2007, Lucena et al., 2008, Tafazoli et 
al., 2005a, Watanabe et al., 2003). 
 
Association-studies on troglitazone-prescribed Japanese type II diabetes mellitus 
patients with elevated ALT (< 9 times upper limits of normal or ULN) and AST levels (< 
5 times ULN) revealed gene-polymorphisms with combined null glutathione-S-
transferase theta 1 (Gstt1) and glutathione-S-transferase mu1 (Gstm1) genotypes 
(Watanabe, et al., 2003).  A correlation of Gstt1-/- and Gstm1-/- genotype in humans with 
troglitazone-associated liver transaminase elevation suggested that these acquired genetic 
factors at least partially predispose certain groups of patients to troglitazone-induced 
toxicity. Similar to this, but in a separate clinical retrospective study, Gstm1-/- genotype 
and Sod2 polymorphisms increased the risk of anti-tuberculosis-DILI5
DILI susceptibility to perturbation in antioxidant defence, in particular GSH depletion. 
And because such sources of pathological changes are latent, there seems to be a 
 (Huang, et al., 
2007).  Lastly and most importantly, Lucena and colleagues of the Spanish Group for the 
Study of Drug-Induced Liver Disease found that null mutations of Gstt1and Gstm1 in 
Spanish patients exposed to a wide variety of drugs such as amoxicillin-clavulanate, 
nimsulide, flutamide and naproxen increased their susceptibility to DILI (Lucena, et al., 
2008). Taken together, the large pool of clinical evidence highlighted the convergence of  
                                                 
5 Names of anti-tuberculosis drugs were not provided in the publication 
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potentially strong correlation of silent genetic abnormalities in ROS detoxification and 
GSH-cycling to the underlying factors or contributors to DILI outcomes such as 
troglitazone-induced liver toxicity. The HET mouse model and the clinical analysis 
suggest that the preclinical, inherited impairment of oxidative stress defence may proceed 
for many years in the absence of observable symptoms until drug exposure sensitizes 
these individuals to the adverse effects of drugs. This is consistent with the rarity and 
unpredictable nature of idiosyncratic DILI. Further verification studies extending to the 
review of patient records in larger study cohorts will be critical in determining the role of 
irregularities in GSH cluster in troglitazone-induced liver injuries in a feasible fashion. 
Further confirmation of the role of GSH imbalance is demonstrated in studies performed 
in rats which showed that troglitazone has the highest propensity to oxidize GSH, and the 
highest pro-oxidant activity that caused hepatocytotoxicity (Tafazoli et al., 2005b). If 
increased oxidant stress due to a compromised mitochondrial antioxidant defence is 
indeed a susceptibility factor in DILI, the HET mouse and the concomitted in-depth study 
on mGSH cycling could be a very promising tool for predicting not only troglitazone-
toxicity but also other drugs such as the anti-tuberculosis drug mentioned above. 
Application of innovative molecular tools such as proteomics could signify a new 
paradigm in advancing mechanistic toxicity knowledge.  
 
In this study and a recent publication, toxicological and biochemical evidence 
supported the hypothesis further of acquired mitochondrial dysfunction as a susceptibility 
factor in idiosyncratic DILI by showing how cellular and mitochondrial injuries translate 
to liver failure upon extended troglitazone administration (Ong, et al., 2007). 
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Furthermore, this study confirmed that troglitazone, when chronically administered to 
HET mice at doses that resulted in systemic exposure levels similar to the clinical 
situation, caused overt hepatic necrosis. Combining the results from proteomics with 
conventional toxicological endpoints and histopathological studies, we were able to 
correlate molecular level with cellular and tissue-level alterations. Such an approach is 
known as phenotypic anchoring and can be defined as “the process of determining the 
relationship between a particular expression profile and the pharmacological or 
toxicological phenotype of the organism for a particular exposure or dose and at a 
particular time” (Tennant, 2002, Waters & Fostel, 2004). Together with the use of 
conventional endpoints, the proteomic pattern is reinforced to visible phenotypic changes 
and therefore aids in the definition of the sequence of molecular events that corresponds 
to the dose, time and mode-of-action of the toxicant. This is crucial, because each 
individual toxicant exerts different effects at different doses and duration – acute or 
chronic, upon re-challenge and so forth, and phenotypic anchoring helps to establish the 
molecular changes at the proteome level, to the toxicant’s specific mechanisms given a 
particular situation or condition. 
 
4.2.2.3. PPAR-agonist mitochondrial targets 
 
Among the changes in the mitoproteome, it is important but not always possible 
to distinguish between the drug-specific effects (including pharmacological effects) and 
non-specific, common toxic response pathways that merge or branch out more distally 
and that are shared with other hepatotoxicants (Kaplowitz, 2005). Specifically for 
troglitazone, effects on altered glucose and lipid homeostasis (PPARγ-dependent and –
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independent processes) should therefore be differentiated from effects arising as a 
consequence of, for example, intramitochondrial oxidative stress that triggers the 
ASK1/JNK pathway that led to lethal hepatocyte injury. For example, compound-
selective effects observed after 2 weeks included regulatory changes in fatty acid α- and 
β-oxidation, in particular upregulation of ACADM (the first step in β-oxidation) and 
HADH (the third step in β-oxidation), as well as 2-hydroxyacyl-CoA lyase (α-oxidation). 
Interestingly, the final step of β-oxidation (3-ketoacyl-CoA thiolase) was down-regulated 
at the protein level. Overall, this may reflect an adaptive response to the well-known 
inhibitory effects of thiazolidinediones on fatty acid oxidation, which is a consequence of 
an inhibition of acyl-CoA synthase (Fulgencio et al., 1996). Similarly, the observed up-
regulation of HMG-CoA synthase after 2 weeks could be a result of TDZ binding to 
PPARα/γ, which would transactivate HMG-CoA synthase by binding to its promoter 
region (Hegardt, 1999). With continued troglitazone administration, some of the changes 
that reflect disturbances in fatty acyl metabolism were still obvious. For example, 
ketoacyl-CoA thiolase and palmitoyl-CoA oxidase levels were decreased. 
 
The functional clustering analysis demonstrated that several of these clusters were 
less likely to play important roles in initiating or precipitating troglitazone-induced liver 
toxicity in the HET mouse. In some cases, it may be for the reason to curtail excessive 
cellular damage that the functional cluster remained at a basal state. For instance, the β-
oxidation cluster remained at basal levels even with extended troglitazone-administration. 
This is crucial because free fatty acids can enhance mitochondrial-generated ROS by 
inhibiting the OXPHOS and by interfering with electron flow (Schonfeld & Wojtczak, 
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2008). Alternatively, this could also imply troglitazone’s toxicity on this functional 
cluster given that this was opposite to troglitazone’s role in restoring defective β-
oxidation in human skeletal muscle and liver of the Zucker diabetic fatty rats (Cha, et al., 
2005, Ide et al., 2000). In addition, disruption of β-oxidation will result in hepatic 
steatosis (Bartlett & Eaton, 2004, Eaton et al., 1994). As such, adverse consequences to 
the mitochondria can be minimized if β-oxidation is regulated. It is important to note that 
it is PPARα, which is highly expressed in the liver rather than PPARγ that is likely 
driving the expressions of these β-oxidation enzymes. This remains a paradox as to how 
troglitazone exerts its effects when the expression of its receptor is low in the liver 
(Citters & Forman, 2004).  To this, it has been suggested that troglitazone is a dual 
agonist to PPARα and more strongly, PPARγ (Camp et al., 2000, Etgen et al., 2004, 
Lehmann et al., 1995).  
 
The overall decrease in PPAR-responsive genes/proteins suggested an association 
of PPAR-dependent toxicity under increased mitochondrial oxidative stress. While this 
mechanism has been proposed before (Peraza et al., 2006), it did not account for the low 
incidence and delayed onset of troglitazone DILI. Rather, accumulating evidence pointed 
to mitochondria and ROS in predisposing individuals to troglitazone DILI (Julie et al., 
2008). Such susceptibility factors could act in synergy with PPAR-ligand-induced 
toxicity and cause earlier and/or more severe manifestations of liver injuries potentially. 
 
Although hepatic PPARγ levels did not increase appreciably upon troglitazone 
treatment, a notable point is the binding potencies of thiazolidinediones to PPARγ. 
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Previous studies have shown that the affinity of different thiazolidinediones species to 
PPARγ can be ranked in the following order: rosiglitazone > pioglitazone > troglitazone 
= ciglitazone (Camp, et al., 2000, Willson et al., 1996, Young et al., 1998) and this 
preferential affinity may have direct influence on the degree of expression of PPARγ-




Sometimes, unbiased highthroughput approaches generate results that are counter-
intuitive. Impairment of OXPHOS has been a logical area of focus for mechanistic 
information of troglitazone-induced cytotoxicity (Nadanaciva, et al., 2007, Tirmenstein, 
et al., 2002). However, our in vivo results suggested that troglitazone-mediated ETC-
targeted toxicity may be early, if not transient, as denoted by healthy livers after 2 weeks 
of troglitazone treatment. In the Sod2-/- mouse brain, SDHB, a complex II subunit 
sensitive to Sod2 loss was observed to decrease in abundance (Hinerfeld, et al., 2004). In 
contrast, in the HET mouse, SDHB remained at basal levels, and decreased marginally 
after 2 weeks of troglitazone administration. Interestingly, continual troglitazone 
treatment led to SDHB up-regulation, presumably as a compensatory response for any 
ROS-induced defects mediated by troglitazone. One ETC subunit was particularly 
interesting. In both short- and long-term troglitazone treatments, NDUFS4 was down-
regulated. For this reason, NDUFS4, a nuclear-encoded ETC subunit, may be a sensitive 
protein biomarker to both early and sustained ROS toxicity.  The potential value of using 
NDUFS4 as biomarker was demonstrated by the Ndufs4-/- mutant mouse. Ndufs4-/- mice 
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die by 7 weeks (the usual lifespan of WT mice ranges from 60 to 104 weeks), thus 
suggesting the detrimental cumulative effect of NDUFS4 deficiency (Kruse et al., 2008), 
which is a useful characteristic in predicting long-term mitochondrial toxicity. 
  
4.2.2.5. Valine metabolism 
 
Other changes (e.g., increases in 3-hydroxyisobutyryl-CoA hydrolase and 
isobutyryl-CoA dehydrogenase) include alterations of enzymes involved in valine 
catabolism. Valine catabolism occurs in the mitochondria, and among the metabolic 
intermediates, methacrylyl-CoA (MC-CoA) is potentially mitotoxic by reacting with thiol 
groups on proteins or GSH (Taniguchi et al., 1996). In addition, MC-CoA can inhibit 
sulfhydryl-containing mitochondrial enzymes which must be maintained in the reduced 
form for proper function. MC-CoA is detoxified by two steps by MC-CoA hydratase and 
3-hydroxyisobutyryl-CoA (HIB-CoA) hydrolase. Interestingly, the subsequent catalysis 
of HIB-CoA by HIB-CoA hydrolase has been suggested to be cytoprotective against the 
toxic effects of MC-CoA (Taniguchi, et al., 1996). Thus, the increase in HIB-CoA 
hydrolase may be important in detoxifying MC-CoA as a result of increased valine 
catabolism. Preceding the formation of toxic MC-CoA is the catabolism of valine and 
isobutyryl-CoA. Unexpectedly, isobutyryl-CoA dehydrogenase (ACAD8) was shown to 
increase, which would result in more MC-CoA generated. Why this occurs is unclear. 
However, troglitazone reduces gluconeogenesis in the liver, and since valine is a 
glucogenic amino acid, upregulation of ACAD8 could generate more succinyl-CoA to 
enter the Krebs cycle for energy production. 
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4.2.2.6. Redox and Stress Response Proteins 
 
In contrast, the most prominent effects pointing to a drug-induced non-specific 
cell stress was a clear stress response signal and upregulation of the mitochondrial protein 
import machinery. After 2-weeks of drug treatment, members of the heat shock protein 
superfamily, mortalin (HSPA9) and HSP7C were modified and predominantly down-
regulated. These proteins are involved in refolding damaged proteins (chaperone 
function) and importing proteins into mitochondria; the changes may reflect adaptive 
responses that indicate underlying oxidant stress that can damage proteins including some 
stress response proteins themselves. Along the same line, Lon protease (LONP1), a 
matrix-selective protease that is involved in the removal of oxidatively damaged proteins 
was up-regulated (Bota & Davies, 2002). These data at the proteome level confirmed 
earlier findings obtained by Western blotting and showed that thiazolidinediones can 
induce members of HSP70 in non-hepatic and transformed liver cells in vitro (Maggi et 
al., 2000b, Maniratanachote, et al., 2005). Free and protein-bound methionine residues 
are oxidation-sensitive and readily oxidized to methionine sulfoxide derivatives which 
are in turn economically repaired by methionine sulfoxide reductase A (MSRA) 
(Moskovitz et al., 2001, Vogt, 1995). Methionine has been proposed to act as an intrinsic 
oxidation sink to protect other more oxidation-labile amino acids and structures (Levine 
et al., 1996, Stadtman et al., 2002), especially at sites with high ROS-production such as 
the mitochondria. Accordingly, the mitochondrial proteome contains more methionine 
than nuclear proteomes (Bender et al., 2008) and MSRA was found to be up-regulated in 
both 2- and 4-weeks study groups, possibly as a measure to repairing oxidized 
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methionine residues. In fact, the prolonged administration of troglitazone may have 
caused an overall up-regulation of stress response proteins and import proteins to cope 
with the challenge, but clearly, this compensatory response was insufficient and hepatic 
necrotic lesions ensued. With regards to drug-induced oxidant stress, additional markers 
indicative of mitochondrial oxidant stress thus became more apparent; for example, 
SOD2 was upregulated, while catalase was less abundant. In addition, Clp protease (an 
ATP-dependent protease) was up-regulated. These changes likely reflect adaptations to 
oxidative damage to proteins. In spite of this, mitochondrial protein carbonylation and 
nitration was significantly higher, indicating that there was an overwhelming oxidant 
stress on the mitoproteome which could neither be completely compensated by stress 




Taken together, the proteomic results demonstrate that low repeated doses of 
troglitazone given to HET mice (whose mitochondrial antioxidant defence is slightly 
compromised) resulted in a two-stage oxidant injury to liver mitochondria by afflicting 
several sensitive functional clusters (Figure 43). The first phase was an adaptation to a 
prooxidant challenge, as reflected in the modification and up-regulation of stress 
genes/proteins and the lack of increases in levels of markers of protein oxidation. Such a 
cellular stress response can be viewed as an early marker of impending toxicity (Heinloth 
et al., 2004). The subsequent phase was characterized by oxidative damage to and 
decreased abundance of a number of key proteins, among which ACO2 was identified as 
a potential biomarker of oxidant stress in liver mitochondria. In accordance with this, 
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protein oxidative damage and overt liver necrosis were increased after 4-week treatment. 
It is not known what determines the shift from adaptive responses (without overt signs of 
toxicity) to a toxic response. Because troglitazone itself is not being accumulated in liver 
over time despite higher hepatic levels as compared to plasma (Chojkier, 2005), it is 
likely that a cumulative adverse effect was building up, again compatible with 
mitochondrial injury. It is important to understand that it is the accumulation of a drug’s 
off-target effects that lead to liver injury, rather than the accumulation of troglitazone in 
the liver. The 2D-DIGE results have been published (Lee et al., 2008b) and our more 
recent findings based on 8-plex iTRAQ™ will be published shortly.    
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Figure 43. Proposed model of troglitazone-induced liver injury in the Sod2+/- mouse 
The intrinsic diminished mitochondrial antioxidant defense, especially the mGSH cycling, acts as a fragile point of sensitazation 
for troglitazone-induced oxidative stress to extend its adverse effects on the liver. Alterations to mitoproteome and protein 
oxidation are some of the consequential effects that form a vicious cycle, ultimately leading to livery injury. The red balls 
represent the cumulative effect of troglitazone and its adverse effects that build up and lead to injury and eventually 
mitochondrial and liver injury 
 167 
4.3. Aconitase-2 as a Potential Biomarker to Early Prediction of Toxicity 
 
The terminology of biomarkers was defined by the Biomarkers Definitions 
Working Group under National Institutes of Health  Director’s Initiative on Biomarkers 
and Surrogate Endpoints as “a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes, or pharmacological 
responses to a therapeutic intervention” (Atkinson et al., 2001). Biomarkers contribute 
information of the pathophysiological state and are valuable in assessing the efficacy of 
certain treatments, and serving as proof-of-concept.  
 
Because of the difficulty in picking up possible drug toxicities in normal and 
healthy murine models, there has been growing controversy on the value of using such 
mice as surrogates for studying human diseases (Dixit & Boelsterli, 2007, Nierkens & 
Pieters, 2005). In addition, there has been a recent change in strategies during 
toxicological evaluation by suggesting new mutant mouse models as surrogates to screen 
for drug toxicities (Dixit & Boelsterli, 2007, Griffin, 2006, Wallace, 1999). One strategy 
is to use the HET mouse in evaluating drug safety profiles. Hence in this study, 
proteomics and conventional toxicological endpoints were integrated to mine for 
potential protein signatures to predict idiosyncratic DILI. Importantly, the markers that 
most clearly pointed to a direct oxidative injury in mitochondria were associated with a 
decreased abundance of these proteins. Comparison between the 2 and 4 week study 
groups revealed only a few proteins which were concurrently affected by the toxicant in 
both groups. One such protein is ACO2. ACO2 is well recognized for its enhanced 
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sensitivity to oxidative stress due to its 4[Fe-s] clusters that are sensitive to prooxidants 
(Gardner et al., 1995; Nulton-Persson & Szweda, 2001) and has been proposed as a 
candidate biomarker in other proteomic studies (Bi et al., 2006, Hunzinger et al., 2006). 
Importantly, biochemical analysis has demonstrated that under increased oxidative stress, 
functional defects of ACO2 in the HET mouse do not necessarily correspond to 
significant changes in its  activity (Williams, et al., 1998). This can be attributed to a 
known PTM of ACO2, known as carbonylation (Yan et al., 1997). Therefore ACO2 
abundance alone is not sufficient to determine its utility as a sensitive and specific 
biomarker of oxidative stress. Note that iTRAQ™ did not detect changes in ACO’s 
expression. ACO2 undergoes three different fates under varying stages of oxidative 
stress. Under mild oxidant stress, ACO2 is carbonylated. Following more oxidative 
stress, carbonylated ACO2 is marked for proteolysis by Lon protease (Delaval, et al., 
2004). Lastly when exposed to more severe oxidant stress, ACO2 may form high-
molecular weight aggregates which is no longer a substrate for Lon protease (Bota & 
Davies, 2002), which we also consistently found after troglitazone treatment. 
 
Using 2D-DIGE, the changes occurring in ACO2 expression/PTM were partially 
demonstrated. In the 2 weeks study, the HET mouse is mildly sensitized by ROS-
inducing troglitazone, the decrease in ACO2 abundance levels correlated well with 
increased Lon protease expression thus representing the increased Lon-mediated 
degradation of ACO2. This is consistent with biochemical studies that showed an 
increase in Lon protease,  corresponding to increased degradation of oxidized ACO2 
under mild prooxidant conditions (Bota & Davies, 2002). With prolonged troglitazone 
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treatment the HET mitochondria is subjected to chronic oxidative stress and ACO2 
aggregated by becoming a poor substrate for Lon. However, aggregated ACO2 and Lon 
protease were not significantly modulated, as seen on the 2D-DIGE gels.  
 
 ACO2 has a peculiar sensitivity to oxidative damage and ability in distinguishing 
mild or chronic oxidative stress through a sustained change in expression and PTM over 
time. In addition, ACO2 function was also attenuated in  ex vivo mitochondria from 
troglitazone-treated HET mice (Ong, et al., 2007). These factors make ACO2 a promising 
candidate for a biomarker of mitochondrial oxidant stress and ensuing toxicity. Although 
further in-depth studies are still required, ACO2 can be a promising oxidative stress 
marker for early detection as well as for diagnosing a biological system’s redox status in 
response to oxidative insults, although not necessarily limited to troglitazone-induced 
ROS elevations but the early detection of ROS-inducing effects of drugs in general.  
 
4.4. Mechanistic toxicology of troglitazone-induced DILI 
 
Activation of JNK and p38 have been implicated as a mechanism in which 
troglitazone exerts its hepatocytotoxicity in vitro (Bae & Song, 2003, Lim et al., 2008). 
Here we show the in vivo ASK1-JNK1/2 activation in troglitazone-induced 
hepatotoxicity in the HET mouse, analogous to the major role JNK activation in 
acetaminophen-induced mouse liver injury (Gunawan et al., 2006, Tothova et al., 2007). 
There could be signalling crosstalk between ROS-mediated ASK1-JNK and FOXO3a 
through JNK-dependent phosphorylation of 14-3-3 (Sunayama et al., 2005, Sunters et al., 
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2006, Tsuruta et al., 2004) which led to the activation of FOXO3a governing the 
mitoproteome.  Interestingly, FOXO3a activation and translocation into the nucleus took 
place even when AKT remained phosphorylated. AKT phosphorylation regulates 
FOXO3a phosphorylation which in turn retains FOXO3a in the cytosol. This suggests 
that JNK antagonises AKT-mediated survival signals when the redox status is tipped 
towards that of a stressed one (Sunayama, et al., 2005).  This was in parallel with a 
marked increase in Sod2 expression following continual troglitazone treatment under 
inadequate mitochondrial oxidative stress management. Consistent with FOXO3a and its 
activation with a rise in ROS levels (Honda & Honda, 1999, Kops et al., 2002), 
prolonged troglitazone exposure in the HET liver led to dephosphorylation and nuclear 
translocation of FOXO3a to facilitate its role as a transcription factor. Such phenomenon 
can be intepreted as that of FOXO3a playing a significant role in modulating the 
mitochondrial antioxidant defence and possibly the mitoproteome during chronic 
toxicant-related liver injury. The ASK1-JNK-FOXO3a is therefore an attractive pathway 
for the development of toxicity tests ascribed to the detection of drugs with mitochondrial 
liability.  
 
Although this model cannot explain idiosyncratic liver failure in patients 
(Jaeschke, 2007), it demonstrated that a small, discreet defect in a mitochondrial 
antioxidant system (heterozygous Sod2 deficiency) can have dramatic consequences in 
vivo after challenge with therapeutic doses of troglitazone for a prolonged period of time. 
Furthermore, this model could help explain at the molecular level why patients who are 
exposed to drugs causing idiosyncratic DILI and who develop mild asymptomatic 
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transient increases in ALT most likely adapt to the potential prooxidant adverse effects of 




5.1. Implications of Studying the HET Hepatic Mitoproteome in Drug Safety 
Evaluation 
 
Idiosyncratic drug-induced hepatotoxicity represents a major problem in drug 
development due to a paucity of suitable animal models to predict such unwanted side 
effects (Dixit & Boelsterli, 2007). Therefore the HET mouse has been suggested as a 
preclinical mouse model for toxicological evaluation of drugs. So how does this current 
study contribute to the toxicology field? Firstly, we were able to link impairment of 
mitochondrial function to phenotype relevant to humans by taking into account the 
presence of a clinically latent ailment. Such animals are sensitized to the toxic effects of 
normally-mild drugs not seen in healthy, normal laboratory mice (Boelsterli, 2003a). This 
also offers a mechanistic reasoning as to why small groups of patients may be more 
susceptible from the larger population exposed to the drug. Secondly, through the use of 
proteomics, we were able to globally analyze the mitochondrial proteome after 
troglitazone treatment. The functional consequences of short-term and long-term 
troglitazone administration on the hepatic mitochondria are important in defining the 
mechanisms that underlie the delayed toxicity in humans. Presently, this represents one of 
the few mouse models that can mimic the human situation. Therefore, this study, through 
the integration of proteomics with conventional toxicological endpoints achieved the 
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three objectives set out initially. This includes addressing the suitability of the HET 
mouse to unmask potential idiosyncratic drug-induced adverse events, the role of 
genetically-acquired mitochondrial dysfunction in predisposing individuals to toxic 
effects and finally, giving new insights to the mechanisms of rare, idiosyncratic DILI 
When such a strategy is employed, more efforts can be made to better understand the key 




In this study we sought to determine the potentiality of the HET mouse in 
unmasking normally undetected toxic effects of drugs meant for improving the well-
being of patients. Because of the intrinsic redox disequilibrium in the HET mouse, it is a 
powerful animal model to study drug-induced pathogenesis under a lack of mitochondrial 
antioxidant protection. The absence of single Sod2 allele led to the increased ROS levels 
and also altered the expression and modification of a collection of mitochondrial proteins 
involved in redox homeostasis such as GPX1, GSTK1 and MGST1 and mitochondrial 
metabolic functions. This sustained increase in ROS was neither sufficient to deplete 
mGSH, nor was it severe enough to adversely affect normal mitochondrial functioning of 
the urea cycle, TCA cycle, OXPHOS and β-oxidation. This discreet and small deficit in 
mitochondrial antioxidant defence represents a “1st hit” which is particularly useful for 
modelling toxicant-related diseases (“2nd hits”) that converges on compromised 
mitochondrial function that progressively develops over a prolonged period of time.  
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We combined proteomics with classical toxicological endpoints in this study, 
generating a deeper understanding of the time-course and mechanisms of troglitazone-
induced toxicity on the HET hepatic mitochondria. Our results clearly revealed a two-
stage response which interestingly resembled the clinical outcome, showing a delayed 
toxic effect only after extended troglitazone exposure. Toxicoproteomic data revealed 
that the early mitochondrial response was compensatory, characterised by a larger 
proportion of up-regulated proteins (approximately 21% up-regulated versus 6% down-
regulated), an induction of the mitochondrial stress response and a lack of oxidized 
mitochondrial proteins. Subsequently, the mitochondria and liver succumbed by 4-weeks. 
In an almost reversal of the 2-weeks situation, we found that approximately 8% of the 
mitoproteome were up-regulated whereas 20% were down-regulated. Mitochondrial 
protein carbonyls and 3-NT adducts were significantly increased, in spite of increased 
SOD2 levels, suggesting that the threshold for oxidative injury has been reached. In 
addition, the mitochondrial GSH transport system was perturbed, indicating this 
functional cluster as a critical cluster in precipitating troglitazone DILI. This is strongly 
supported by independent clinical studies demonstrating that GSH, in the form of GST 
mutations, are linked to troglitazone-induced liver injury (Watanabe, et al., 2003). 
Together, these results link mitoproteome changes to the phenotypic changes on the liver, 
which triggered the abrupt progression of necrotic hepatic lesions. Through our study, we 
found ACO2 to be a potential biomarker candidate for mitochondrial oxidative stress. Its 
exquisite sensitivity to oxidative stress, mitochondrial localization and its various protein 
modifications make ACO2 a highly appropriate protein biomarker for distinguishing the 
different degrees of mitochondrial oxidative stress.  
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At a time when drug-induced toxicities remain an important concern, the US. 
Food and Administration has initiated the Critical Path Activities to modernize the drug 
development process and drug safety evaluation, among which mechanisms underlying 
DILI and its prediction came under the priority topic of “Better Evaluation Tools” (Faca 
et al., 2008, Hennessy & Strom, 2007). The use of proteomics on a mutant mouse model 
of acquired mitochondrial abnormality may therefore tremendously enhance and augment 




6. FUTURE WORK 
 
In this study, we demonstrated that the HET mouse has the potential to reveal 
troglitazone’s toxicity early. Toxicoproteomics was conducted in a comparative time-
course manner to guide better understanding of the underlying mechanisms of 
troglitazone-induced DILI. We have several suggestions to improve this approach.  
 
(1) To further accredit that this mutant mouse model is suitable for preclinical 
detection of drug-induced mitochondrial toxicity across a broader spectrum of drugs, it is 
necessary to rigorously assess the validity of this model across different drug classes. 
This validation of the HET mouse model as a proof-of-concept model was limited to 
troglitazone due to time constraints.  Some drugs of different classes which may help to 
extend the HET mouse model’s validity and show its sensitivity include tolcapone, an 
anti-Parkinson’s disease drug and flutamide, an antiandrogen for the treatment of prostate 
cancer. Such drugs caused idiosyncratic liver injuries in certain patients and they have 
been linked to drug-induced mitochondrial toxicity (Coe et al., 2007, Haasio et al., 2002).  
 
(2) On the basis that many drugs charged with causing idiosyncratic DILI affect 
the mitochondria, its functions or induction of cell death via the mitochondrial pathway, 
the HET mouse is potentially also an ideal surrogate mouse model to model the human 
clinical situation. While there is no conclusive experimental or clinical evidence to 
linking SOD2 deficiency/mutation in susceptible patients to idiosyncratic DILI, 
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association studies, GSH has emerged as a critical molecular in idiosyncratic DILI 
(Huang, et al., 2007, Lucena, et al., 2008, Tafazoli, et al., 2005a, Watanabe, et al., 2003). 
We could apply integrative proteomics to discover the perturbation of mGSH transport 
system with long-term troglitazone administration. We could also suggest the role of DIC 
in exposing hepatocytes to the toxic effects of troglitazone under a compromised 
mitochondrial antioxidative state. Manipulation of DIC by RNA interference can be used 
to investigate the toxicological consequences of altering mGSH upon troglitazone 
treatment and verify that DIC is an important determinant in precipitating troglitazone-
induced hepatotoxicity. Any dramatic changes in sensitivity of cells proceeding after DIC 
knock-down will suggest a constant influx of mGSH levels to maintain resistance to 
troglitazone. Unfortunately, given the time constraints on this study, we were unable to 
conduct RNA interference experiments. This set of experiments remain the next 
critically-importantly experiment to verify the functional role of DIC and its (if any) 
association in precipitating troglitazone DILI. 
 
(3) Historically, discovery proteomics generate a list of proteins which is 
validated based on immunological assays, thus providing the confidence to support the 
mass spectrometry data. In practice, a combination of factors, including the generation of 
redundant tryptic peptides, and thereafter varying ionization efficiencies for different 
amino acids, poor fragmentation and peptide identification resulted in only a fraction of 
the proteins being successfully detected in complex biological samples (Kuster et al., 
2005, Malmstrom et al., 2007). The undetected proteins may represent key components 
of pathways and yet, commercially available antibodies exist for only a small fraction of 
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the proteome. Therefore, this implies that there is a technological gap in the detection and 
quantification of a majority of proteins by existing methodologies. More recently, mass 
spectrometric multiple reaction monitoring or MRM has emerged as a specific, 
quantitative tool for targeted proteomics (Fusaro et al., 2009, Kuhn et al., 2004). 
Therefore as part of any future work, MRM, in combination with large-scale, unbiased 
toxicoproteomics could be employed to measure the presence and abundance of any 
protein-of-interest to obtain a truly global view of a proteome upon drug treatment.  
 
(4) It is worth mentioning that systems toxicology, a variant of systems biology 
has immense potential in advancing the understanding of toxicology in complex 
biological systems (Waters & Fostel, 2004). To leverage on our proteomic dataset and 
functional clustering, computational modelling can also be developed to create dense 
protein-interaction networks to help us understand the adverse effects of oxidative stress 
and troglitazone-induced pathological processes at the functional level. Although 
systemic integration of proteomic information with interactions is useful, they require 
high-quality protein-interaction datasets based on experimentally- and/or 
computationally-derived results. Reports of large-scale mouse protein-protein interactions 
remain modest (Li et al., 2009) and it limits our ability to generate a map of mouse 
protein-interactions using our HET mouse dataset. Mitochondrial protein-interaction 
maps are virtually absent to the best of our knowledge. We eagerly await further 
developments of such databases. 
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In summary, we have shown that toxicoproteomics of the HET mouse is a robust 
method in evaluating the time-course and mechanisms of troglitazone DILI. This fills a 
critical gap in understanding the progression of idiosyncratic DILI, albeit in troglitazone-
induced toxicity only. We hope that with improvements in technologies and 
methodologies such as MRM and protein-interaction networks, greater use of such an 
approach can be better applied to advance our understanding of toxicology in basic 
research and healthcare. Ultimately such knowledge should tremendously reduce drug 





7.1. MS/MS spectrum  
 
• 3-hydroxyisobutyrate dehydrogenase 
IPI00116222 (IPI_mouse_v.3.23) 
Best-scored peptide:  MS/MS Fragmentation of HGYPLILYDVFPDVCK 
MONOISOTOPIC mass of neutral peptide Mr: 1934.96 
Variable modifications:  
C15    : Carbamidomethyl (C) 
Ions Score: 32  Expect: 0.13   
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• Enoyl-CoA hydratase 
IPI00454049 (IPI_mouse_v.3.23) 
Best-scored peptide:  MS/MS Fragmentation of AQFGQPEILLGTIPGAGGTQR 
MONOISOTOPIC mass of neutral peptide Mr: 2110.12 
Ions Score: 33  Expect: 0.088   















































• Hydroxymethylglutaryl-CoA synthase  
IPI00420718 (IPI_mouse_v.3.23) 
Best-scored peptide:  MS/MS Fragmentation of APLVLEQGLR 
MONOISOTOPIC mass of neutral peptide Mr: 1094.64 
Ions Score: 33  Expect: 0.069   



















Residue b y 
A 72.04   
P 169.1 1024.61 
L 282.18 927.56 
V 381.25 814.48 
L 494.33 715.41 
E 623.38 602.33 
Q 751.43 473.28 
G 808.46 345.22 
L 921.54 288.2 
R   175.12 
 




7.2. Protein Tables 
 
 
Mean Centroid Values obtained from proteomic data  
 
Table 11. List of detected proteins used to calculate MCV 
  
B oxidation    
Accession # Name 2 weeks 4 weeks 
IPI:IPI00875372.1 Gene_Symbol=Echdc2 Isoform 2 of Enoyl-CoA 
hydratase domain-containing protein 2, mitochondrial  0.9463 1.2904 
IPI:IPI00387379.1 Gene_Symbol=Decr1 2,4-dienoyl-CoA reductase, 
mitochondrial  1.0006 0.9821 
IPI:IPI00121322.2 Gene_Symbol=Etfdh Electron transfer flavoprotein-
ubiquinone oxidoreductase, mitochondrial  1.0268 1.0189 
IPI:IPI00116753.4 Gene_Symbol=Etfa Electron transfer flavoprotein 
subunit alpha, mitochondrial  0.9453 1.0663 
IPI:IPI00848492.1 Gene_Symbol=LOC100045699 similar to Electron 
transferring flavoprotein, beta polypeptide isoform 2  0.9180 1.0153 
IPI:IPI00134961.1 Gene_Symbol=Acadm Medium-chain specific acyl-
CoA dehydrogenase, mitochondrial  0.9654 0.9922 
IPI:IPI00119203.4 Gene_Symbol=Acadvl Very long-chain specific acyl-
CoA dehydrogenase, mitochondrial  1.0590 1.0966 
IPI:IPI00894588.1 Gene_Symbol=Acadl Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial  1.0603 1.0329 
IPI:IPI00331251.1 Gene_Symbol=Acads Acyl-Coenzyme A 
dehydrogenase, short chain, isoform CRA_a  0.9653 1.0460 
IPI:IPI00330094.4 Gene_Symbol=Cpt1a Carnitine O-
palmitoyltransferase I, liver isoform  1.2898 0.9966 
IPI:IPI00881401.1 Gene_Symbol=Cpt2 carnitine palmitoyltransferase 2  1.1047 1.0996 
IPI:IPI00130804.1 Gene_Symbol=Ech1 Delta(3,5)-Delta(2,4)-dienoyl-
CoA isomerase, mitochondrial  0.9423 0.8760 
IPI:IPI00454049.4 Gene_Symbol=Echs1 Enoyl-CoA hydratase, 
mitochondrial  0.9221 1.1311 
IPI:IPI00121105.2 Gene_Symbol=Hadh Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial  0.9911 0.9936 
IPI:IPI00223092.5 Gene_Symbol=Hadha Trifunctional enzyme subunit 
alpha, mitochondrial  1.0484 0.9273 
IPI:IPI00115607.3 Gene_Symbol=Hadhb Trifunctional enzyme subunit 
beta, mitochondrial  1.0446 0.9955 
IPI:IPI00131584.1 Gene_Symbol=Slc25a20 Mitochondrial 
carnitine/acylcarnitine carrier protein  1.1764 1.0216 
IPI:IPI00653158.1 Gene_Symbol=Acaa2 Acetyl-Coenzyme A 
acyltransferase 2 (Mitochondrial 3-oxoacyl-Coenzyme 
A thiolase), isoform CRA_k 0.9729 1.0094 
IPI:IPI00122139.3 Gene_Symbol=Acaa1b;Acaa1a 3-ketoacyl-CoA 
thiolase B, peroxisomal  1.8786 0.4855 
IPI:IPI00154054.1 Gene_Symbol=Acat1 Acetyl-CoA acetyltransferase, 
mitochondrial  0.9671 0.9511 
IPI:IPI00331692.1 Gene_Symbol=Dci Putative uncharacterized protein  1.0440 1.0077 
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 MCV 1.0604 1.0017 
    
GSH recycling    
Accession # Name 2 weeks 4 weeks 
IPI:IPI00135231.2 Gene_Symbol=Idh1 0 day neonate lung cDNA, 
RIKEN full-length enriched library, clone:E030024J03 
product:isocitrate dehydrogenase 1 (NADP+), soluble, 
full insert sequence  1.0745 0.5321 
IPI:IPI00273164.1 Gene_Symbol=Aldh5a1 Succinate-semialdehyde 
dehydrogenase, mitochondrial  0.8826 1.0085 
IPI:IPI00121051.3 Gene_Symbol=Gstk1 Glutathione S-transferase kappa 
1  1.0470 0.8088 
IPI:IPI00230754.5 Gene_Symbol=Slc25a11 Mitochondrial 2-
oxoglutarate/malate carrier protein  1.0523 1.0804 
IPI:IPI00317074.3 Gene_Symbol=Slc25a10 Mitochondrial dicarboxylate 
carrier  1.2446 0.8863 
IPI:IPI00319652.2 Gene_Symbol=Gpx1 Glutathione peroxidase 1  0.8510 1.0472 
IPI:IPI00109109.1 Gene_Symbol=Sod2 Superoxide dismutase [Mn], 
mitochondrial  0.9572 1.2302 
IPI:IPI00135857.3 Gene_Symbol=Sod1 (BLAST score 313, P = 3e-84) 
EG667310;LOC545845 hypothetical protein isoform 4  0.9004 0.7967 
 MCV 1.0012 0.9238 
    
Redox detoxification    
Accession # Name 2 weeks 4 weeks 
IPI:IPI00109109.1 Gene_Symbol=Sod2 Superoxide dismutase [Mn], 
mitochondrial  0.9572 1.2302 
IPI:IPI00121051.3 Gene_Symbol=Gstk1 Glutathione S-transferase kappa 
1  1.0470 0.8088 
IPI:IPI00135857.3 Gene_Symbol=Sod1 (BLAST score 313, P = 3e-84) 
EG667310;LOC545845 hypothetical protein isoform 4  0.9004 0.7967 
IPI:IPI00319652.2 Gene_Symbol=Gpx1 Glutathione peroxidase 1  0.8510 1.0472 
IPI:IPI00378120.2 Gene_Symbol=Glrx5 Glutaredoxin-related protein 5  0.9794 1.1829 
IPI:IPI00896110.1 Gene_Symbol=Prdx5 Prdx5 protein  0.8965 1.0364 
IPI:IPI00116192.1 Gene_Symbol=Prdx3 Thioredoxin-dependent peroxide 
reductase, mitochondrial  1.0291 1.2911 
IPI:IPI00223367.5 Gene_Symbol=Uox Uricase  1.6255 0.5534 
IPI:IPI00111218.1 Gene_Symbol=Aldh2 Aldehyde dehydrogenase, 
mitochondrial  1.0188 1.0302 
 MCV 1.0339 0.9974 
    
Import Machinery   
Accession # Name 2 weeks 4 weeks 
IPI:IPI00751137.1 Gene_Symbol=Tomm70a Adult male thymus cDNA, 
RIKEN full-length enriched library, 
clone:5830412L10 product:Mitochondrial proteins 
import receptor (Translocase of outer membrane 
TOM70), full insert sequence  1.114 0.846 
IPI:IPI00125776.1 Gene_Symbol=ENSMUSG00000045455;Timm8a1 
Mitochondrial import inner membrane translocase 0.655 1.070 
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subunit Tim8 A  
IPI:IPI00134484.1 Gene_Symbol=Timm10;Timm13 Mitochondrial 
import inner membrane translocase subunit Tim13  0.709 1.222 
IPI:IPI00221608.3 Gene_Symbol=Samm50 Sorting and assembly 
machinery component 50 homolog  1.372 1.007 
IPI:IPI00170126.4 Gene_Symbol=Pitrm1 Isoform 1 of Presequence 
protease, mitochondrial  0.942 1.109 
IPI:IPI00117083.1 Gene_Symbol=Grpel1 GrpE protein homolog 1, 
mitochondrial  0.981 1.302 
IPI:IPI00274656.6 Gene_Symbol=Pmpcb Mitochondrial-processing 
peptidase subunit beta  0.889 1.286 
 MCV 0.952 1.120 
    
Tricarboxylic acid cycle 
Accession # Name 2 weeks 4 weeks 
IPI:IPI00405699.2 Gene_Symbol=Aldh4a1 Delta-1-pyrroline-5-
carboxylate dehydrogenase, mitochondrial  0.9840 1.0870 
IPI:IPI00109169.1 Gene_Symbol=Idh3g Isocitrate dehydrogenase [NAD] 
subunit gamma, mitochondrial  0.8768 1.0186 
IPI:IPI00126635.1 Gene_Symbol=Idh3b Tumor-related protein  0.9022 0.9376 
IPI:IPI00874456.1 Gene_Symbol=Dld Dihydrolipoyl dehydrogenase, 
mitochondrial  0.9035 1.0850 
IPI:IPI00134809.2 Gene_Symbol=Dlst Isoform 1 of Dihydrolipoyllysine-
residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial  0.9075 1.0970 
IPI:IPI00459725.2 Gene_Symbol=Idh3a Isoform 1 of Isocitrate 
dehydrogenase [NAD] subunit alpha, mitochondrial  0.9180 1.0072 
IPI:IPI00114710.2 Gene_Symbol=Pcx Activated spleen cDNA, RIKEN 
full-length enriched library, clone:F830201B12 
product:pyruvate carboxylase, full insert sequence  1.0633 1.4495 
IPI:IPI00261627.1 Gene_Symbol=Sucla2 Succinyl-CoA ligase [ADP-
forming] subunit beta, mitochondrial  0.9228 1.0914 
IPI:IPI00338536.1 Gene_Symbol=Sdhb Succinate dehydrogenase 
[ubiquinone] iron-sulfur subunit, mitochondrial  0.9480 1.1639 
IPI:IPI00113141.1 Gene_Symbol=Cs Citrate synthase, mitochondrial  0.9570 1.0160 
IPI:IPI00337893.2 Gene_Symbol=Pdha1 Pyruvate dehydrogenase E1 
component subunit alpha, somatic form, mitochondrial  0.9690 0.9875 
IPI:IPI00129928.2 Gene_Symbol=Fh1 Isoform Mitochondrial of 
Fumarate hydratase, mitochondrial  0.9707 1.1420 
IPI:IPI00323592.2 Gene_Symbol=Mdh2 Malate dehydrogenase, 
mitochondrial  0.9712 1.1020 
IPI:IPI00153660.4 Gene_Symbol=Dlat Dihydrolipoyllysine-residue 
acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial  0.9753 0.9653 
IPI:IPI00116074.1 Gene_Symbol=Aco2 Aconitate hydratase, 
mitochondrial  0.9813 1.0820 
IPI:IPI00845652.1 Gene_Symbol=Ogdh Isoform 3 of 2-oxoglutarate 
dehydrogenase E1 component, mitochondrial  1.0010 1.0916 
IPI:IPI00132042.1 Gene_Symbol=Pdhb Pyruvate dehydrogenase E1 
component subunit beta, mitochondrial  1.0197 1.0619 
IPI:IPI00461197.1 Gene_Symbol=Ldhd 10 days neonate skin cDNA, 1.0394 1.5385 
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RIKEN full-length enriched library, 
clone:4733401P21 product:weakly similar to 
PUTATIVE D-LACTATE DEHYDROGENASE 
(CYTOCHROME) OXIDOREDUCTASE PROTEIN  
IPI:IPI00406442.2 Gene_Symbol=Suclg1 Succinyl-CoA ligase [GDP-
forming] subunit alpha, mitochondrial  1.0159 1.0708 
IPI:IPI00459487.3 Gene_Symbol=Suclg2 Isoform 1 of Succinyl-CoA 
ligase [GDP-forming] subunit beta, mitochondrial  1.0329 1.0502 
IPI:IPI00875110.1 Gene_Symbol=Idh2 52 kDa protein  1.2126 0.9286 
IPI:IPI00117312.1 Gene_Symbol=Got2 Aspartate aminotransferase, 
mitochondrial  0.9640 1.1201 
IPI:IPI00230351.1 Gene_Symbol=Sdha Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, mitochondrial  0.9884 1.1603 
IPI:IPI00556699.1 Gene_Symbol=Gcsh Putative uncharacterized protein  0.9494 1.2510 
IPI:IPI00121218.5 Gene_Symbol=Fahd2a Fumarylacetoacetate hydrolase 
domain-containing protein 2A  1.0118 1.1611 
IPI:IPI00135231.2 Gene_Symbol=Idh1 0 day neonate lung cDNA, 
RIKEN full-length enriched library, clone:E030024J03 
product:isocitrate dehydrogenase 1 (NADP+), soluble, 
full insert sequence  1.0745 0.5321 
 MCV 0.9831 1.0845 
    
Urea cycle    
Accession # Name 2 weeks 4 weeks 
IPI:IPI00405699.2 Gene_Symbol=Aldh4a1 Delta-1-pyrroline-5-
carboxylate dehydrogenase, mitochondrial  0.9840 1.0870 
IPI:IPI00114209.1 Gene_Symbol=Glud1 Glutamate dehydrogenase 1, 
mitochondrial  0.9862 1.2509 
IPI:IPI00776257.1 Gene_Symbol=Otc Otc protein  0.9645 1.0244 
IPI:IPI00111908.8 Gene_Symbol=Cps1 Carbamoyl-phosphate synthase 
[ammonia], mitochondrial  0.9196 1.2264 
IPI:IPI00223367.5 Gene_Symbol=Uox Uricase  1.6255 0.5534 
IPI:IPI00119945.1 Gene_Symbol=Nit2 Nitrilase homolog 2  0.9843 0.9547 
IPI:IPI00117312.1 Gene_Symbol=Got2 Aspartate aminotransferase, 
mitochondrial  0.9640 1.1201 
IPI:IPI00110843.3 Gene_Symbol=Agmat Agmatinase, mitochondrial  0.7623 1.0844 
IPI:IPI00113073.3 Gene_Symbol=Aldh1b1 Aldehyde dehydrogenase X, 
mitochondrial  0.8547 1.4719 
IPI:IPI00124372.3 Gene_Symbol=Aldh9a1 aldehyde dehydrogenase 9, 
subfamily A1  0.9230 0.9621 
IPI:IPI00230084.5 Gene_Symbol=Aldh7a1 aldehyde dehydrogenase 
family 7, member A1 isoform a  1.0447 1.1818 
 MCV 1.0012 1.0834 
    
Transporters    
Accession # Name 2 weeks 4 weeks 
IPI:IPI00125853.1 Gene_Symbol=Slc25a15 Mitochondrial ornithine 
transporter 1  1.031 1.267 
IPI:IPI00109275.1 Gene_Symbol=Slc25a22 Mitochondrial glutamate 
carrier 1  1.052 0.972 
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IPI:IPI00230754.5 Gene_Symbol=Slc25a11 Mitochondrial 2-
oxoglutarate/malate carrier protein  1.052 1.080 
IPI:IPI00850430.1 Gene_Symbol=Slc25a3 LOC100046151 similar to 
Solute carrier family 25 (mitochondrial carrier, 
phosphate carrier), member 3  1.084 1.059 
IPI:IPI00131584.1 Gene_Symbol=Slc25a20 Mitochondrial 
carnitine/acylcarnitine carrier protein  1.176 1.022 
IPI:IPI00276926.3 Gene_Symbol=Slc25a1 NOD-derived CD11c +ve 
dendritic cells cDNA, RIKEN full-length enriched 
library, clone:F630026H16 product:solute carrier 
family 25 (mitochondrial carrier  1.177 1.158 
IPI:IPI00135651.1 Gene_Symbol=Slc25a13 Calcium-binding 
mitochondrial carrier protein Aralar2  1.226 1.076 
IPI:IPI00317074.3 Gene_Symbol=Slc25a10 Mitochondrial dicarboxylate 
carrier  1.245 0.886 
IPI:IPI00127841.3 Gene_Symbol=Slc25a5 ADP/ATP translocase 2  1.385 1.116 
IPI:IPI00117312.1 Gene_Symbol=Got2 Aspartate aminotransferase, 
mitochondrial  0.964 1.120 
IPI:IPI00230540.1 Gene_Symbol=Vdac1 Isoform Mt-VDAC1 of 
Voltage-dependent anion-selective channel protein 1  1.068 1.082 
IPI:IPI00122547.1 Gene_Symbol=Vdac2 Voltage-dependent anion-
selective channel protein 2  1.147 1.101 
IPI:IPI00876341.1 Gene_Symbol=Vdac3 Voltage-dependent anion-
selective channel protein 3  1.495 1.096 
IPI:IPI00648829.1 Gene_Symbol=Nipsnap3a Nipsnap homolog 3A  0.861 1.116 
 MCV 1.140 1.082 
    
Stress response    
Accession # Name 2 weeks 4 weeks 
IPI:IPI00133270.1 Gene_Symbol=Clpp Putative ATP-dependent Clp 
protease proteolytic subunit, mitochondrial  0.918 1.272 
IPI:IPI00880839.1 Gene_Symbol=Hspa9 heat shock protein 9  0.963 1.127 
IPI:IPI00788396.1 Gene_Symbol=Clpx caseinolytic protease X isoform 2  1.068 1.025 
IPI:IPI00475322.1 Gene_Symbol=Msra Msra protein  1.109 1.116 
IPI:IPI00761408.2 Gene_Symbol=Lonp1 Lon protease homolog, 
mitochondrial  1.133 1.096 
IPI:IPI00132762.1 Gene_Symbol=Trap1 Heat shock protein 75 kDa, 
mitochondrial  1.065 1.004 
IPI:IPI00308885.6 Gene_Symbol=Hspd1 Isoform 1 of 60 kDa heat shock 
protein, mitochondrial  0.867 1.138 
IPI:IPI00263863.8 Gene_Symbol=Hspe1 10 kDa heat shock protein, 
mitochondrial  0.865 1.112 
IPI:IPI00319992.1 Gene_Symbol=Hspa5 78 kDa glucose-regulated 
protein  1.045 0.662 
IPI:IPI00223216.5 Gene_Symbol=Tst Thiosulfate sulfurtransferase  1.014 1.096 
 MCV 1.005 1.065 
    
Fatty acid metabolism   
Accession # Name 2 weeks 4 weeks 
IPI:IPI00126625.1 Gene_Symbol=Acsm1 Isoform 1 of Acyl-coenzyme A 1.062 1.119 
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synthetase ACSM1, mitochondrial  
IPI:IPI00886014.1 Gene_Symbol=Acss3 Isoform 1 of Acyl-CoA 
synthetase short-chain family member 3, 
mitochondrial  0.965 1.018 
IPI:IPI00122633.3 Gene_Symbol=Acsf2 Acyl-CoA synthetase family 
member 2, mitochondrial  1.025 1.018 
IPI:IPI00230113.5 Gene_Symbol=Cyb5 Cytochrome b5  1.050 0.594 
IPI:IPI00874376.1 Gene_Symbol=Apool 10, 11 days embryo whole body 
cDNA, RIKEN full-length enriched library, 
clone:2810024N24 product:hypothetical protein, full 
insert sequence  1.336 1.203 
IPI:IPI00831119.1 Gene_Symbol=Lypla1 21 kDa protein  0.931 0.918 
IPI:IPI00130804.1 Gene_Symbol=Ech1 Delta(3,5)-Delta(2,4)-dienoyl-
CoA isomerase, mitochondrial  0.942 0.876 
IPI:IPI00222430.5 Gene_Symbol=Dbi diazepam binding inhibitor 
isoform 1  0.702 1.193 
IPI:IPI00113073.3 Gene_Symbol=Aldh1b1 Aldehyde dehydrogenase X, 
mitochondrial  0.855 1.472 
IPI:IPI00273164.1 Gene_Symbol=Aldh5a1 Succinate-semialdehyde 
dehydrogenase, mitochondrial  0.883 1.009 
IPI:IPI00124372.3 Gene_Symbol=Aldh9a1 aldehyde dehydrogenase 9, 
subfamily A1  0.923 0.962 
IPI:IPI00379694.4 Gene_Symbol=Hmgcl 3-hydroxy-3-methylglutaryl-
Coenzyme A lyase  0.937 1.012 
IPI:IPI00875372.1 Gene_Symbol=Echdc2 Isoform 2 of Enoyl-CoA 
hydratase domain-containing protein 2, mitochondrial  0.946 1.290 
IPI:IPI00230084.5 Gene_Symbol=Aldh7a1 aldehyde dehydrogenase 
family 7, member A1 isoform a  1.045 1.182 
 MCV 0.972 1.062 
    
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 
Accession # Name 2 weeks 4 weeks 
IPI:IPI00855212.1 Gene_Symbol=1110020G09Rik Isoform 2 of 
UPF0465 protein C5orf33 homolog  0.8837 1.0150 
IPI:IPI00648318.1 Gene_Symbol=Ak2 Adult male liver tumor cDNA, 
RIKEN full-length enriched library, 
clone:C730019E03 product:ADENYLATE KINASE 2 
homolog  0.8764 1.0009 
IPI:IPI00742309.1 Gene_Symbol=Kmo Isoform 2 of Kynurenine 3-
monooxygenase  1.2105 1.1066 
IPI:IPI00133034.3 Gene_Symbol=Hint2 Histidine triad nucleotide-
binding protein 2  0.9080 1.0788 
IPI:IPI00221769.5 Gene_Symbol=Ak3 GTP:AMP phosphotransferase 
mitochondrial  0.9106 1.0956 
 MCV   
    
PPAR signalling    
Accession # Name 2 weeks 4 weeks 
IPI:IPI00420718.4 Gene_Symbol=Hmgcs2 Hydroxymethylglutaryl-CoA 
synthase, mitochondrial  1.069 0.992 
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IPI:IPI00222430.5 Gene_Symbol=Dbi diazepam binding inhibitor 
isoform 1  0.702 1.193 
IPI:IPI00134961.1 Gene_Symbol=Acadm Medium-chain specific acyl-
CoA dehydrogenase, mitochondrial  0.965 0.992 
IPI:IPI00119203.4 Gene_Symbol=Acadvl Very long-chain specific acyl-
CoA dehydrogenase, mitochondrial  1.059 1.097 
IPI:IPI00330094.4 Gene_Symbol=Cpt1a Carnitine O-
palmitoyltransferase I, liver isoform  1.290 0.997 
IPI:IPI00881401.1 Gene_Symbol=Cpt2 carnitine palmitoyltransferase 2  1.105 1.100 
 MCV 1.032 1.062 
    
Electron Transport Chain   
Accession # Name 2 weeks 4 weeks 
IPI:IPI00133006.1 Gene_Symbol=Ndufab1 Acyl carrier protein, 
mitochondrial  1.147 1.049 
IPI:IPI00130460.1 Gene_Symbol=Ndufv1 NADH dehydrogenase 
[ubiquinone] flavoprotein 1, mitochondrial  1.045 1.073 
IPI:IPI00120212.1 Gene_Symbol=Ndufa9 NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 9, 
mitochondrial  1.138 0.955 
IPI:IPI00125929.2 Gene_Symbol=Ndufa4 NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 4  0.871 1.134 
IPI:IPI00130322.5 Gene_Symbol=Ndufa7 NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 7  0.969 1.132 
IPI:IPI00116748.1 Gene_Symbol=Ndufa10 NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 10, 
mitochondrial  1.169 1.144 
IPI:IPI00169925.2 Gene_Symbol=Ndufv2 Isoform 1 of NADH 
dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial  1.069 0.986 
IPI:IPI00387430.1 Gene_Symbol=Ndufb8 NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 8, 
mitochondrial  0.998 1.145 
IPI:IPI00120232.1 Gene_Symbol=Ndufs7 NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 7, mitochondrial  1.134 1.172 
IPI:IPI00308882.4 Gene_Symbol=Ndufs1 NADH-ubiquinone 
oxidoreductase 75 kDa subunit, mitochondrial  1.064 1.054 
IPI:IPI00230715.5 Gene_Symbol=Ndufa13 NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 13  1.200 0.983 
IPI:IPI00170093.3 Gene_Symbol=Ndufs8 NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 8, mitochondrial  0.943 1.009 
IPI:IPI00881750.1 Gene_Symbol=Ndufb5 14 kDa protein  1.117 1.032 
IPI00880613.1 Gene_Symbol=Ndufb10 18 kDa protein  1.023 1.109 
IPI:IPI00132623.3 Gene_Symbol=Ndufb9 NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 9  0.827 1.130 
IPI:IPI00133403.1 Gene_Symbol=Ndufb3 NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 3  1.063 0.991 
IPI:IPI00133399.1 Gene_Symbol=Ndufa6 NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 6  0.995 1.126 
IPI:IPI00662861.1 Gene_Symbol=LOC635087 similar to NADH 
dehydrogenase (ubiquinone) 1, subcomplex unknown, 1.219 0.976 
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2  
IPI:IPI00229008.2 Gene_Symbol=Ndufs4 NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 4, mitochondrial  0.774 0.875 
IPI:IPI00128023.3 Gene_Symbol=Ndufs2 NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 2, mitochondrial  0.828 1.259 
IPI:IPI00114246.2 Gene_Symbol=Ndufb11 NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 11, 
mitochondrial  0.922 1.090 
IPI:IPI00121309.2 Gene_Symbol=Ndufs3 NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 3, mitochondrial  0.774 0.957 
IPI:IPI00648743.1 Gene_Symbol=Ndufb6 NADH dehydrogenase 
(Ubiquinone) 1 beta subcomplex, 6  0.924 1.333 
IPI:IPI00315302.5 Gene_Symbol=Ndufa2 NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 2  0.507 0.998 
IPI:IPI00230351.1 Gene_Symbol=Sdha Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, mitochondrial  1.017 1.171 
IPI:IPI00338536.1 Gene_Symbol=Sdhb Succinate dehydrogenase 
[ubiquinone] iron-sulfur subunit, mitochondrial  0.948 1.164 
IPI:IPI00119138.1 Gene_Symbol=Uqcrc2 Cytochrome b-c1 complex 
subunit 2, mitochondrial  0.986 1.040 
IPI:IPI00555000.2 Gene_Symbol=Uqcrb Cytochrome b-c1 complex 
subunit 7  0.964 1.118 
IPI:IPI00653598.2 Gene_Symbol=Uqcrc1 ubiquinol-cytochrome c 
reductase core protein 1  1.035 1.171 
IPI:IPI00224210.5 Gene_Symbol=Uqcrq Cytochrome b-c1 complex 
subunit 8  0.908 0.986 
IPI:IPI00133240.1 Gene_Symbol=Uqcrfs1 Cytochrome b-c1 complex 
subunit Rieske, mitochondrial  0.971 0.988 
IPI:IPI00230113.5 Gene_Symbol=Cyb5 Cytochrome b5  1.050 0.594 
IPI:IPI00222419.5 Gene_Symbol=ENSMUSG00000058927;Cycs 
Cytochrome c, somatic  0.899 1.128 
IPI:IPI00117978.1 Gene_Symbol=Cox4i1 Cytochrome c oxidase subunit 
4 isoform 1, mitochondrial  0.962 1.130 
IPI:IPI00785410.1 Gene_Symbol=Cox5b Cytochrome c oxidase subunit 
5B, mitochondrial  0.848 1.028 
IPI:IPI00131771.3 Gene_Symbol=Cox6c Cytochrome c oxidase 
polypeptide VIc  0.978 1.049 
IPI:IPI00225390.5 Gene_Symbol=Cox6b1 Cytochrome c oxidase subunit 
VIb isoform 1  0.809 1.132 
IPI:IPI00120719.4 Gene_Symbol=Cox5a Cytochrome c oxidase subunit 
5A, mitochondrial  0.931 1.129 
IPI:IPI00131176.1 Gene_Symbol=mt-Co2 Cytochrome c oxidase subunit 
2  1.255 1.030 
IPI:IPI00355248.5 Gene_Symbol=mt-Co1 cytochrome c oxidase subunit I  1.304 0.815 
IPI:IPI00132728.2 Gene_Symbol=Cyc1 Isoform 1 of Cytochrome c1, 
heme protein, mitochondrial  1.187 1.003 
IPI:IPI00468481.2 Gene_Symbol=Atp5b ATP synthase subunit beta, 
mitochondrial  0.946 1.065 
IPI:IPI00130280.1 Gene_Symbol=Atp5a1 ATP synthase subunit alpha, 
mitochondrial  0.968 1.052 
IPI:IPI00623553.1 Gene_Symbol=Atp5h (BLAST score: 326, P = 4e-88) 1.068 0.969 
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LOC100044492;ENSMUSG00000068706 
hypothetical protein  
IPI:IPI00341282.2 Gene_Symbol=Atp5f1 ATP synthase subunit b, 
mitochondrial  1.120 0.909 
IPI:IPI00118986.1 Gene_Symbol=Atp5o;LOC100047429 ATP synthase 
subunit O, mitochondrial  1.008 1.030 
IPI:IPI00776084.1 Gene_Symbol=Atp5c1 ATP synthase gamma chain  1.100 1.137 
IPI:IPI00125460.1 Gene_Symbol=Atp5j;LOC674583 ATP synthase-
coupling factor 6, mitochondrial  0.726 1.028 
IPI:IPI00271986.6 Gene_Symbol=Atp5j2 ATP synthase subunit f, 
mitochondrial  0.956 1.084 
IPI:IPI00453777.2 Gene_Symbol=Atp5d ATP synthase subunit delta, 
mitochondrial  0.852 1.055 
IPI:IPI00116896.1 Gene_Symbol=mt-Atp8 ATP synthase protein 8  1.005 1.116 
IPI:IPI00111770.7 Gene_Symbol=Atp5k ATP synthase subunit e, 
mitochondrial  0.804 0.987 
IPI:IPI00169862.1 Gene_Symbol=Coq9 Ubiquinone biosynthesis protein 
COQ9, mitochondrial  0.824 1.101 
IPI:IPI00273164.1 Gene_Symbol=Aldh5a1 Succinate-semialdehyde 
dehydrogenase, mitochondrial  0.883 1.009 
IPI:IPI00848492.1 Gene_Symbol=LOC100045699 similar to Electron 
transferring flavoprotein, beta polypeptide isoform 2  0.918 1.015 
IPI:IPI00116753.4 Gene_Symbol=Etfa Electron transfer flavoprotein 
subunit alpha, mitochondrial  0.945 1.066 
IPI:IPI00121322.2 Gene_Symbol=Etfdh Electron transfer flavoprotein-
ubiquinone oxidoreductase, mitochondrial  1.027 1.019 
 MCV 0.981 1.053 
    
Ca2+    
Accession # Name 2 weeks 4 weeks 
IPI:IPI00131177.1 Gene_Symbol=Letm1 LETM1 and EF-hand domain-
containing protein 1, mitochondrial  0.906 0.927 
IPI:IPI00135651.1 Gene_Symbol=Slc25a13 Calcium-binding 
mitochondrial carrier protein Aralar2  1.226 1.076 
IPI:IPI00115824.1 Gene_Symbol=Nipsnap1 Protein NipSnap homolog 1  1.063 1.139 
 MCV 1.065 1.047 
    
Detoxification   
Accession # Name 2 weeks 4 weeks 
IPI:IPI00226140.5 Gene_Symbol=Maob Amine oxidase [flavin-containing] B  1.139 1.051 
IPI:IPI00223216.5 Gene_Symbol=Tst Thiosulfate sulfurtransferase  1.014 1.096 
IPI:IPI00230113.5 Gene_Symbol=Cyb5 Cytochrome b5  1.050 0.594 
IPI:IPI00895177.1 Gene_Symbol=Cyb5r3 13 days embryo liver cDNA, RIKEN 
full-length enriched library, clone:2500002N19 
product:NADH-CYTOCHROME B5 REDUCTASE homolog  1.050 0.932 
IPI:IPI00123276.1 Gene_Symbol=Mosc2 MOSC domain-containing protein 2, 
mitochondrial  1.598 0.898 
IPI:IPI00762185.2 Gene_Symbol=Mpst 3-mercaptopyruvate sulfurtransferase  0.967 0.967 
IPI:IPI00318750.4 Gene_Symbol=Dhrs4 NADPH-dependent retinol 
dehydrogenase/reductase isoform 1  1.156 0.631 
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IPI:IPI00111218.1 Gene_Symbol=Aldh2 Aldehyde dehydrogenase, mitochondrial  1.019 1.030 
IPI:IPI00113073.3 Gene_Symbol=Aldh1b1 Aldehyde dehydrogenase X, 
mitochondrial  0.855 1.472 
IPI:IPI00153144.3 Gene_Symbol=Suox Sulfite oxidase, mitochondrial  0.862 1.038 
 MCV 1.071 0.971 
    
Morpholgy and structure   
Accession # Name 2 weeks 4 weeks 
IPI:IPI00875638.1 Gene_Symbol=Immt Isoform 3 of Mitochondrial inner 
membrane protein  0.840 1.037 
IPI:IPI00653064.1 RANDOMIZED Gene_Symbol=Mfn1 Mitofusin-1  1.275 1.311 
IPI:IPI00855011.1 Gene_Symbol=LOC100046998 similar to optic atrophy 1  0.872 0.900 
IPI:IPI00131177.1 Gene_Symbol=Letm1 LETM1 and EF-hand domain-
containing protein 1, mitochondrial  0.906 0.927 
IPI:IPI00420706.4 Gene_Symbol=Lrpprc Leucine-rich PPR motif-containing 
protein, mitochondrial  1.026 0.988 
IPI:IPI00317074.3 Gene_Symbol=Slc25a10 Mitochondrial dicarboxylate carrier  1.245 0.886 
 MCV 1.027 1.008 
    
Apoptosis    
Accession # Name 2 weeks 4 weeks 
IPI:IPI00776047.1 Gene_Symbol=Aifm1 Apoptosis-inducing factor, 
mitochondrion-associated 1  1.051 1.103 
IPI:IPI00222419.5 Gene_Symbol=ENSMUSG00000058927;Cycs Cytochrome c, 
somatic  0.905 1.155 
IPI:IPI00127841.3 Gene_Symbol=Slc25a5 ADP/ATP translocase 2  1.385 1.116 
IPI:IPI00230540.1 Gene_Symbol=Vdac1 Isoform Mt-VDAC1 of Voltage-
dependent anion-selective channel protein 1  1.068 1.082 
IPI:IPI00122547.1 Gene_Symbol=Vdac2 Voltage-dependent anion-selective 
channel protein 2  1.147 1.101 
IPI:IPI00876341.1 Gene_Symbol=Vdac3 Voltage-dependent anion-selective 
channel protein 3  1.495 1.096 
IPI:IPI00648318.1 Gene_Symbol=Ak2 Adult male liver tumor cDNA, RIKEN 
full-length enriched library, clone:C730019E03 
product:ADENYLATE KINASE 2 homolog  0.876 1.001 
 MCV 1.132 1.093 
    
Amino acid metabolism   
Accession # Name 2 weeks 4 weeks 
IPI:IPI00273146.1 Gene_Symbol=Chdh Choline dehydrogenase, mitochondrial  1.095 1.137 
IPI:IPI00136213.5 Gene_Symbol=Sardh Sarcosine dehydrogenase, mitochondrial  0.953 1.065 
IPI:IPI00226140.5 Gene_Symbol=Maob Amine oxidase [flavin-containing] B  1.139 1.051 
IPI:IPI00130535.1 Gene_Symbol=Dbt Lipoamide acyltransferase component of 
branched-chain alpha-keto acid dehydrogenase complex, 
mitochondrial  0.933 1.054 
IPI:IPI00762346.1 Gene_Symbol=Aadat Kynurenine/alpha-aminoadipate 
aminotransferase mitochondrial  1.114 0.998 
IPI:IPI00114209.1 Gene_Symbol=Glud1 Glutamate dehydrogenase 1, 
mitochondrial  0.986 1.251 
IPI:IPI00129178.1 Gene_Symbol=Oat Ornithine aminotransferase, mitochondrial  1.148 1.041 
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IPI:IPI00405699.2 Gene_Symbol=Aldh4a1 Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial  0.984 1.087 
IPI:IPI00320850.3 Gene_Symbol=Mccc1 Methylcrotonoyl-CoA carboxylase 
subunit alpha, mitochondrial  0.900 0.976 
IPI:IPI00454008.1 Gene_Symbol=Shmt2 Serine hydroxymethyltransferase  0.979 1.166 
IPI:IPI00468653.3 Gene_Symbol=Pccb Propionyl Coenzyme A carboxylase, beta 
polypeptide  0.951 1.168 
IPI:IPI00117312.1 Gene_Symbol=Got2 Aspartate aminotransferase, 
mitochondrial  0.964 1.120 
IPI:IPI00274222.2 Gene_Symbol=Acad8 Isobutyryl-CoA dehydrogenase, 
mitochondrial  1.206 1.124 
IPI:IPI00116222.1 Gene_Symbol=Hibadh 3-hydroxyisobutyrate dehydrogenase, 
mitochondrial  0.879 0.910 
IPI:IPI00471246.2 Gene_Symbol=Ivd Isovaleryl-CoA dehydrogenase, 
mitochondrial  0.960 1.046 
IPI:IPI00127267.4 Gene_Symbol=Gldc Glycine dehydrogenase 
[decarboxylating], mitochondrial  0.939 1.277 
IPI:IPI00624210.3 Gene_Symbol=Glyal (BLAST score 619, P = 1e-176) 
EG240549 Glycine N-acyltransferase-like protein  1.052 1.076 
IPI:IPI00121218.5 Gene_Symbol=Fahd2a Fumarylacetoacetate hydrolase 
domain-containing protein 2A  1.012 1.161 
IPI:IPI00130804.1 Gene_Symbol=Ech1 Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial  0.942 0.876 
IPI:IPI00553717.6 Gene_Symbol=Mccc2 Methylcrotonoyl-CoA carboxylase beta 
chain, mitochondrial  0.810 1.130 
IPI:IPI00265352.1 Gene_Symbol=Gpt2 Alanine aminotransferase 2  0.827 1.230 
IPI:IPI00120123.1 Gene_Symbol=Dmgdh Dimethylglycine dehydrogenase, 
mitochondrial  0.853 1.072 
IPI:IPI00113073.3 Gene_Symbol=Aldh1b1 Aldehyde dehydrogenase X, 
mitochondrial  0.855 1.472 
IPI:IPI00556699.1 Gene_Symbol=Gcsh Putative uncharacterized protein  0.949 1.251 
IPI:IPI00273164.1 Gene_Symbol=Aldh5a1 Succinate-semialdehyde 
dehydrogenase, mitochondrial  0.883 1.009 
IPI:IPI00136655.1 Gene_Symbol=Gcat 2-amino-3-ketobutyrate coenzyme A 
ligase, mitochondrial  0.906 1.080 
IPI:IPI00461964.3 Gene_Symbol=Aldh6a1 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondrial  0.915 1.071 
IPI:IPI00848492.1 Gene_Symbol=LOC100045699 similar to Electron transferring 
flavoprotein, beta polypeptide isoform 2  0.918 1.015 
IPI:IPI00124372.3 Gene_Symbol=Aldh9a1 aldehyde dehydrogenase 9, subfamily 
A1  0.923 0.962 
IPI:IPI00379694.4 Gene_Symbol=Hmgcl 3-hydroxy-3-methylglutaryl-Coenzyme 
A lyase  0.937 1.012 
IPI:IPI00330523.1 Gene_Symbol=Pcca Propionyl-CoA carboxylase alpha chain, 
mitochondrial  0.941 1.038 
IPI:IPI00420718.4 Gene_Symbol=Hmgcs2 Hydroxymethylglutaryl-CoA 
synthase, mitochondrial  1.069 0.992 
IPI:IPI00230084.5 Gene_Symbol=Aldh7a1 aldehyde dehydrogenase family 7, 
member A1 isoform a  1.045 1.182 
 MCV 0.969 1.094 
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Gluconeogenesis   
Accession # Name 2 weeks 4 weeks 
IPI:IPI00760085.1 Gene_Symbol=Agxt Isoform Peroxisomal of Serine--pyruvate 
aminotransferase, mitochondrial  0.9617 0.7917 
IPI:IPI00114710.2 Gene_Symbol=Pcx Activated spleen cDNA, RIKEN full-
length enriched library, clone:F830201B12 product:pyruvate 
carboxylase, full insert sequence  1.0633 1.4495 
IPI:IPI00113073.3 Gene_Symbol=Aldh1b1 Aldehyde dehydrogenase X, 
mitochondrial  0.8547 1.4719 
IPI:IPI00230084.5 Gene_Symbol=Aldh7a1 aldehyde dehydrogenase family 7, 
member A1 isoform a  1.0447 1.1818 
 MCV 0.9811 1.2237 
    
Mito translation/transcription   
Accession # Name 2 weeks 4 weeks 
IPI:IPI00830581.1 Gene_Symbol=Hsd17b10 hydroxyacyl-Coenzyme A 
dehydrogenase type II  1.108 1.211 
IPI:IPI00118963.1 Gene_Symbol=Mrpl12 39S ribosomal protein L12, 
mitochondrial  0.897 1.064 
IPI:IPI00126634.1 Gene_Symbol=Poldip2 Polymerase delta-interacting protein 2  0.910 1.091 
IPI:IPI00130640.5 Gene_Symbol=Hrsp12 Ribonuclease UK114  0.948 0.801 
 MCV 0.965 1.042 
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7.3. List of PPAR-responsive genes 
 
Table 12. List of PPAR-responsive genes/products using bioinformatics 
 








1 Btbd17 NO    41 Iqcf3 NO   
2 Lck NO    42 Abca3 NO   
3 Pparg NO    43 Gbl NO   
4 Sept1 NO    44 Asrgl1 NO   
5 Acvrl1 NO    45 AC121967.3-2 NO   
6 Fkbp10 NO    46 Lgals12 NO   
7 Tmem143 NO    47 Ablim1 NO   
8 S3-12 NO    48 Maged1 NO   
9 Etv1 NO    49 Cbx8 NO   
10 Etfb YES 0.918 1.015  50 Slc25a10 YES 1.2446 0.886 
11 Ubqln1 NO    51 Acat1 YES 1.0454 0.951 
12 Pan2 NO    52 Mobkl3 NO   
13 Cd247 NO    53 Il8rb NO   
14 Pknox1 NO    54 Abcb6 NO   
15 1110036O03Rik NO    55 Nr5a2 NO   
16 Ly6g6c NO    56 BC005624 NO   
17 Abhd8 NO    57 Usp20 NO   
18 Mgst1 NO    58 Api5 NO   
19 Clec4f NO    59 Csrp2bp NO   
20 Ppt2 NO    60 Defb22 NO   
21 Prrt1 NO    61 Etfdh YES 1.0268 1.019 
22 Lpl NO    62 Nphp3 YES 1.3297 0.469 
23 Qdpr NO    63 Cyr61 NO   
24 Eapa2 NO    64 Gcat YES 1.3855 1.08 
25 Dnahc1 NO    65 5430416O09Rik NO   
26 Aifm2 NO    66 Sema3c NO   
27 Lyrm7 NO    67 Slc4a2 NO   
28 Rrm2 NO    68 Cdk5 NO   
29 Cdc27 NO    69 Mthfr NO   
30 Nt5c NO    70 Clcn6 NO   
31 Txndc17 NO    71 Chic2 NO   
32 Zfyve21 NO    72 Zfp326 NO   
33 Xrcc3 NO    73 Mmab NO   
34 Cast NO    74 1700012A03Rik NO   
35 C9 NO    75 Chl1 NO   
36 Cd96 NO    76 Aldh1l1 NO   
37 Ccdc80 NO    77 4632434I11Rik NO   
38 Fyttd1 NO    78 Pdha1 YES 0.969 0.988 
39 Adipoq NO    79 Angpt2 NO   












81 Carkd NO    121 BC027072 NO   
82 Wrn NO    122 Lrtm1 NO   
83 Hp NO    123 Ppp1r15b NO   
84 2400003C14Rik NO    124 Myct1 NO   
85 2310065K24Rik NO    125 C230078M08Rik NO   
86 Crispld2 NO    126 Lonp2 NO   
87 Pla2g15 NO    127 D930001I22Rik NO   
88 Abcg4 NO    128 1110034B05Rik NO   
89 Nudt16 NO    129 Purg NO   
90 Ilvbl NO    130 Clrn2 NO   
91 Tpsg1 NO    131 Rspry1 NO   
92 Reep4 NO    132 Tmc8 NO   
93 Clec18a NO    133 Olfr690 NO   
94 Vav3 NO    134 BC030396 NO   
95 Tpsb2 NO    135 1100001G20Rik NO   
96 Gpr142 NO    136 Olfr284 NO   
97 Plvap NO    137 Ubxn8 NO   
98 Mrpl34 NO    138 2310001K24Rik NO   
99 Ubd NO    139 F730015K02Rik NO   
100 Wdr38 NO    140 Olfr354 NO   
101 Fbxl21 NO    141 Gapdh NO   
102 Pkd2l1 NO    142 Sh2d3c NO   
103 EG70793 NO    143 Slc35e3 NO   
104 Scarf1 NO    144 V1re3 NO   
105 Rras NO    145 Myl4 NO   
106 Scaf1 NO    146 Prcp NO   
107 Gdf15 NO    147 Olfr525 NO   
108 Ubn2 NO    148 Cfd NO   
109 Gcnt1 NO    149 Fabp4 NO   
110 Orm1 NO    150 Olfr1351 NO   
111 Sec24c NO    151 U6 NO   
112 Syngr4 NO    152 U6 NO   
113 Cmtm5 NO    153 mmu-mir-218-2 NO   
114 Mslnl NO    154 Cd209b NO   
115 Gpr110 NO    155 Olfr1143 NO   
116 Ccnb1 NO    156 Lyz2 NO   
117 Mvk NO    157 Ddx43 NO   
118 Kcna4 NO    158 Utp3 NO   
119 Pars2 NO    159 AU023871 NO   








161 ACADVL NO 1.059 1.097 
162 GK NO   
163 HADHA YES 1.0484 0.927 
164 HADHB YES 1.0446 0.995 
165 LIPC NO   
166 SLC25A20 YES 1.1764 1.022 
167 BLVRB NO   
168 ADFP NO   
169 ECH1 YES 0.9423 0.876 
170 FABP1 YES 1.2179 0.541 
171 ACAA1 YES 0.9482 0.485 
172 CAT YES 1.0682 0.435 
173 CPT1A YES 1.1457 0.997 
174 ACSL1 YES 1.0252 0.731 
175 HMOX1 NO   
176 PCK1 NO   
177 PDZK1 NO   
178 SULT2A1 NO   
179 VNN1 NO   
180 AQP3 NO   
181 HMGCS2 YES 1.0693 0.992 
182 ACAA2 YES 0.9671 1.009 
183 ANGPTL4 NO   
184 ABHD3 NO   
 
Combined list of PPAR-responsive genes from proteomic datasets. In order to screen for 
PPAR-responsive genes, accession numbers were first extracted from IPI and converted 
to Ensembl accession numbers and compared against the reference. Genes highlighted in 
grey were detected in the proteomics screen. Their associating fold change in 2 weeks 
and 4 weeks are shown.
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Figure 47. Scatterplot of fold change ratios against peptides 
Plot showing the distribution of averaged fold change ratios (115/114 and 117/16) 
identified proteins against the number of peptide identified using MS/MS. A normal 
distribution can be observed. Each spot represents one protein.  
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